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Neuromyelitis optica spectrum disorder (NMOSD) is a chronic disease of the central 
nervous system that primarily affects the optic nerves and spinal cord. Despite 
similarities with relapsing-remitting multiple sclerosis (MS), NMOSD was recently 
recognized as a separate disease entity with different pathophysiological 
mechanisms and prognosis, and its clinical and imaging features are still being 
described. This project aims to explore brain and cervical spinal cord pathology in 
NMOSD by employing myelin water imaging, a magnetic resonance imaging 
method that has seen several applications in MS research. mcDESPOT is a novel 
technique based on multicomponent relaxometry that yields several quantitative 
tissue parameters, including the myelin water fraction, an index of myelin content, 
and T1 and T2 relaxation times, as well as structural volumetric measures. In this 
work, a mcDESPOT brain protocol was first acquired across three time points in 
healthy older adults on a single 3 Tesla scanner. Data on the test-retest reliability of 
mcDESPOT-derived indices are reported. Brain and cord mcDESPOT datasets 
were used to characterise focal and diffuse pathology in NMOSD in contrast with 
healthy controls. Results revealed abnormal parameters in several white matter 
regions, raising questions about the nature of non-lesional damage in the brain. 
Investigation of the thalamus showed normal volume, preserved microstructural 
integrity, and a link with a measure of information processing speed. Finally, cross-
sectional and longitudinal measures of myelin content and atrophy in the cervical 
cord showed differences between NMOSD, MS and control groups. This work 
brings further evidence to address outstanding questions in NMOSD research 
regarding the nature and extent of brain involvement, the correlates of cognitive 
impairment, and the existence of subclinical disease progression between clinical 
relapses, and supports the use of mcDESPOT as an informative technique in the 
study of this rare disease in particular, and neurological disorders involving white 
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Chapter I. Introduction 
 
This thesis is an investigation into brain and cervical spinal cord pathology in 
neuromyelitis optica spectrum disorder (NMOSD) using myelin water imaging 
(MWI). 
NMOSD is a relapsing disease of the central nervous system (CNS) that causes 
inflammation of the optic nerves and spinal cord. Despite similarities with relapsing-
remitting multiple sclerosis (MS), NMOSD was recently recognized as a separate 
disease entity, and is now known to be an immune-mediated astrocytopathy, with 
secondary demyelination occurring in the brain as well as in the cord and optic 
nerves. Magnetic resonance imaging (MRI) plays a central role in the diagnosis and 
evaluation of both diseases, and MRI investigations into brain and cord pathology 
have shown great promise in helping differential diagnosis and disease 
management. While advanced, quantitative, MRI techniques - and in particular MWI 
- have greatly informed understanding of the extent, temporal dynamics, and clinical 
correlates of demyelination in MS, the imaging features of NMOSD have only 
recently started to be described. Thus, there is interest in using biologically specific 
MRI methods to probe tissue pathology in this condition. 
Histopathological and imaging studies in both MS and NMOSD have endeavoured 
to describe CNS injury beyond focal pathology. In NMOSD, the number of these 
studies is limited, and these vary greatly in their conclusion regarding the existence 
or extent of widespread abnormalities. Discrepancies in those findings may be 
influenced by the choice of MRI technique and analysis methods, as well as small 
sample sizes due to the rarity of this condition. In addition to the relatively consistent 
findings of abnormalities in the optic and spinal pathways, there is some evidence 
for the presence of subtle normal-appearing tissue damage that may become 
evident with the use of more sensitive imaging techniques. 
This project aims to explore brain and cervical spinal cord pathology in NMOSD by 
employing multicomponent Driven Equilibrium Single Pulse Observation of T1 and 
T2 (mcDESPOT), a novel MWI method. mcDESPOT yields estimates of several 
quantitative tissue parameters, including the T1 and T2 relaxation times, and the 
myelin water fraction, an index of myelin content. Due to its three-dimensional 
acquisition and high spatial resolution compared to other similar methods, individual 
scans from the protocol can also be used to derive structural volumetric measures. 
mcDESPOT protocols have been developed for the brain and cervical spinal cord, 
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and have seen previous applications in MS research. The overall aim of this work is 
to contribute to establishing mcDESPOT as a valuable technique in this setting, 
firstly by demonstrating the test-retest reliability of one implementation of the 
protocol, and then by employ it to advance current knowledge of NMOSD pathology 
in vivo. 
Following the current introductory chapter, this thesis includes a chapter on the 
theoretical background behind the work presented, three separate studies, and 
concluding remarks in the form of a sixth chapter. 
In Chapter II, I review the main principles behind quantitative relaxometry and 
myelin water imaging, with a focus on the mcDESPOT technique. The main clinical 
and imaging features of MS and NMOSD are introduced. 
In Chapter III, I report an investigation on the scan-rescan reliability of mcDESPOT-
derived measures in the brain in healthy adults, at three time points, on a single 3 
Tesla scanner. The aim of this study is to inform on the repeatability of the 
technique, thus providing evidence to support its use in single-site, longitudinal 
studies. Data on the test-retest reliability of mcDESPOT-derived indices are 
reported. I then present two applications of the method in the brain and cervical 
spinal cord in NMOSD. 
In Chapter IV, I aim to characterise subcortical brain pathology in NMOSD using 
mcDESPOT, focusing on the thalamus and normal-appearing white matter. The 
study investigates abnormalities of myelin content and T1 in various regions of 
interest, including regions typically vulnerable to secondary demyelination, as well 
as others that are not. It investigates thalamic volume and microstructural integrity 
and assess their relationship with a measure of information processing speed, a 
cognitive domain known to be subject to impairment in demyelinating diseases, 
seeking evidence for the potential role of the thalamus in cognition in NMOSD. 
In Chapter V I present a longitudinal study of cervical cord pathology in NMOSD 
and MS subjects. I report cross-sectional and longitudinal measures of cord volume 
and myelin water fraction at baseline and after one year, in the absence of clinical 
relapses. The study aims to determine whether myelin content is abnormal in 
seemingly preserved areas of the cord, differentiating between lesional and normal-
appearing areas. Given the known lack of clinical disease progression between 
attacks in NMOSD, we aim to compare the evolution of these parameters over time 
between the MS and NMOSD groups. 
Concluding remarks are found in Chapter VI.  
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Chapter II. Theoretical background 
 
This chapter is organized in two sections. In Part 1, we discuss quantitative 
magnetic resonance imaging and specifically the technique of interest in this thesis. 
In Part 2, we provide an introduction to multiple sclerosis and neuromyelitis optica 
spectrum disorder. 
 
Part p: Quantitative magnetic 
resonance imaging of the central 
nervous system 
 
In this section we present a basic introduction to nuclear magnetic resonance 
imaging (MRI), focusing on quantitative MRI and especially relaxation time 
measurement. We describe the principles behind myelin water imaging and in 
particular the mcDESPOT technique, describe current evidence for the validation of 
this method and show its applications in the study of demyelination in neurological 
disease. 
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II.1. White matter imaging in vivo  
II.1.1. Myelin in the central nervous system 
II .1.1.1.  Basic neuroanatomy 
The human central nervous system (CNS) is comprised of the brain and spinal cord, 
within which are distinguished two tissue types. The grey matter (GM) is formed of 
neuronal cell bodies, and includes the cortex, forming the outer surface of the brain 
and organized in layers, and subcortical structures termed ‘deep’ GM nuclei (DGM). 
Within the brain, the white matter (WM), named for its clear appearance on 
dissection, is made up of myelinated axons, forms connections between the cortical 
and subcortical GM and links with the brainstem and spinal cord. WM makes up 
about half the volume of brain tissue in humans (Mancall and Brock, 2011). 
Cerebrospinal fluid (CSF) is found in interstitial and ventricular spaces within the 
brain, and a central canal within the cord. 
The spinal cord connects the PNS to the brain, and is responsible for afferent and 
efferent nerve transmission, enabling movement, sensation and autonomic 
functions. Like the cerebrum is protected by the skull, the cord is located within the 
vertebral column, a skeletal structure formed of 33 vertebral bodies, organized in 
levels: cervical, thoracic, lumbar and sacral levels, and coccyx. The cord is situated 
in the CSF-filled spinal canal, dorsal to the vertebral bodies. 
Unlike in the brain, the WM is situated on the outside of the spinal cord, with the GM 
within it having the characteristic shape of a butterfly. Without myelin, the cord 
would have to be the size of “a good-sized tree trunk” to achieve similar neuronal 
transmission speed (Morell and Quarles, 1999). 
The spinal cord is a highly eloquent structure, meaning that due to its size and 
compact organization, its functional redundancy is limited, and therefore most 
insults to the tissue will manifest clinically. This is in contrast to the concept of ‘brain 
reserve’, according to which tissue injury may be clinically silent due to 
compensatory mechanisms or functional redundancy (i.e. the number and strength 
of existing connections exceeding that needed for effective functioning). Moreover, 





I I .1.1.2.  Myelin role and biology 
In the CNS, electrical impulses are carried between neurons via axons forming 
synaptic connections, the basis of neuronal activity. Healthy axons are covered in 
myelin, an insulating membrane made up of lipids (~70-80%), proteins, and water 
(Mancall and Brock, 2011). Oligodendrocytes are the glial cells responsible for 
creating and maintaining myelin, by wrapping around axons in layers to form the 
myelin sheath (Figure II.1) in what has been described as “one of the most 
spectacular and intimate cell–cell interactions in the nervous system” (Nave, 2010). 
In the peripheral nervous system (PNS), this function is assumed by Schwann cells 
that myelinate a single axonal segment, while oligodendrocytes can be responsible 
for several axons. Glial cells protect as well as promote optimal functioning of the 
axon. Myelin allows electrical impulses to travel faster via the phenomenon of 
saltatory conduction, as well as lowering energy demands by limiting the surface of 




Figure II.1. Illustration of a neuron and its myelin sheath in the central nervous system. 




I I .1.1.3.  Functional relevance of myelin in health and disease 
Myelin is necessary for efficient neuronal transmission, and therefore serves a 
crucial role in motor, sensory and higher order functions underlying behaviour and 
cognition. Myelination evolves through the lifespan and in response to stimuli; 
relationships between WM integrity, demographic factors (e.g. gender, age, 
handedness, and education), and neuropsychological performance have been 
observed (Fields, 2008). The role of WM in functional plasticity has been observed 
on a time scale of months following learning, training, or behavioural interventions. 
Such dynamics can be observed with myelin-sensitive MRI (Filley and Fields, 2016), 
as will be seen in later sections of this chapter. Myelin health is also subject to 
ageing-related decline and mediates the relationship between age and 
neuropsychological performance across several domains, highlighting the 
importance of WM in supporting cognitive function (Gunning-Dixon et al., 2009). 
WM changes are also observed in a range of psychiatric conditions (Filley, 2010). 
Abnormalities of myelin can be idiopathic (dysmyelination), or occur as a result of 
pathology or injury (demyelination). Animal models of transiently induced 
demyelination (e.g. cuprizone-fed mice), as well as genetically determined models 
(e.g. canine model of congenital hypomyelination, or ‘shaking pup’ syndrome) are 
available (Duncan and Radcliff, 2016). Primary demyelination refers to a disease or 
injury process that will result in damage to the myelin sheath itself and/or to the 
oligodendrocytes via inflammation, autoimmune reaction, toxicity, etc. Secondary 
demyelination refers to myelin degradation following axonal injury, as is the case in 
Wallerian degeneration (the degeneration of an axon and its sheath distal to a site 
of focal injury) (Kandel et al., 2000). Different scenarios of secondary neuronal 
degeneration and demyelination mechanisms are illustrated in Figure II.2. 
Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) are 
generally considered primary demyelinating disorders, although these mechanisms 
may also play a role in damage to the CNS in both diseases; these are discussed 
Part 2: Multiple sclerosis and neuromyelitis optica spectrum disorder. 
MRI in the clinical and research setting has brought considerable advances in the 
study of white matter diseases. In the next section, we go over the basic principles 




Figure II.2. Different mechanisms of neuronal damage and demyelination. a) Healthy 
neurons (yellow, green) with myelinated axons (red) forming a synaptic connection. 
b) Anterograde transsynaptic degeneration following injury to the axon, causing 
damage to the axon downstream (grey). c) Retrograde degeneration, causing death 
of the affected axon’s parent neuron. d) Wallerian (anterograde) degeneration, 
causing degeneration to the part of the axon distal to injury. e) Case of both 




II.1.2. Quantitative MRI and relaxometry 
I I .1.2.1.  Magnetic resonance and the relaxation properties of 
t issue 
An MRI system is, simplistically, an extremely powerful magnet, within which 
magnetic field gradients and radiofrequency (RF) pulses are used to manipulate the 
nuclear magnetic resonance properties of imaged objects. The principle behind MRI 
is that protons will react to these external magnetic forces, and will emit a signal that 
can be spatially and temporally encoded to allow reconstruction into a two- or three-
dimensional image. Most human applications in research and medicine are 
conducted on scanners ranging in strength from 0.5 to 7 Tesla (T), with the greatest 
number of machines operating at 1.5 or 3T. 
The MRI scanner can be conceptualized using a three-dimensional frame of 
reference: a ‘longitudinal’ z axis parallel to the scanner bore, and a ‘transverse’ two-
dimensional plane defined by x and y axes. When placed into the scanner’s main 
magnetic field, termed B0, the hydrogen protons of water in human tissue, or ‘spins’, 
align along z in either direction. Fortuitously, a small difference will exist between 
the number of spins pointing ‘up’ and ‘down’ along z, thereby creating the 
opportunity for MR imaging. The sum of aligned vectors corresponding to spins’ 
orientation corresponds to the net magnetization M, which, when perturbed, will give 
rise to the measured signal in the xy plane. 
A spin system within the scanner is governed by relaxation phenomena, i.e. the 
tendency of magnetization to revert to a state of natural equilibrium after being 
perturbed. These parameters are dependent on both magnetic field and tissue 
properties. With knowledge of these interactions, MRI sequences can be designed 
to probe specific tissue properties, and we gain the capacity to visualize tissue in 
vivo. The basic dynamics of relaxation in the longitudinal and transverse planes are 
illustrated in Figure II.3, and described below. 
Protons can be ‘excited’ by the application of an RF pulse that tips M into the 
transverse plane to a degree determined by a chosen flip angle. In addition to their 
tendency to align along z, spins are also subject to precession, i.e. rotating about 
their axes at a speed that is determined by the total magnetic field they are 
subjected to, which includes the effects of their biological environment. 
When an RF ‘excitation’ pulse is applied, the net magnetization M is tipped into the 
transverse plane by a second magnetic field known as B1, giving rise to Mxy. In a 
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rotating frame of reference, the amplitude of Mxy is dependent on the individual 
spins precessing with the same phase. Within one tenth of a second, the spins will 
naturally tend to lose phase coherence, and the amplitude of Mxy gradually decays. 
This is due to two phenomena: interactions between the spins themselves (T2 
relaxation), and inhomogeneity in the main magnetic field (T2* effect). Through 
manipulation of Mxy using gradient and/or RF pulses, this dephasing can be 
reversed and the signal in the xy plane measured; this is called a signal echo, and 
occurs at a determined moment called the echo time (TE). The duration between 
repeated cycles of excitation and signal readout is called the repetition time (TR). 
 
 
Figure II.3. Schema of the relative time scales of T1 and T2 relaxation times in human tissue. 
Source: (McRobbie et al., 2006). 
 
T2* is the time it takes for signal to drop from its maximum intensity, immediately 
after a 90° pulse, to ~37%, while T2 is the time taken to drop to the same extent in a 
perfectly uniform magnetic field, or when the effects of inhomogeneity are 
refocussed using a spin-echo acquisition. T2 is expressed in time units and on the 
order of 50-100 milliseconds (ms) in human tissue. Simultaneously and over a time 
scale of about a second, the protons interact with the surrounding biological 
environment (the tissue or ‘lattice’) and naturally realign along z to a state of 
equilibrium. This phenomenon of spin-lattice relaxation is characterized by the 
relaxation time T1, defined as the time it takes for Mz to recover to ~63% of its 
maximum amplitude, M0, along the longitudinal axis. In tissue, T1 > T2 > T2*. With 
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increasing field strength, T1 lengthens, and T2 shortens, although T1 is more field 
strength-dependent than T2 (McRobbie et al., 2006). 
 
I I .1.2.2.  Beyond tradit ional MR contrast 
Because T1 and T2 relaxation occur simultaneously, the acquired signal depends on 
both T1 and T2 to different degrees depending on acquisition parameters, field 
strength, and the density of protons found in the imaged volume (three-dimensional 
pixel or ‘voxel’). The resulting image is said to have varying degrees of T1 or T2-
weighting. For instance, CSF appears dark on a T1-weighted image due to having 
very long T1, but bright on a T2-weigthed image due to having longer T2. 
In addition to visualization of anatomy, a number of pathological characteristics of 
tissue give rise to different contrasts, making MRI a useful diagnostic tool. However, 
in conventional imaging, image intensities are a mixture of several parameters, and 
arbitrarily scaled. Weighted images lack biological specificity, and hold no 
quantitative information – limiting their use to radiological interpretation, or 
extraction of structural information, e.g. volumetric or morphometric measures that 
rely on contrast differences between tissue classes or areas (e.g. measurement of 
GM concentration via voxel-based morphometry (Ashburner and Friston, 2000)). 
Moreover, the main and transmitted magnetic fields in an MR system are subject to 
hardware limitations and biophysical phenomena that can give rise to imperfections 
or inhomogeneities. These can cause signal loss or spatially distributed artefacts 
that increase in severity at higher field strength. 
Quantitative MRI methods aim to decompose the MR signal into scalable 
parameters, so that voxel intensities become reliable, reproducible, and can be 
interpreted as potentially biologically meaningful metrics. Relaxation time mapping, 
or relaxometry, consists of measuring actual T1 and T2 values; this is usually 
achieved by sampling the recovery and decay curves at different time points. The 
gold standard approaches to T1 and T2 quantification are described below. 
 
I I .1.2.3.  T1 mapping 
The most commonly used methods for T1 quantification are inversion recovery (IR)-
based sequences. These methods rely on 180° or ‘inversion’ pulses that flip Mz 
vertically, a manipulated inversion time (TI) delay during which Mz recovers, 
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followed by a 90° pulse that flips M into the transverse plane for signal 
measurement. IR-based methods are generally considered optimal in terms of 
accuracy. However, because T1 in tissue is on the order of a second, and TR must 
be at least 5 times T1 to allow for the complete restoration of M0 along the 
longitudinal axis, each TR cycle contains a lot of ‘dead time’. IR sequences are 
therefore often unpractically long for in vivo multi-slice experiments, although some 
marginally faster variants exist (saturation recovery, Look-Locker, MP-RAGE 
methods) (McRobbie et al., 2006). 
With all of these techniques, T1 can be measured by fitting the data to an 
exponential model of the longitudinal recovery curve (Cheng et al., 2012). T1 
mapping methods can be confounded by inaccurate flip angles, which is most 
commonly corrected for with separate acquisition of a B1 field map. 
For situations where speed is a main concern, variable flip angle (VFA)-based 
methods offer an alternative approach. In this framework, contrast in a series of T1-
weighted images with constant TR and TE is made dependent only on flip angle, 
proton density (PD) and T1 (Stikov et al., 2015). Both TR and flip angles can be 
small, making this a fast acquisition. DESPOT1 is one such method, presented in 
II.2.3. 
 
I I .1.2.4.  T2 mapping 
The gold standard for T2 measurement is a Carr-Purcell-Meiboom-Gill (CPMG) 
sequence, relying on a 90° pulse followed by a series (‘train’) of regularly-spaced 
180° pulses to sample the decay curve at different TEs. A typical sequence will 
employ 32 echoes with 10 ms spacing (Bydder et al., 2012). T2 values are 
calculated voxelwise by fitting single-exponential curves to all available echoes; this 
is typically done offline using a least-squares minimization approach1 (Tofts, 2003a). 
                                                
1 The least-squares approach to optimization works by finding the set of parameters – here, 
tissue biophysical parameters such as relaxation times – that best explain the available data. 
This is achieved by generating theoretical data for a range of possible parameters, and 
comparing how well these predicted data points match the acquired data. The differences 
between each pair of data point, i.e. the residuals, are calculated, squared and added up to 
provide a measure of discrepancy between predicted and acquired data. The optimal 
solution is the one with the smallest ‘sum-of-squares’. 
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Characterization of the decay curve, and thus T2 measurement precision, increases 
with the number of echoes acquired. This is generally considered a long sequence 
with poor spatial coverage, and thus often limited to single-slice or partial coverage 
acquisitions. 
DESPOT2 offers an alternative approach based on a different principle – creating a 
steady state with both T1 and T2 contributions, and utilizing prior PD and T1 
information to calculate T2 – described in II.2.3. 
 
I I .1.2.5.  Relaxation does not follow a single-exponential  
behaviour in t issue 
At the current spatial resolution of MRI, typically ~1 millimetre (mm)3, several 
cellular environments or ‘compartments’ are known to exist within each voxel, and 
all are expected to have their own T1 and T2 relaxation properties. 
Because water protons move very fast between environments relative to the scale 
of T1 relaxation, it is harder to untangle the relative contributions of signal from each 
compartment to the T1 recovery curve. Therefore, using conventional T1 relaxation 
mapping methods, T1 relaxation can generally be assumed to have a mono-
exponential profile, with the corresponding single T1 time being a weighted average 
of the T1 values of the individual compartments. 
On the other hand, sampling experiments of the T2 decay curve have shown that 
several components can be reliably identified, related to the different water 
compartments in tissue. The single-exponential fitted T2 value in a voxel is known to 
be different from the sum, or a weighted average, of its various components (Boulby 
and Rugg-Gunn, 2003); therefore, summing up these different components with a 
single T2 value is not a trivial problem. Moreover, these different components have 
the potential to provide information about tissue microstructure. Exploitation of these 
properties has given rise to myelin water imaging, which is described in the next 
section. 
 
II.1.3. Myelin water imaging 
II .1.3.1.  Overview and general principle 
Imaging myelin in vivo has many clinical and research applications for the study of 
neurodevelopment, functional plasticity, and disease. However, even in highly 
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myelinated structures, myelin only represents a relatively small portion of the tissue. 
While traditional techniques are sensitive to myelin, most lack biological specificity. 
An area of research pioneered by MacKay et al. and expanded upon over the last 
25 years has aimed to develop and apply an advanced MRI framework that exploits 
the T2 properties of myelinated tissue to gain information about tissue microstructure 
(MacKay et al., 1994). 
T2 relaxometry assumes a mono-exponential decay curve – that is, that a single 
number is sufficient to characterize the properties of all tissue within the voxel. 
However, due to the architecture of tissue at the sub-millimetre scale, it stands to 
reason that within one imaging voxel – typically a volume of 1 mm3 – several cellular 
environments are found, the relaxation characteristics of which differ. Multi-echo 
techniques allow the T2 decay curve to be observed and decomposed into 
contributions from these different compartments. When applied to the CNS, where 
one of the distinguishable compartments corresponds to water within the myelin 
sheath, this technique is termed myelin water imaging (MWI). 
 
I I .1.3.2.  The three-pool model of t issue 
In healthy myelinated tissue, the sampled T2 decay curve in human brain can be 
separated into the following components which, when displayed as a histogram 
(spectrum) of signal intensity versus T2, appear as follows. 
1) A short, fast-relaxing peak at ~40 ms (10-55 ms) attributed to water trapped 
within the myelin sheath, between the lipid bilayers. In this tightly packed 
environment, water protons are in close proximity with non-aqueous 
molecules, e.g. lipids and proteins, and therefore loss of phase coherence 
occurs faster. The width of this peak is thought to be due to measurement 
error rather than true biological variation. 
2) A long, slow-relaxing component at ~80 ms (70-95 ms), corresponding to 
water in the cytoplasmic (intracellular) and extracellular spaces. Currently 
achievable signal-to-noise ratios (SNR) do not allow for distinction between 
these two biologically distinct environments in the CNS (MacKay et al., 
2006). 
3) A third component corresponding to CSF (‘free water’), around ~2 seconds. 
This is especially relevant in voxels affected by partial volume effects with 
CSF. Earlier studies have used a two-pool model, fitting only the two 
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components above, but the inclusion of this third peak is recommended, as 
signal contamination by free water can occur in WM, but to a greater extent 
in DGM and even more so in cortical GM (Whittall et al., 1999). 
 
I I .1.3.3.  Myelin water imaging using multi-echo T2 relaxometry 
Sampling the T2 decay curve can be achieved with a CPMG sequence, described 
above in II.1.2. In a CPMG experiment, the acquired signal is characterized by the 
measured amplitude at each TE. Starting with a TE of 10 ms ensures that only 
aqueous protons contribute to the signal, since non-aqueous protons (e.g. in lipids) 
have an extremely fast decay rate (under 1 ms) (MacKay et al., 1994). The T2 decay 
curve can be converted to a spectrum of T2 signal amplitude by T2 time via 
nonlinear non-negative least-squares (NNLS) fitting2 (Figure II.4). 
 
 
Figure II.4. Spectrum of T2 distributions from human white matter: amplitude of T2 signal 
(A(T2)) by relaxation time (in milliseconds, on a logarithmic scale). The inset (left) shows a 
135,000x magnified axonal transection in canine spinal cord for illustrative purposes. In blue 
are the myelin layers and corresponding ‘short’ myelin water T2 component. In purple are the 
intra/extra-cellular water compartment and corresponding ‘long’ peak. Source: (MacKay and 
Laule, 2016). 
                                                
2 NNLS is used to find non-negative solutions only, since the parameters to determine are 
intrinsically null or positive (in this context, signal amplitudes). 
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This approach operates with the following specification (Whittall et al., 1997): 
1) solutions are null or positive; 
2) the number of exponential components to be fitted is unspecified; 
3) a regularization feature is employed that favours broad peaks and a ‘smooth’ 
distribution, which is a better representation of tissue microstructure while 
being more robust in the presence of noise in the acquired data; 
4) no initial guess at the solution is required. 
The signal time (T2 value) is an intrinsic characteristic of each water pool. The fitting 
procedure does not require peaks to be discrete, and thus defining the area for each 
component requires cut-off values to be assigned: typically below 50 ms for the 
short peak, and above 1 second for the long CSF peak (MacKay et al., 2006). 
The signal amplitude is proportional to the quantity of water protons with a particular 
T2. The sum of all components corresponds to the signal from all mobile protons, 
and is therefore proportional to the total water content. By normalizing the area of 
the short myelin-associated peak to the total area under the curve, we get a 
measure of the proportion of physical space taken by the associated water pool 
within the voxel. This is the myelin water fraction (MWF). Performing this analysis 
voxelwise, MWF maps can be obtained. 
In healthy WM, the MWF was first estimated at 1.5T to be ~10-15%, an estimate 
corroborated by in vitro studies (MacKay et al., 1994), and 2-6% in GM (Whittall et 
al., 1997). Calculated MWF values increase with field strength; the reasons for this 
are not yet fully understood (Kolind et al., 2009a). 
 
I I .1.3.4.  Available methods for MWI 
The original MWI technique was based on a multi-echo spin-echo acquisition, as 
described above. This experiment was initially performed using a 32-echo CPMG 
sequence, which produced a single 5-mm thick slice image with in-plane voxel size 
of 0.86 x 1.7 mm in 25 minutes at 1.5T (Whittall et al., 1997). This technique, 
referred to as multi-echo T2 (MET2), remains the gold standard, although acquisition 
time is long and thus often limited to single-slice or 2D acquisitions. Prasloski et al. 
proposed a combined gradient and spin-echo sequence (GRASE) to shorten scan 
time to under 15 minutes and enable 3D acquisitions (Prasloski et al., 2012b). 
Moreover, improvements have been made to the original NNLS method, including 
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correction for imperfect RF pulses (Prasloski et al., 2012a), and spatial 
regularization to reduce noise and improve measurement consistency while 
preserving structure (Yoo and Tam, 2013). 
More recent techniques have attempted to reduce acquisition times and improve 
coverage by implementing alternative T2 curve sampling methods; these are 
described in a comprehensive comparative review by Alonso-Ortiz et al (Alonso-
Ortiz et al., 2015). Some of these methods, such as multi-gradient echo (Hwang et 
al., 2010) and direct Visualization of Short Transverse relaxation time component 
(ViSTa) (Oh et al., 2013), are based on quantifying T2* relaxation to calculate the 
MWF, which is advantageous in terms of acquisition time and coverage, but comes 
at the expense of increased vulnerability to additional sources of noise in the decay 
curve such as motion artefacts, reduced SNR, and inhomogeneity effects. 
The MWI technique of interest to the present work is mcDESPOT, which will be 
described in section II.2. 
 
I I .1.3.5.  Specif icity and potential  confounds 
Here we discuss the specificity and limitations of the MWF as a measure of myelin. 
First and foremost, MWI is a direct measurement of myelin water, which makes up 
~40% of the myelin sheath space (Siegel and Agranoff, 1999) – a ‘negative space’ 
measure of the myelin sheath structure of sorts. Therefore, the tenet that probing 
myelin water is equivalent to measuring the myelin membrane itself is an 
assumption (Laule et al., 2007a). In addition, several parameters apart from myelin 
content may affect the MWF, and thus potentially confound interpretation; these are 
discussed below. 
First, the MWF is scaled to total water content, which in the case of pathology may 
be affected by oedema. Laule et al. proposed a model of different scenarios of 
oedema, demyelination, and cellular infiltration, and compared these with observed 
measures of relative water content obtained from MET2 relaxation data, MWF and 
volume in MS brain tissue, to determine which scenario was in each case most 
likely (Laule et al., 2004). This approach can be useful to differentiate between 
oedema and demyelination when tracking longitudinal changes in MS lesions 
(Vavasour et al., 2009). 
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Changes in water content are mainly thought to be a potential confound in 
pathology, as hydration status has been found not to have an effect on total water 
content in healthy controls (Meyers et al., 2016). When assessing myelin changes in 
MS lesions, it has been suggested that the MWF, as a measure affected by the 
combined influences of increased water content and decreased myelin, still reflects 
the degree of severity of an inflammatory event (Vargas et al., 2015). Alternatively, 
normalization using a water phantom, or concurrent absolute water content 
mapping, can help address this limitation (Meyers et al., 2017). 
Looking at T2 spectra in ex vivo animal models of inflammation and demyelination, 
Stanisz’ group characterized the myelin- and IE-water associated peaks under 
different scenarios, and showed strong associations between MWF and 
demyelination, while observation of the full spectra (peak positions and widths) 
could help distinguishing between different biological scenarios (Odrobina et al., 
2005; Stanisz et al., 2004). MET2-derived MWF also proved insensitive to 
inflammatory-related changes in the NAWM in an animal model of MS (Gareau et 
al., 2000). 
The short T2 component may reflect signal from myelin debris, as well as intact 
myelin, indiscriminately. This has been shown in a model of Wallerian degeneration 
in the rat sciatic nerve (Webb et al., 2003), and using histological myelin staining in 
a longitudinal study of spinal cord injury in rat (Kozlowski et al., 2008). 
 
I I .1.3.6.  Validation studies 
Despite these limitations, the validity of the MWF as a measure of myelination has 
been supported by a number of in and ex vivo human and animal studies, which 
have shown good qualitative and quantitative correspondence between histological 
measures of myelin and MWF maps. 
Good qualitative and quantitative agreement has been found between measures of 
myelin (staining, histomorphometry) and MWF in the guinea pig (Stewart et al., 
1993) and rat spinal cord (Kozlowski et al., 2008), and in a rat model of PNS 
primary demyelination (Pun et al., 2005). 
Post-mortem MRI validation is also possible in human specimens, as the tissue 
compartments do not undergo major change after death and fixation, with T2 times 
becoming shorter but the decay curves remaining qualitatively similar (Laule et al., 
2006). Moore et al. successfully compared a MWF map derived using the previously 
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described 32-echo CPMG method to myelin staining using Luxol Fast Blue in brain 
(Moore et al., 2000). This was reproduced by Laule et al. using quantitative 
comparisons between optical density measures of myelin staining and MWF maps 
in a series of post-mortem MS brain specimens, across several WM regions and 
areas of pathology (Laule et al., 2008, 2006). 
Studying human neurodevelopment, Deoni et al. found good agreement between 
MWF maps stratified by age in the first few years of life, and known spatio-temporal 
patterns of myelination determined histologically (Deoni et al., 2012, 2011). 
 
I I .1.3.7.  Other methods for in vivo  myelin imaging 
In this section we present a brief overview of other imaging methods for myelin 
measurement in vivo. 
The use of diffusion-weighted (DWI) and DTI in research is extremely widespread. 
DWI offers fast, high-resolution acquisitions and flexible, informative options for 
visualization of WM tracts. However, despite an active field of research and 
constant improvements in reconstruction models, it suffers from relatively low 
biological specificity to WM content. DTI measures reflect myelination in a broad 
sense, but are affected by tissue architecture (e.g. crossing fibres, fibre orientation 
coherence), and come with their own lot of artefacts, theoretical problems and 
implementation issues (Jones et al., 2013). One of the advantages of MWI is not 
being susceptible to these same confounds (Groeschel et al., 2016; Mädler et al., 
2008). 
Creation of ‘myelin-enhanced contrast’ maps has been proposed via combination of 
T1 and T2-weighted conventional scans (Glasser and Van Essen, 2011). However, 
the specificity of this approach has been disputed, and this ratio was found not to be 
correlated with the MET2-derived MWF in cerebral WM (Arshad et al., 2017). 
Magnetization transfer ratio (MTR) imaging is based on the relationship and 
exchange characteristics between ‘bound’ and free protons, i.e. the ratio of protons 
bound to macromolecules (e.g. cell membranes, proteins). Although MTR 
dependence on myelin is strong in WM, the technique has very low specificity and is 
also influenced by other tissue parameters such as axonal density, inflammation, 
and oedema (Vavasour et al., 2011). MTR is considered a ‘semi-quantitative’ 
technique due to dependence on the choice of acquisition parameters (Mallik et al., 
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2014). Quantitative MT measurements are possible, although suffer from the same 
limitations regarding specificity to myelin (Tozer et al., 2003). 
Macromolecular tissue volume (MTV) imaging uses 1 minus PD (as an 
approximation of water content) to calculate the proportion of a voxel not occupied 
by water, assumed to be taken up by macromolecules. By combining T1 
measurement with PD mapping, measures of ‘macromolecular composition’ can be 
obtained (Mezer et al., 2013). However, the biological specificity of the MTV fraction 
remains to be determined, and further clinical application studies are warranted to 
ascertain its utility in representing healthy tissue characteristics and disease states. 
Recent work with positron emission tomography (PET) aims at using myelin-binding 
tracers to quantify and track myelin dynamics in vivo with high specificity and 
precision (Bodini and Stankoff, 2016), although use of PET imaging is hampered by 
its very high costs and safety profile. 
 
II.2. mcDESPOT 
An alternative MWI technique is the multicomponent Driven Equilibrium Single 
Pulse Observation of T1 and T1 (mcDESPOT). In this section, we discuss the theory 
and implementation of the single- and multi-component DESPOT sequences, their 
advantages and pitfalls, and present some applications focusing on the study of 
white matter disease. 
 
II.2.1. Overview 
DESPOT1&2 refer to the acquisition and analysis techniques for T1 and T2 mapping 
from spoiled gradient recalled (SPGR) and balanced steady-state free precession 
(bSSFP) data, respectively. Both were initially developed at 1.5T. Extensions to 
these methods have been developed to compensate for the artefacts that arise at 
higher field strength. DESPOT1 with High-Speed Incorporation of RF Field 
Inhomogeneities (DESPOT1-HIFI) enables correction for imperfect transmit flip 
angles using an additional inversion recovery-prepared SPGR (IR-SPGR) scan. 
DESPOT2 with Full Modelling (DESPOT2-FM) makes use of additional bSSFP data 
collected with a different RF phase cycle to correct for off-resonance effects, using 
prior information from DESPOT1. 
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mcDESPOT is a MWI technique that extends these methods using additional data 
for multi-component analysis. By acquiring a series of spoiled T1-weighted and T2-
weighted balanced steady-state images over a range of flip angles, the longitudinal 
and transverse relaxation times T1 and T2 can be measured, and the contributions 
from different water pools within each voxel modelled, including the proportion of 
signal attributable to myelin water. This allows for voxelwise mapping of T1, T2 and 
MWF. 
The DESPOT techniques are summarized in Table II.1. A typical processing 
pipeline for multi-component analysis will involve: DESPOT1-HIFI to obtain T1, PD 
and B1 maps; DESPOT2-FM to obtain an off-resonance (f0) map; multi-component 
analysis. 
 
Table II.1. Summary of DESPOT techniques. 
Technique Purpose Acquisition Output Original reference 
DESPOT1 T1 mapping Dual-angle SPGR T1, PD maps (Deoni et al., 2003) 
DESPOT1-HIFI B1 correction DESPOT1, IR-SPGR B1 map (Deoni, 2007) 
DESPOT2 T2 mapping DESPOT1, dual-angle bSSFP T2 map 
(Deoni et al., 
2003) 
DESPOT2-FM B0 correction DESPOT2, multi-angle bSSFP f0 map (Deoni, 2009a) 
mcDESPOT Myelin water imaging 
Multi-angle SPGR, multi-
angle bSSFP, B1 and f0 maps 
11 parameter 
maps; see II.2.4 
(Deoni et al., 
2008a) 
B0: main field. B1: transmit field. bSSFP: balanced steady-state free precession. DESPOT: 
Driven Equilibrium Single Pulse Observation of T1 and T2. f0: off-resonance. FM: full 
modelling. HIFI: high-speed incorporation of radiofrequency field inhomogeneities. 
mcDESPOT: multi-component DESPOT. PD: proton density. 
 
Below we describe the mcDESPOT acquisition protocol in II.2.2 and present the 
single- and multi-component analysis techniques in II.2.3 and II.2.4. Example 




II.2.2. Acquisition protocol 
I I .2.2.1.  Steady-state sequences 
Steady-state sequences are gradient echo techniques that take advantage of the 
relative time scales for T1 and T2 relaxation to collect data at high SNR (maximising 
the magnitude of signal received) within very short TRs and using low flip angles. 
‘Steady state’ refers to an equilibrium state where either transverse, or both 
transverse and longitudinal magnetization reach a constant magnitude from one TR 
cycle to the next. A spoiled steady-state sequence only achieves steady state for 
the longitudinal component, resulting in primarily T1-weighted contrast, while in 
‘classic’ sequences steady state is reached by both longitudinal and transverse 
magnetization (Chavhan et al., 2008). Steady-state sequences eliminate the 
necessity to wait for full longitudinal or transverse relaxation between TR cycles, 
which reduces acquisition times. 
mcDESPOT acquisition in the brain is usually done at a resolution of 1.7 x 1.7 x 1.7 
mm3, for an acquisition time of ~15 minutes. It typically includes 8 SPGR scans at 
increasing flip angles up to 18°, one IR-SPGR scan for DESPOT1-HIFI, and 8 
bSSFP scans across a range of flip angles (e.g. up to 70°) acquired twice with two 
different RF phase cycles. 
The SPGR, IR-SPGR, and bSSFP sequences are described in the next sections. 
 
I I .2.2.2.  SPGR 
SPGR3 images are a type of T1-weighted gradient echo scan with short TR (TR < 
T2*) in which longitudinal steady state is achieved; this mechanism is described 
below. 
When TR > T2*, the transverse magnetization Mxy will naturally decay between TR 
cycles. In order to achieve even shorter TR, and to eliminate the need to wait for 
transverse signal decay, Mxy can be spoiled, or eliminated at the end of each cycle. 
Excitatory RF pulses are used that will give Mxy random phases across successive 
                                                
3 SPGR scans on GE systems correspond to Fast Low-Angle Shot (FLASH) on Siemens, 
and Fast Field Echo (FFE) on Philips. 
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TRs, preventing the build-up of transverse magnetization from one cycle to the next 
(i.e. preventing transverse steady state) (Chavhan et al., 2009). 
A longitudinal steady state occurs when the amount of longitudinal magnetization Mz 
recovered within a TR cycle is equal to the amount that is excited by the next RF 
pulse. Since residual Mxy is spoiled before the next TR, then the amount of Mz 
magnetization tipped into the transverse plane in the next cycle will only depend on 
a constant amount of T1 recovery. Thus, after each excitation pulse, the measured 
signal is a function of T1, TR, flip angle, and spin density M0 (equivalent to PD) 
(Chang et al., 2008). 
In DESPOT sequences, two or more SPGR images are acquired with short TR (< 
10 ms) and TE, both parameters being kept constant, and varying flip angles. 
 
I I .2.2.3.  IR-SPGR 
An IR-SPGR scan with identical TR/TE as the SPGR can be acquired as part of the 
DESPOT1-HIFI method. A brief explanation of IR sequences has been given in 
II.1.2, and the DESPOT1-HIFI method for B1 correction is described below in II.2.3. 
A TI of 450 ms is currently used in most protocols. This value is optimized in terms 
of accuracy and precision for the T1 of human tissue T1 (on the order of 1 second),. 
Since the transmit field B1+ should follow a smooth variation across the imaged 
volume, this scan can be collected at lower resolution than the SPGR and bSSFP to 
speed up acquisition (Deoni, 2007). 
 
I I .2.2.4.  bSSFP 
In SSFP sequences, both longitudinal and transverse magnetization reach dynamic 
equilibrium. Free precession refers to the state in which, when TR << T2, the 
induced, naturally decaying signal and the echo signal overlap, i.e. the transverse 
signal never fully dephases. 
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A special case of SSFP sequence is balanced (or ‘fully refocussed’) SSFP4. A 
bSSFP sequence uses the same principle as an SPGR acquisition, i.e. using a train 
of RF pulses and with TR < T2. Instead of spoiling the transverse magnetization, 
fully refocusing gradients are used for slice-encoding, phase-encoding, and readout. 
With all gradients remaining constant, effectively cancelling themselves out within 
one TR, Mz and Mxy hold constant magnitude across repeated cycles. Thus, both 
longitudinal and transverse magnetization can achieve steady state, and signal 
intensity is dependent on relaxation times and acquisition parameters. 
At high field strength, acquisition of bSSFP images will be subject to off-resonance 
effects caused by inhomogeneities in the main field. In these areas, local B0 
inhomogeneity will cause the precession phase in the transverse plane to be slightly 
offset with regards to readout, resulting in decreased signal. These ‘banding’ 
artefacts tend to occur in areas near air/tissue interfaces: in the brain, above the 
sinuses and in temporal lobe areas.  
To remedy this, two bSSFP acquisitions can be collected with different RF phase 
cycle patterns (often 0° and 180°), resulting in identical scans except for the areas 
of signal loss occurring in non-overlapping areas of the imaged structure (Deoni, 
2009a). The off-resonance correction scheme using these data is described in 
II.2.3. 
 
II.2.3. T1 and T2 mapping with single-component DESPOT 
II .2.3.1.  DESPOT1&2 
DESPOT1 is a VFA-based T1 mapping method (see II.1.2) that uses SPGR data as 
described in II.2.2. By keeping TR/TE constant and only varying the flip angle, the 
SPGR signal equation can be linearized so that only two data points are required to 
find PD and T1 (Deoni et al., 2003; Homer and Beevers, 1985). 
DESPOT2 relies on a similar principle. In the absence of off-resonance artefacts, 
the bSSFP signal equation can be transformed to a linear expression. By keeping 
flip angle and TR constant, creating longitudinal and transverse steady states thus 
creating signal dependence on both T1 and T2, and using PD and T1 information 
                                                
4 bSSFP sequences are implemented as FIESTA on GE, TrueFISP on Siemens, and 
balanced Fast Field Echo (bFFE) on Philips systems. 
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acquired with DESPOT1, the signal equation can be resolved and T2 estimated. 
DESPOT2 is possible from only two bSSFP flip angles, but additional scans allow 
nonlinear fitting and hence greater accuracy (Deoni et al., 2003). 
The DESPOT algorithms were originally developed at 1.5T. At higher field strength, 
several problems arise with regards to image quality. Correction schemes have 
been proposed that involve additional acquisitions and offline analysis, which are 
described below. The only implementations of the technique at 7T so far have been 
preclinical (Hurley et al., 2010; Wood et al., 2013, 2016). 
 
I I .2.3.2.  DESPOT1-HIFI 
Imperfections in the transmitted RF field, as well as dielectric effects in tissue 
(interference of the body’s composition on RF wavelengths) lead to discrepancies 
between the flip angle that is prescribed, and what it actually is across the imaged 
volume. Deviations of ± 10% will have a significant effect on MWF estimation 
(Deoni, 2011). A solution for this is transmit field (B1+ or simply B1) mapping: 
calculating the difference between nominal and actual flip angle, which can be used 
to provide the algorithm with the correct flip angles in post-processing. 
B1 mapping can be achieved via a separate, stand-alone sequence; some of these 
include actual flip angle (AFI) and Bloch-Siegert methods, that come at the expense 
of an additional sequence (McRobbie et al., 2006).  
DESPOT1-HIFI was developed as an extension of the DESPOT1 method and only 
requires an additional IR-SPGR scan. The IR-SPGR inversion pulse is adiabatic, 
meaning that it is intrinsically insensitive to B1 inhomogeneity. The IR-SPGR signal 
equation is determined by TR, the prescribed and actual flip angles, PD and T1. 
Therefore, using both the SPGR and IR-SPGR data, a simultaneous fit for the three 
parameters PD, T1, and B1 can be achieved via least squares fitting (Deoni, 2007). 
DESPOT1-HIFI yields a B1 map that describes the actual transmitted flip angle as a 
fraction of the prescribed flip angle (e.g. from ~0.8 to ~1.2). Some degree of 
smoothing (e.g. Gaussian or median filtering) may be used, as the B1 field is 




I I .2.3.3.  DESPOT2-FM 
As seen in II.2.2, areas of decreased signal intensity (banding) can arise in bSSFP 
scans due to main field inhomogeneity. Using maximum intensity projection to 
correct the images themselves is possible, but not optimal, and leads to inaccurate 
T2 values, with no increase in SNR. A correction scheme using alternating phase 
cycles across the chosen range of flip angles, in an interleaved fashion, was initially 
proposed but also proved insufficient at high field strength (Deoni et al., 2004). 
The currently used method, DESPOT2-FM, requires the acquisition of two series of 
bSSFP scans, with at least two flip angles each, identical parameters but different 
phase-cycling schemes (see II.2.2). With prior calculation of T1 and B1 with 
DESPOT1-HIFI, it enables T2 and off-resonance (f0, in Hertz) fitting. The bSSFP 
scans can be normalized voxelwise to their mean across flip angles and phase-
cycling patterns, which eliminates the need for PD to be included as an additional 
parameter. A region contraction approach was initially proposed (Deoni, 2009a), but 
subsequent implementations have used nonlinear least-squares fitting. 
 
II.2.4. Myelin water imaging with mcDESPOT 
II .2.4.1.  Overview 
DESPOT1&2 perform single-component analysis, relying on the assumption that the 
relaxation times measured in a voxel arise from tissue with homogeneous properties 
(Deoni et al., 2008a). Here, we present the mcDESPOT approach to multi-
component relaxometry. 
The multi-compartment characteristics of tissue in the CNS, and the principles 
behind MWI have been described in II.1.3. As seen therein, resolving the T2 signal 
into contributions from different compartments requires plotting the T2 decay curve. 
This cannot be achieved with bSSFP data only, since signal also includes T1-
weighting. Moreover, T1 recovery is known to be multi-exponential, albeit at a time 
scale that is hard to probe due to fast exchange. Therefore, untangling the 
contributions of T1 and inter-compartment exchange on the T2 curve also requires 
multi-angle SPGR data. A B1 map can be used to calibrate acquired flip angles, and 
a f0 map computed from phase-cycled bSSFP data can be included as an additional 
parameter (Deoni, 2011). 
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Multi-angle SPGR and bSSFP acquisitions, the single-component methods for 
relaxation time mapping, and the accompanying correction schemes for high-field 
implementation have been described in II.2.2 and II.2.3. In this section we describe 
the unique algorithm and the three-pool biophysical model of tissue used in 
mcDESPOT analysis, the advantages and drawbacks of this approach for MWI, and 
provide some example applications. 
 
I I .2.4.2.  Stochastic Region Contraction 
Least-squares methods belong to the category of local optimization curve-fitting 
strategies. In the context of mcDESPOT analysis, for the multiple-parameter 
estimation problem at hand, we run the risk of having the algorithm converge at a 
local optimum: one set of solutions that satisfies the algorithm’s requirements for 
stopping the search, that may be the best set within close range of the starting 
point, but not necessarily the ‘true’ solution. 
On the other hand, global optimization methods look for solutions within a 
predefined search-space5, and converge to find the best of all possible solutions – 
the global optimum. In the present case, some parameters have a wide range of 
possible values – especially the slow and fast-relaxing species’ respective 
residence times, since less is known about the possible values these parameters 
can take in human tissue. This would make the use of a global optimization method 
prohibitively computationally expensive (Deoni et al., 2008a). 
A first proposed approach for mcDESPOT analysis was based on a genetic 
algorithm (Deoni et al., 2008a). In this framework, pairs of possible solutions were 
chosen based on their residuals, combined to create new solutions, and tested 
against the data. Local optimization was then used to refine the ‘surviving’ solutions 
before the next step. However, this approach came with extremely taxing computing 
demands (Deoni, 2011). 
After the above as well as traditional fitting approaches proved inappropriate to 
resolve the complex combination of parameters in multi-angle SPGR and bSSFP 
data, Deoni et al. proposed an innovative solution that is a hybrid of the above 
                                                
5 The search-space refers to the ensemble of possible solutions for each parameter, 
delimited by user-defined limits or ‘bounds’. 
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optimization methods (Deoni et al., 2008a). They used an iterative stochastic region 
contraction (SRC) algorithm that tests sets of solutions, which converge from 
random priors within constrained, biologically plausible ranges, to the optimal 
solution for each parameter. The use of this algorithm is a first in neuroimaging 
research since its original implementation in acoustic signal processing (Berger and 
Silverman, 1991). 
It was designed to maintain the speed of local search methods, while retaining the 
power of global optimization methods to deal with large starting ranges for 
parameter estimates, and to operate regardless of initial guesses. The initial bounds 
for each parameter can be adjusted depending on considerations of time, 
computational power, and expectations regarding the underlying biology, informed 
by the literature as well as known relationships between parameters6. 
The algorithm follows the following steps (Deoni, 2011). 
1) 5000 random combinations are picked from a uniform distribution within the 
chosen starting bounds. 
2) Theoretical SPGR and bSSFP data are created and compared against real 
data using least-squares fitting. The sum-of-squares residuals are calculated 
cumulatively across all images. 
3) The 50 solutions with the smallest residuals are kept. The search-space is 
narrowed by using the minimum and maximum value for each parameter 
within these top solutions. 
4) Steps 2 and 3 are repeated, choosing 5000 new combinations within the 
contracted search-space and testing them against real data, ranking them, 
and contracting the search-space before a new iteration. The new 5000 
selections were initially random, but the use of a Gaussian distribution from 
the top solutions (the minimum and maximum of which having defined the 
search-space) was subsequently proposed. Each contracted search-space 
is slightly expanded by a factor of 0.02 (one 50th) to prevent discarding the 
true solution should it lie at the very ‘edge’ of a parameter search-space 
(Deoni and Kolind, 2015). 
                                                
6 These include: the three compartmental volume fractions adding up to one; fIE comprising 




5) The process repeats 6-8 times, or until each parameter converges to a 
unique solution on its own (convergence being defined as successive 
solutions lying within 0.5-1% of each other). The number of repetitions may 
be increased for enhanced precision, at the cost of longer computational 
time. 
 
I I .2.4.3.  The three-pool model in mcDESPOT 
The first version of the algorithm involved a two-pool model, only modelling the IE 
and myelin water components, resulting in a six-dimensional problem: T1 and T2 for 
each of the two compartments, residence time and volume fraction of the short 
myelin-associated component. 
However, as seen in II.1.3, a long T2 component is known to exist in voxels with 
partial volume (i.e. neighbouring meningeal or ventricular CSF), and has also been 
observed in abnormal WM in MS and phenylketonuria (Laule et al., 2007b). A three-
pool model was therefore proposed that incorporated bulk ‘free’ water, comprising 
two exchanging pools, and a third non-exchanging one (see Figure II.5) which is 
therefore thought to be more appropriate in CSF-adjacent areas or in pathology 
(Deoni et al., 2013). Using a statistical model selection approach, performance of 
the three-pool model was found similar to that of the two-pool model in tissue and 
superior in PVE voxels as well as globally on a voxelwise basis (Deoni et al., 2013). 
Thus, for each of the three compartments, the T1, T2, and volume fraction are 
estimated, as well as residence time, adding up to nine free parameters which are 
described below. 
• The T1 and T2 of each of the three compartments. Of particular interest, 
an increase in the T2 of the IE compartment (IET2) has been linked with 
inflammation in animal peripheral nerve (Odrobina et al., 2005; Stanisz et al., 
2004). Abnormalities in this parameter have been observed in both 
amyotrophic and progressive lateral sclerosis groups (Kolind et al., 2013). It 
has been suggested that intra- and extra-axonal water pools may have 
different characteristics, however these are not readily resolved using 
current acquisition and analysis strategies (Deoni and Kolind, 2015). 
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• The myelin water fraction (fM7). Description, validation and potential 
confounds for this parameter are found in II.1.3. The IE water fraction (fIE) is 
directly estimated in a three-pool model, otherwise it is simply defined as 1 – 
fM. 
• The residence time of the fast-relaxing component (τm), expressed in 
time units (or the inverse of the exchange rate). This parameter models the 
time spent by water in the myelin-associated pool before moving to the IE 




Figure II.5. Schema of the three-pool model of compartmental relaxation in human brain. In 
the case of tissue that includes ‘free’ water, as is the case in the ventricle-adjacent voxel 
depicted here (red box), three compartments are found each having different T1, T2, and 
volume fraction. The vertical yellow dotted line represents membrane permeability between 
the intra/extra-cellular (IE) and myelin (M) pools, with corresponding residence times (τ). 
Source: (Deoni et al., 2012). 
 
                                                
7 The myelin water fraction derived from various techniques is referred to in the literature as: 
MWF, MVF (myelin volume fraction), VFm (volume fraction of myelin water), Mf or fM (fraction 
of myelin water), etc. In an effort to differentiate between different methods, in this work we 
reserve the abbreviation MWF for MET2-based methods, and refer to the mcDESPOT-
derived myelin water fraction as fM. 
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Parameters not directly estimated by the model are: 
• The CSF water fraction (fCSF) is the proportion of ‘free’ water in the voxel, 
computed as 1 – (fIE + fM). 
• As in DESPOT2-FM, the need to fit for PD is eliminated by normalizing both 
the SPGR and bSSFP data to their means across flip angles. 
• B1 is calculated a priori using DESPOT1-HIFI, and used to calibrate 
transmitted flip angles. 
• f0 can be supplied a priori using the scheme described in II.2.3, or estimated 
within the model. 
 
I I .2.4.4.  Effect of water exchange 
Exchange refers to the motion of water molecules between compartments, 
exchange time being the inverse of the residence time. 
Animal experiments have shown a potentially negligible role of exchange, but in 
human tissue and especially in pathological cases, it is likely to have an impact 
(Deoni et al., 2008a). Slow exchange will have a negligible effect on the relaxation 
of either compartment, and can thus be omitted (Deoni et al., 2008a). In human 
neural tissue, it is estimated between 100-500 ms, and may therefore be a confound 
on the timescale of MET2 measurements. Fast exchange will lead to lower MWF, 
since water protons may move away from the myelin-associated environment and 
into another compartment before full transverse relaxation has taken place (Bydder 
et al., 2012). 
Exchange is a heterogeneous, variable, poorly characterized parameter influenced 
by a number of factors including temperature (although this is only relevant ex vivo), 
cell biology, and pathology (Deoni and Kolind, 2015). Accounting for exchange is 
one of the strengths of the mcDESPOT approach: exchange between the IE and 
myelin water compartments is explicitly modelled, and its influence on fM is 
minimized (Kolind and Deoni, 2011). Exchange between CSF and tissue water is 
prevented by the blood-brain barrier, although this may be untrue in cases of 
breakdown due to pathology; this is not accounted for in current models (Deoni et 
al., 2013). 
Reductions in myelin residence time (τm) have been seen in preclinical studies, and 
a few preliminary observations exist in humans. A possible interpretation of short τm 
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is a thinning of the myelin sheath, which has been observed in the rat spinal cord 
using MET2-based MWI (Dortch et al., 2013; Dula et al., 2010; Harkins et al., 2012). 
Average τm in WM was markedly reduced in a mildly disabled MS patient compared 
to four healthy controls in Deoni and Rutt’s original mcDESPOT experiment, using a 
two-pool model (Deoni et al., 2008a). It was reduced in a small sample of MS 
patients with chronic neuropathic pain compared with matched pain-free patients 
(Kolind et al., 2009b), and may be increased in the corpus callosum of MS and 
NMOSD patients compared with healthy controls (Lee et al., 2017). The biological 
specificity of this parameter may warrant further investigation. 
 
I I .2.4.5.  Algorithm stabil i ty 
In the original two-pool model, estimate precision was found to increase with higher 
SNR, fM, and longer residence time, possibly due to these characteristics making 
the signal curves more distinct from those that would characterize a single-
exponential relaxation (Deoni et al., 2008a). 
The precision of the two-pool model under unconstrained vs. constrained conditions 
(i.e. provision of initial boundaries for each parameter) has been questioned 
(Lankford and Does, 2013). However, these authors used a wholly or partially 
unconstrained approach, leaving all parameters (or all but the transverse relaxation 
times and τM) free to adopt any value regardless of biological plausibility, which is 
not usually done in practice. 
The three-pool model was found to have high accuracy using simulations on a 
numerical phantom representing different realistic values of fM and fCSF, and under 
realistic noise conditions (less than 10% error, i.e. comparable or superior accuracy 
to the two-pool model). Iterated results tended to follow a Gaussian distribution 
around the ‘true’ solution, meaning that convergence operates consistently around 
the global optimum (Deoni and Kolind, 2015). 
Using this model, good precision and accuracy were achieved in simulations under 
a range of priors (Deoni and Kolind, 2015). As with the two-pool model, accuracy 
increased with fM values. When numerical phantom characteristics were 
manipulated to represent different biological environments, such as cases of axonal 
swelling or inflammation, bias in fM estimation ranged from negligible (1% error) to 
moderate (11.5%). It was shown that fM estimation depends most on accurate 
compartmental T2 times measurement, a problem inherent to all MWI techniques. 
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Careful consideration is required to reach a compromise between constraining the 
search-space to increase precision, and choosing priors broad enough to 
encompass the true solution. 
 
I I .2.4.6.  Advantages and crit iques 
fM values derived from mcDESPOT have been found consistently higher than those 
from MET2 experiments, even with a three-pool model. Inadequate B1 and B0 
correction schemes will both result in fM overestimation (Deoni, 2011), as will 
magnetization transfer (MT). 
MT effects (i.e. the transfer of magnetization from macromolecule-bound to ‘free’ 
water protons, influencing MR signal) are known to occur with the use of short RF 
pulses, which are used to induce steady state in the bSSFP scans. These effects 
may influence the SPGR and bSSFP signal equations, and lead to a loss of 
accuracy and precision in T1/T2 measurement (Deoni et al., 2008a). 
Zhang et al. (J. Zhang et al., 2015) showed the presence of MT effects in bSSFP, 
which manifested as loss of signal amplitude, especially in WM which has a higher 
macromolecular content than GM. However, the effect on two-pool-model-derived fM 
values was minimal when compared to a modified mcDESPOT protocol that used 
longer RF pulses. Instead, MT effects manifested via other parameters (IET1 and 
τM). This investigation however used very large starting bounds for fM, as well as a 
two-pool model, and so results should be interpreted with caution. 
Advantages of mcDESPOT over other techniques include its three-dimensional 
nature and complete coverage of the brain or cervical cord in feasible times (e.g. 
~14 minutes for a whole-head acquisition). Another advantage is the simultaneous 
calculation of other parameters with potential biological relevance, as described 
above. 
 
I I .2.4.7.  Preclinical and clinical applications 
Applications of T1 and T2 mapping using single-component DESPOT are described 
in III.5.3. 
Preliminary investigations in animal models have shown the feasibility of 
mcDESPOT at ultra-high field, and good qualitative agreement between histological 
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measures of myelin and fM maps in a canine (Hurley et al., 2010) and a rat model of 
demyelination (Wood et al., 2016). These projects are so far the only published 
histological validation studies on mcDESPOT. 
mcDESPOT has been used in large-scale cohort studies of neurodevelopment to 
study developmental patterns of myelination ((Croteau-Chonka et al., 2016; Deoni 
et al., 2016, 2012; O’Muircheartaigh et al., 2014); list not exhaustive), using a 
version that trades in longer scan time for lower noise and specific absorption rate 
levels (Deoni et al., 2011) as well as age-specific protocols customized for time, 
field of view, acquisition parameters in relation to expected relaxation values in each 
age group in the first 5 years of life (Deoni et al., 2012). Other applications of the 
protocol have been to characterize group differences in neurological diseases such 
as Parkinson’s disease (Dean et al., 2016), amyotrophic and primary lateral 
sclerosis using fM and IET2 (Kolind et al., 2013), disorders involving dysmyelination 
such as schizophrenia (Flynn et al., 2003), and developmental conditions like 
autism (Deoni et al., 2015). It has also been suggested to hold promise in the study 
of traumatic brain injury (Jurick et al., 2016). In MS, mcDESPOT has been used to 
reveal abnormalities of myelin content using atlas-based approaches discriminating 
between MS subtypes and disability levels (Kitzler et al., 2012; Kolind et al., 2012), 
and related to functional indices in primary progressive MS (Kolind et al., 2015b). 
Applications in NMOSD are few, but will be mentioned in Chapter IV. The protocol 
has also been successfully implemented in the cervical spinal cord (Kolind and 
Deoni, 2011), which will be discussed in Chapter V.  
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Part ~: Multiple sclerosis and 
neuromyelitis optica spectrum disorder 
 
Herein we provide a brief introduction to multiple sclerosis and neuromyelitis optica 
spectrum disorder, focusing on the concepts of disease progression and the 
contributions of advanced quantitative magnetic resonance imaging to the study of 
these conditions. 
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II.3. Multiple sclerosis 
II.3.1. Clinical and epidemiological features 
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous 
system (CNS). It is one of the most prevalent neurological disease in the Western 
world, and a leading cause of disability in young adults (Compston and Coles, 
2008). The hallmark of MS is the presence of demyelinating lesions (or ‘plaques’) in 
the brain and spinal cord, that ‘wax and wane’ as new pathology appears, forming 
MRI-visible scars (sclerosis). MS most often presents with a highly variable clinical 
course, with periods of clinical quiescence interspersed with flare-ups or attacks that 
cause a wide range of motor, sensory, and cognitive symptoms. As a ‘young adult’ 
disease, with an average age at onset of 34 years and an often unpredictable 
evolution at the individual level (Compston et al., 2005), it has heavy impact at the 
individual, familial, and socio-economic level (Giovannoni et al., 2016). 
MS affects women more frequently than men, at a ratio of 2:1 or higher. Onset 
occurs most frequently between 20 and 50 years, although paediatric and older-
onset cases exist. A number of environmental factors have been linked with MS, 
although causal relationships have yet to be established. These factors include, but 
are not limited to: a family history of autoimmune disease, exposure to viral agents, 
smoking, vitamin D intake during childhood mediated by sun exposure (leading to 
an intriguing trend on the geographical distribution of disease prevalence by 
latitude). Epidemiological and genetic studies have revealed that gene-environment 
interactions may be at play, and that the aetiology of the disease is likely 
multifactorial and complex (Ramagopalan et al., 2010). 
 
II.3.2. Diagnosis 
A diagnosis of MS is made according to the revised McDonald criteria (McDonald et 
al., 2001; Polman et al., 2011), often on the basis of a clinical event “consistent with 
CNS demyelination” (Traboulsee et al., 2005). 
These criteria can be summed up by the shorthand of ‘dissemination in time and 
space’, which refers to the evolving nature of MS pathology. Dissemination in time 
is the occurrence of at least two distinct episodes of CNS damage, suggestive of a 
relapsing course, which can be identified prospectively or retrospectively. In the 
latter case, this can be done via collection of clinical history, or from a single 
imaging exam: in some cases, the appearance of lesions at various stages. The 
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observation of enhancing and non-enhancing lesions simultaneously can point to 
the occurrence of previous episodes, and may constitute sufficient evidence to 
establish dissemination in time. Dissemination in space requires the identification 
of T2-hyperintense lesions at two of four CNS locations typical of MS: 
periventricular, juxtacortical and infratentorial regions, and the spinal cord (Filippi et 
al., 2016). The exclusion of other conditions is required (Polman et al., 2011). 
Diagnosis can be made on clinical grounds only, although a neurological 
assessment can be supplemented by imaging or laboratory exams, (Noseworthy et 
al., 2000). MRI is crucial to an easier, faster diagnosis (Rovira et al., 2015), and 
repeat exams are recommended (Polman et al., 2011). 
 
II.3.3. Disease course and subtypes 
The concepts of relapses and disease progression are central to MS diagnosis and 
management. 
A relapse (or attack, flare-up, episode) is defined as a clinical episode of 
neurological dysfunction lasting at least 24 hours and not attributable to fever or 
infection (Polman et al., 2011). 
Disease progression is defined clinically as a gradual increase in symptoms that 
do not recede during remission (Lublin and Reingold, 1996). In the context of clinical 
trials, disability progression is typically assessed via changes in score on a global 
measure of disability, such as the Expanded Disability Status Scale (EDSS) 
(Kurtzke, 1983). 
MS is stratified into the following diagnostic categories (Compston et al., 2005; 
Lublin et al., 2014).  
• Radiologically isolated syndrome (RIS) refers to the (often incidental) 
identification of an MRI profile suggestive of MS in the absence of overt 
symptoms, i.e. a clinically silent episode. Clinically isolated syndrome 
(CIS) refers to the occurrence of a single attack that does not fulfil all 
diagnostic criteria, namely evidence for the dissemination of symptoms in 
time. In a large-scale retrospective database study, Okuda et al. found that 
34% of RIS patients presented with a clinical event within 5 years (Okuda et 
al., 2014). Progression of RIS into CIS as patients become symptomatic is 
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therefore frequent, as is subsequent conversion from CIS to a definite 
diagnosis of MS (Polman et al., 2011). 
• Relapsing-remitting MS (RRMS) is the most frequent form of the disease, 
which 85% of patients are initially diagnosed with (Compston et al., 2005). 
The disease course is characterized by periods of remission interspersed 
with unpredictable relapses. MRI activity occurs even between attacks, but 
may be clinically silent (Noseworthy et al., 2000). 
• Secondary progressive MS (SPMS) occurs when RRMS patients enter a 
progressive phase of the disease, with or without ‘superimposed’ relapses. 
In one prospective, single-centre, observational study, conversion occurred 
in 18.1% patients at a median disease duration of 16.8 years, translating to a 
risk of conversion of 6.4% 10 years after disease onset. Age at onset, male 
sex, and disease duration were found to increase risk of conversion from 
RRMS to SPMS. In this actively treated cohort, risk estimates were more 
favourable than previously assessed in natural history studies (Cree et al., 
2016). 
• Around 15% of patients have an initial diagnosis of primary progressive 
MS (PPMS), typically characterised by a progressive course from onset, and 
the steady accumulation of pathology and disability over time. A diagnosis of 
PPMS requires the observation of disease progression over a period of 
months. An estimated one-third of this patient group will also present with 
superimposed relapses (Wolinsky and the PROMiSe Study Group, 2003) – 
previously the ‘progressive relapsing’ phenotype, now described as ‘active 
PPMS’. Between 12-16% present with Gadolinium-enhancing lesions on 
MRI at a given time (Wolinsky et al., 2007; Wolinsky and the PROMiSe Trial 
Study Group, 2004). 
Of note, this classification system is continually being questioned. It has been 
hypothesized that these phenotypes only represent different configurations or 
stages of the same disease process. SPMS and PPMS would then be the same 
disease entity, on the basis of indistinguishable imaging and pathological 
characteristics other than clinical course and symptomatology. In the case of PPMS, 
successful functional compensation would effectively mask the relapsing stage, and 
disease progression would manifest only when these resources are exhausted, 
giving the illusion of a progressive course from onset (Absinta et al., 2016; 
Ransohoff et al., 2015). Whether PPMS is a pathologically distinct variant of MS, or 
should be considered as part of the spectrum of progressive MS disease is 
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therefore a matter of debate, although the latter is generally regarded as more likely 
(Antel et al., 2012). 
Recent consensus guidelines have also proposed to characterize disease as 
active/inactive (occurrence of relapses), with/without worsening (confirmed 
incomplete recovery from relapse-related disability), and with/without progression 
(see above definition) in addition to classification into a subtype, to better represent 




MS is thought to be an inflammatory, immune-mediated disease (Lassmann, 2014), 
although its pathophysiological mechanisms are complex, and its aetiology still 
considered uncertain. 
The two main components of MS pathology are inflammation and 
neurodegeneration. In the typical course of the disease, inflammatory activity comes 
and goes, while neurodegeneration is ongoing. Over time, the inflammatory activity 
and accompanying relapses become less frequent, while neurodegeneration and 






Figure II.6. Schema of the course of disease progression in MS and NMO. MS: multiple 
sclerosis. NMO: neuromyelitis optica. Source: (Kawachi and Lassmann, 2017). 
 
 
During an MS attack, infiltration of inflammatory agents through a weakened blood-
brain barrier causes oedema (influx of fluid in the extracellular space) and tissue 
damage. Different mechanisms of lesion formation via oligodendrocyte and/or 
myelin injury have been identified using post-mortem histology (Lucchinetti et al., 
1996). These appeared consistent within subjects, suggesting the possibility of 
different immunological profiles culminating in a common manifestation (Lucchinetti 
et al., 2000). 
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In addition to demyelination, tissue injury in MS involves axonal loss within and 
outside lesions due to Wallerian degeneration, and neuronal loss causing brain and 
spinal cord atrophy. Oligodendrocyte depletion may contribute to demyelination 
through loss of support to the myelin sheath and impaired remyelination, while 
astrogliosis (reactive proliferation of astrocytes) and astrocytic scarring can prevent 
neuronal regrowth (Miller, 2002). 
During remission, resolution of oedema, reorganization of sodium channels on 
axons, and remyelination may play a role in restoring function following an attack 
(Trapp and Nave, 2008), although cortical reorganisation is more likely to be a major 
factor in maintaining function (Frohman et al., 2005). 
In the consensus theory of MS pathogenesis, repeated inflammation causes severe 
axonal damage, and eventually exhausts the compensation reserves of the CNS, at 
which point a neurodegenerative process starts occurring with or without continuing 
relapses – the progressive phase of the disease (Duncan and Radcliff, 2016). 
An opposing view purports that recurring inflammation could be a consequence, and 
not the cause, of neurodegeneration (Nave, 2010). Progressive disease would be 
the ‘true’ disease process, and neurodegeneration the primary component of MS 
pathology, with a possible superimposed secondary component: an “aberrant” 
immune response causing relapses (Stys et al., 2012). 
Genetic variants conferring increased risk for MS are consistent with an 
autoimmune aetiology, and neuropathological studies have found evidence for the 
presence of cortical inflammation predating signs of neurodegeneration early in the 
disease course – evidence for it occurring “on a background of inflammation” 
(Ransohoff et al., 2015). The observation that neurodegeneration dies down as 
inflammatory activity subsides in the progressive phase also supports inflammation 
as the driving factor (Frischer et al., 2009). MS as a primarily autoimmune disease, 
with a secondary neurodegenerative component, therefore remains the prevailing 
theory. 
Knowing this and with the idea that preventing damage is easier than repairing it, 
recent education initiatives have stressed the importance of early treatment under 
the banner of “time is brain”, suggesting an aggressive approach to treatment 




II.3.5. Conventional MRI findings in MS 
MRI is not required for MS diagnosis, but can serve to greatly increase confidence; 
allow for more criteria to be assessed using a single exam; and enable ruling out 
other pathology. It can serve to establish dissemination in space according to known 
criteria of location and, in some cases, dissemination in time by observing old in 
addition to acute lesions. Further along in the disease course, atrophy can also be 
assessed (Traboulsee et al., 2005). 
The hallmark appearance of a brain affected by MS is multiple lesions in the WM. 
Typical sites of focal pathology include the temporal lobes, periventricular areas, 
brainstem, cerebellum, and juxtacortical areas (involving U-shaped association 
fibres) (Compston et al., 2005). Cortical and deep grey matter (GM) involvement 
(basal ganglia, thalamus) is less common (Fox, 2008); GM pathology in MS will be 
further discussed in Chapter IV. 
The following sequences are part of a ‘typical’ brain MRI exam for MS; we describe 
the most often-seen features of the disease in this context. These different contrasts 
are shown in Error! Reference source not found.. 
 
 
Figure II.7. Conventional MRI scans used in the radiological assessment of MS. a) Proton 
density, b) T2-weighted, and c) FLAIR scans showing small hyperintense white matter 
lesions. Source: (Traboulsee et al., 2005). 
 
Lesions may be seen on PD and T2-weighted (fast) spin-echo scans. For improved 
visualization of periventricular, juxtacortical and cortical lesions, fluid-attenuated 
inversion recovery (FLAIR) scans are used to suppress signal from the adjacent 
CSF. The bright appearance of lesions on these scans is due to the increase in 
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water content typical of MS lesions, which leads to lengthened T1 and T2 relaxation 
times (Traboulsee et al., 2005). Typical ‘T2 lesions’ have a round or ovoid shape, 
and vary in size; T2 lesion load is highly heterogeneous across subjects, and non-
normally distributed in a given sample (Traboulsee et al., 2005). Areas of 
predilection include periventricular regions, and especially the corpus callosum 
(CC). Callosal lesions tend to spread radially from the inner ventricular surface of 
the CC towards the surrounding WM, in a pattern known as Dawson’s fingers that is 
best seen on sagittal scans (Fox, 2008). 
Gadolinium (Gd)-enhancing lesions appear on T1-weighted scans after injection of a 
contrast agent. Common enhancement patterns include an ovoid, homogeneous 
appearance with clearly-defined borders (nodular lesion), and a ‘ring’ shape with a 
hyperintense border and T1-hypointense center. Although complete or partial ring 
enhancement is not exclusive to MS, ‘open-ring’ lesions are a specific sign of 
demyelination (Davis et al., 2010). Enhancement signifies blood-brain barrier 
disruption, and therefore areas of acute inflammation, and occurs on the time-scale 
of weeks. However, not all new lesions are enhancing, and old lesions can 
‘reactivate’ (Martino et al., 2002). The detection of enhancing lesions can also be 
dependent on the technical details of contrast injection and image acquisition. After 
initial enhancement, lesions usually shrink and leave a T2-visible scar (Traboulsee 
et al., 2005). 
Diffuse, T2-hyperintense pathology extending outside of focal lesions denotes 
diffusely-abnormal WM (formerly known as ‘dirty-appearing WM’). These areas 
appear as large, periventricular lesions with poorly defined boundaries. They are 
underpinned by myelin pathology, mild axonal damage and gliosis, to an 
intermediate degree between healthy and lesioned tissue (Laule et al., 2011), which 
may be consistent with Wallerian degeneration (Seewann et al., 2009). 
T1-hypointense areas are suggestive of tissue destruction, and can underlie lesions 
that are currently enhancing (acute), resolving, or chronic. Concurrent T1-
hypointensity of a T2 lesion is indicative of greater axonal loss (Traboulsee et al., 
2005). T1-hypointensity is more specific than T2 contrast when differentiating lesions 
with different degrees of remyelination (Barkhof et al., 2003). T1 ‘black holes’, 
indicating severe tissue damage, are more often seen in the cerebrum than the 
posterior fossa and spinal cord (Fox, 2008). 
Spinal cord pathology occurs in 80-90% of MS patients, with frequent involvement 
of the cervical cord. In RRMS, multiple T2-hyperintense focal lesions are often seen. 
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Plaques most often appear in the cervical portion of the cord, often less than two 
segments in length, most often located in the dorsal and lateral WM and occupying 
under half of the cord area. Swelling and Gd-enhancement are commonly seen in 
the acute stage (Lycklama et al., 2003). Cord involvement in MS is further 
discussed in Chapter V. 
 
II.3.6. Role of advanced MRI in MS 
Biomarkers are, in general, measures that reflect a specific biological or 
pathological process, and can serve to improve diagnosis confidence, inform 
prognosis, study disease mechanisms or monitor treatment effects. 
In MS specifically, MRI plays a crucial role in disease diagnosis, monitoring, and 
evaluation of treatment outcomes. The conventional MRI methods described in the 
previous section form part of a routine MRI exam in the clinical setting. The wide 
array of advanced MRI methods available have been applied to the study of MS; 
however, due to factors like cost and lack of standardisation in acquisition and 
analysis protocols, the use of these methods in the clinical setting is limited. At this 
stage, the benefits of advanced MRI for improving diagnosis of individual cases, 
guide treatment decisions, or inform prognosis is limited, and will require to be 
ascertained via prospective studies (Rovira et al., 2015), and these methods have 
yet to see widespread use in the clinic. 
Validation of biomarkers requires establishing adequate sensitivity, specificity, and 
reliability, and superiority against existing measures (e.g. in terms of statistical 
power). Established biomarkers can be used as surrogate endpoints in clinical trials 
if indicative of, and correlated with clinical indices (Bielekova and Martin, 2004). In 
MS, evidence of disease activity using lesion-based measures can be detected 5 to 
10 times more frequently than relapse rate (Filippi and Agosta, 2010), but lesion 
load correlates poorly with clinical symptoms and outcome. A reduction in whole-
brain volume, or an increased atrophy rate, correlates more strongly with clinical 
outcomes, but is difficult to interpret; atrophy represents the end result of several 
processes, including axonal and myelin loss, tissue shrinkage due to gliosis 
(Traboulsee et al., 2005), and changes in water content (Miller, 2002). 
Currently, lesion load (T2-hyperintense and Gd-enhancing lesions) and cerebral 
atrophy can serve as primary endpoints in phase 2 clinical trials in MS, and are 
used as secondary outcome measures in phase 3 trials. In the latter, clinical 
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measures, i.e. EDSS and relapse rate measures, are used as the primary endpoints 
(Cohen et al., 2012; van Munster and Uitdehaag, 2017). 
Development of MRI biomarkers for MS has been impeded by the fact that 
correlations between conventional MRI metrics and clinical status in MS are 
notoriously moderate at best. This discrepancy is termed the ‘clinico-radiological 
paradox’: the gap between MRI-visible disease activity and the burden of symptoms 
displayed by a patient at the individual level (Barkhof, 2002). Several reasons for 
this can be invoked. 
First, standard MRI measures may lack the specificity required to isolate the 
pathological processes that affect clinical status (e.g. lesion load without 
consideration of lesion location; cerebral atrophy representing the end-point 
outcome of several long-term pathological processes). As many as 9 out of 10 
cerebral lesions may be asymptomatic (Traboulsee et al., 2005); conversely, 
currently used clinical tools may not reflect all aspects of neurological dysfunction. 
Lesions in broadly functional regions may lead to more subtle manifestations than, 
for instance, impairment of autonomic or motor functions, or compensatory 
mechanisms may work to preserve function even in the presence of increasing 
pathology. Spinal cord measures are not always considered, despite most clinical 
tools being heavily geared towards locomotor dysfunction (van Munster and 
Uitdehaag, 2017). 
This phenomenon highlights the importance of advanced MRI methods for 
understanding pathology in vivo, with greater biological specificity (Filippi and 
Agosta, 2010); increasing efficiency of clinical trials (i.e. assessing treatment effects 
over a shorter time period and/or with smaller sample sizes) (Traboulsee et al., 
2005); and probing diffuse, MRI-occult changes in the normal-appearing tissue, a 
concept central to the pathology of MS (Filippi et al., 2012). Region-specific volume 
measurements, cervical spinal cord area, DTI and magnetization transfer ratio-
based measures have been proposed as the main candidates for translation into the 
clinical setting (van Munster and Uitdehaag, 2017). From a research perspective, 
the wide array of available advanced MRI methods has been extensively applied in 
the study of MS, and has brought to light important features of the disease, 
including the role of axonal damage in disease progression, the nature and extent of 
cortical pathology, and the role of brain plasticity in compensating structural damage 
(Frohman et al., 2005). In particular, due to myelin pathology being central to the 
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disease, the development of in vivo myelin quantification methods has gone hand in 
hand with their application to MS research. 
 
II.4. Neuromyelitis optica spectrum disorder 
II.4.1. Clinical and epidemiological features 
Neuromyelitis optica (NMO), previously called Devic’s disease, is an inflammatory 
disorder of the CNS characterised by autoimmune attacks against the optic nerves 
and spinal cord, leading to severe disability. Previously considered a rare, severe 
variant of MS, emerging imaging and laboratory features have helped define it as a 
separate relapsing disease. 
The prevalence of NMO is estimated at 1 to 3/100,000 (Etemadifar et al., 2015). It is 
especially prevalent in non-Caucasian populations (Wingerchuk et al., 2006), and 
has a female:male ratio of over 3:1, greater than in MS (Wingerchuk, 2009). The 
proportion of NMO to other demyelinating disorders cases is much higher in Japan 
than elsewhere, making it one of the most prevalent neuroimmunological disorders 
in Asia (Uzawa et al., 2014). 
Disease onset is typically in the late 30’s, slightly older than MS, although childhood, 
adolescence and later-onset cases also occur. While familial cases have been 
reported in Japanese populations, NMO is currently considered a sporadic disease 
(Wingerchuk, 2004). The coexistence of autoimmune disorders (e.g. type 1 
diabetes, coeliac disease, etc.), or family history thereof among patients is very 
common, generally preceding disease onset (Wingerchuk et al., 2007a). 
The main features of the disease are optic neuritis (ON), i.e. uni- or bilateral 
inflammation of the optic nerves, and longitudinally extensive transverse myelitis 
(LETM), i.e. inflammation of the spinal cord extending across 3 or more vertebral 
levels. A typical NMO case features episodic, severe bouts of LETM and/or ON. 
While brain involvement was previously thought to be minimal, standard and 
advanced MRI techniques have shown a distinct pattern of cerebral pathology that 
may aid differential diagnosis. 
 
II.4.2. The NMO spectrum 
According to its initial stringent definition as a monophasic disorder, NMO was 
diagnosed on the basis of simultaneous attacks of bilateral ON and acute myelitis 
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(Wingerchuk et al., 1999). The definition has now been broadened to encompass 
cases that present with index events of ON and myelitis that can occur weeks or 
years apart (Weinshenker, 2003). While exclusion of non-optic-spinal CNS 
symptoms used to be a requirement, significant brain involvement has now been 
demonstrated. 
NMO immunoglobulin G (IgG) is a an autoantibody that targets aquaporin-4 (AQP4), 
a water channel protein found on astrocyte cell membranes; elevated levels in the 
blood serum are associated with NMO (Lennon et al., 2005, 2004). Its high 
specificity for NMO was brought to light in 2004 and 2005 by a Mayo Clinic group 
(ibid), and has greatly helped differentiate NMO from other conditions with similar 
clinical and imaging presentations. 
Serological testing offers excellent specificity for clinically defined NMO (91%) – with 
few false positives, as ‘classic’ MS cases consistently test seronegative – while 
sensitivity varies depending on the method (48-77%) (Jarius et al., 2007; Waters et 
al., 2012; Wingerchuk et al., 2007a). Detection of NMO-IgG can predate fulfilment of 
all necessary clinical criteria, enabling earlier detection and treatment. NMO-IgG 
testing is especially useful in non-clinically-definite cases, such as presenting with 
bilateral or severe ON that may benefit from attentive follow-up or early intervention 
(Marignier et al., 2008). 
Description of NMO as a disease entity fully distinct from MS has been a centraI 
theme of research over the last 15 years, albeit complicated by the heterogeneity in 
clinical presentations (Weinshenker and Wingerchuk, 2014). Around 70% of 
patients who fulfil NMOSD criteria test seropositive (Wingerchuk and Weinshenker, 
2017). Following improvements in serological assays, and knowing that serostatus 
can change over time or be confounded by the effects of immunosuppressive 
treatment (Jarius et al., 2008a), it has been suggested that with careful re-testing, 
NMO-IgG can be detected in up to 88% of diagnosed cases (Jiao et al., 2013). 
However, the prevalence of seronegative cases remains confounding with regards 
to defining NMO as a homogeneous disease entity, with uniform presentation and 
consistent pathogenic mechanisms. 
NMO has come to be considered as a spectrum of disorders not limited to the 
prototypical cases, with clinical presentation, imaging and serological tests coming 
together to aid diagnosis at the individual level (Wingerchuk et al., 2007a, 2006). 
Recent consensus guidelines proposed to merge the concepts of NMO and NMO 
spectrum disorders under the umbrella designation of NMOSD, and to redefine the 
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diagnostic guidelines accordingly, with different criteria incorporating the known 
heterogeneity in clinical presentation, seropositivity, and imaging findings 
(Wingerchuk et al., 2015). Serostatus is a central feature, and diagnosis is based on 
fulfilment of several clinical and MRI criteria that include ON and acute myelitis, as 
well as a characteristic brain MRI profile, including area postrema, brainstem or 
diencephalic syndromes (see II.4.6). 
 
II.4.3. Differential diagnosis 
Misdiagnosis of NMOSD as MS remains an issue, and was among the main focus 
points in the 2010 revisions to the McDonald diagnostic criteria (Polman et al., 
2011). NMOSD is now recognised as following a relapsing course in most cases, 
and thus can ‘mimic’ the course of MS; anecdotal evidence reports patients having 
been misdiagnosed for upwards of 20 years (Braksick et al., 2014). Notwithstanding 
the obvious ethical and psychological considerations of an erroneous diagnosis 
(Mutch et al., 2014), early intervention is crucial in NMO, as clinical deterioration 
during attacks is faster than in MS (over the course of days or weeks), and 
intervention has been linked with improved prognosis (Pittock and Lucchinetti, 
2016). Moreover, immunomodulatory treatments used in MS are ineffective in 
preventing NMO relapses, and can even be harmful; negative effects of MS 
disease-modifying therapies on NMO patients have been reported (Sato et al., 
2012; Solomon et al., 2012), including in seronegative patients (Kitley et al., 2014a). 
In Asia, where the prevalence of MS is lower, the diagnosis of an opticospinal form 
of MS was frequent, and the question of whether these patient groups may overlap 
a matter of debate (Weinshenker, 2008). The current recommendation is that these 
are the same disease entity and that Asian ‘opticospinal MS’ belongs to the NMO 
spectrum (Wingerchuk et al., 2015). 
 
II.4.4. Disease course and progression 
A monophasic course is found in 10-20% of cases (Wingerchuk et al., 2007a), and 
defined as the quasi-simultaneous occurrence of the index events (i.e. ON and 
acute myelitis) over days or weeks, with moderate recovery but no subsequent 
attacks. However, relapses are possible even after a decade (Collongues et al., 
2011), and thus cases of ‘purely’ monophasic NMOSD rare – a delay of at least 5 
years has been recommended before this designation is made (Wingerchuk et al., 
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2015). These patients present with an equal gender prevalence, are generally 
younger at onset than those with a relapsing course, and a lower percentage 
present with the AQP4 antibody (Ketelslegers et al., 2011; Waters and Vincent, 
2008). Compared to the relapsing form, blindness and paraplegia following index 
events are more common, and recovery in motor scores and visual acuity is poorer; 
however, despite a poorer short-term prognosis, long-term recovery and survival 
rates are higher (Wingerchuk et al., 2007a). 
The more common relapsing course (80-90% of cases (Wingerchuk et al., 2007a)) 
is associated with the female sex, an older age at onset compared to the 
monophasic form, a longer interval between index events and the presence of 
systemic autoimmunity, followed within a few years by clusters of severe relapses 
affecting the optic nerves and spinal cord. These patients often experience periods 
of quiescence; attacks, when they occur, may be grouped in bursts over months or 
years. According to one study, the first relapse after index events occurred within 1 
year in 55% of patients, and within 5 years in 90% (Wingerchuk et al., 1999). 
The following negative prognostic factors have been identified: older age at onset, 
high relapse rate in the first year after diagnosis, severity of the first attack and 
subsequent poor recovery, and high number of brain lesions (Kitley et al., 2012; 
Uzawa et al., 2014; Wingerchuk and Weinshenker, 2003). Non-white populations 
generally have a worse prognosis (Collongues et al., 2011; Kitley et al., 2012). In a 
predominantly non-white cohort from the French West Indies, clinical predictors of 
death included a higher relapse rate during the first year, blindness or sphincter 
symptoms at onset, and lack of recovery after the first attack (Collongues et al., 
2011). In addition, the seasonal variation seen in the course of MS (with an increase 
in the risk of relapse in the summer) is not seen in NMOSD (Uzawa et al., 2014). 
Women undertaking pregnancy also face a higher relapse rate within the year after 
delivery, in contrast with the known protective effects of pregnancy in MS (Uzawa et 
al., 2014). 
Around half of patients show severe visual defects or motor impairment within 5 
years after onset (Uzawa et al., 2014); death from respiratory failure is a common 
occurrence (Wingerchuk et al., 1999). Although patients following a monophasic 
course suffer greater impairment following attacks, their long-term prognosis is 
overall better with regards to visual acuity, motor and sensory functions; relapsing 




In MS, disease progression is defined as the gradual accumulation of neurological 
impairment, with or without the presence of relapses (Lublin and Reingold, 1996). 
Wingerchuk and colleagues define a secondary progressive course in NMOSD as 
“continuous, unremitting deterioration” in clinically-assessed visual, motor or 
sensory function over a 6-month period (Wingerchuk et al., 2007b). A secondary 
phase is extremely rare in NMOSD, and cases may even be absent from large 
population-based studies (Aboul-Enein et al., 2013; Cabre et al., 2009; Collongues 
et al., 2014, 2010), despite the fact that the rate and severity of attacks is more 
pronounced, and the median age of onset older, which are both predictive factors 
for conversion to the progressive phase in MS (Wingerchuk et al., 2007b). 
Changes in NMO-IgG status may also inform the clinical course. It is known that 
initially seronegative patients may become positive upon retesting, although 
whether this is due to a genuine change in serostatus, limits in the detection 
thresholds of the assays used, or confounding factors at the time of testing is 
unknown (Jiao et al., 2013). 
Fixed impairment in MS is mostly caused by the progressive phase, whereas in 
NMOSD, residual deficits from more frequent and severe relapses are responsible 
for the accruement of disability in a ‘stepwise’ manner (Collongues et al., 2011; 
Wingerchuk et al., 2007a). The EDSS is frequently used in NMOSD to assess 
disease progression. Its limitations in terms of instrument variability, clinical 
information content, and construct validity are well-document when applied to MS 
(van Munster and Uitdehaag, 2017). Its limitations in assessing the scope of clinical 
impairment in NMOSD have also been noted (Collongues et al., 2011; Wingerchuk 
et al., 2007b). 
 
II.4.5. Pathophysiology 
NMO is an immune-mediated astrocytopathy. The target of immune attacks is the 
AQP4 protein, found on astrocyte cell membranes, which regulates water exchange 
in the CNS (Lucchinetti et al., 2014). Regions of high AQP4 expression include the 
spinal cord, optic nerves especially in posterior regions, and cerebral periventricular 
areas, in line with the preferential and severe inflammation of these areas in 
NMOSD (Pittock et al., 2006b). 
Current evidence suggests that NMO-IgG is produced peripherally, enters the CNS 
secondarily, and that other antibodies may be at the root of the observed BBB 
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disruption (Jacob et al., 2013). Peripheral administration of the antibody to mice fails 
to create an animal model of the disease, while intra-cerebral injection, or peripheral 
injection after induced BBB breakdown, does cause an ensemble of symptoms 
similar to the NMOSD phenotype (Bradl et al., 2009; Saadoun et al., 2010). 
In NMOSD, autoimmune attacks on the AQP4 water channels lead to disruption of 
water homeostasis in the CNS, although the underlying mechanisms remain to be 
fully described (Jarius et al., 2008b; Ransohoff, 2012). Inflammation, water 
retention, oedema, necrosis and demyelination occur in areas where AQP4 
expression is reduced or lost (Hinson et al., 2012). Demyelination in NMOSD is 
thought to be a secondary process, with astrocytes being the primary targets of 
autoimmune attacks (Takano et al., 2010). A possible pathway is that astrocyte 
dysfunction causes lack of support to oligodendrocytes, which in turn fail to support 
myelin (Marignier et al., 2010). Demyelination as a secondary phenomenon may 
also be due to retrograde or anterograde degeneration following neuronal loss 
(Rocca et al., 2004b). 
Neuropathological examinations of NMOSD brains have shown extensive cortical 
neuronal loss and astrogliosis, but no evidence of cortical lesions, and normal AQP4 
and myelin distributions in the cortex. This selective sparing may be due to 
structural and functional differences between WM and cortical GM characteristics 
regarding BBB permeability, or local differences in AQP4 expression that may lead 
to a different immune response in cortical regions (Popescu et al., 2010). 
Immunosuppressive treatment is usually prescribed to prevent relapses (Mealy et 
al., 2014), and plasma exchange to modulate the humoral response associated with 
attacks, stunt lesion development and neurological damage (Bonnan and Cabre, 
2011). 
 
II.4.6. Conventional MRI findings in NMOSD 
Neurological examination and structural brain and spine MRI are routine in the 
clinical assessment of NMOSD. The standard MRI sequences used in MS diagnosis 
have been described in II.3.5. 
Although limited involvement or sparing of the brain is not uncommon in NMOSD, 
definition of a characteristic brain MRI profile has been made possible by advances 
in imaging techniques and the recognition of the NMO spectrum. Since a normal 
brain MRI is extremely rare in RRMS (around 1% of patients (Wingerchuk et al., 
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1999)), a normal-seeming exam can help distinguish the two diseases. It is now 
accepted that around 50-60% of NMOSD patients show cerebral lesions, with 6-
10% displaying an ‘MS-like’ profile on MRI (Bichuetti et al., 2008a; Blanc et al., 
2008; Chan et al., 2011; Pittock et al., 2006a). Lesion load is typically greater in MS 
than in NMOSD (Matthews et al., 2013), although NMOSD patients may tend to 
have a more symmetric distribution pattern (Ito et al., 2009). In addition to qualitative 
assessment of lesion type and distribution (Juryńczyk et al., 2016), quantitative 
probability mapping has shown potential to inform differentiation between MS and 
NMOSD cases (Kister et al., 2013a; Matthews et al., 2013). 
In NMOSD, cerebral lesions are often extensive, with a blurry appearance, of 
heterogeneous intensity, and frequently follow the distribution of AQP4 channels 
around the third and fourth ventricles and cerebral aqueduct, involving the thalamus 
and hypothalamus, corpus callosum, and brainstem, with a predilection for the 
dorsal surface adjoining the fourth ventricle (Barnett et al., 2014; Cabrera-Gomez 
and Kister, 2012; Chan et al., 2011). The absence of cortical lesions, confirmed at 
ultra-high field, is considered specific to NMOSD and also helps distinguish it from 
MS (Calabrese et al., 2012; Kister et al., 2013b; Popescu et al., 2010; Sinnecker et 
al., 2012). Deep GM involvement in NMOSD will be further discussed in Chapter IV. 
Hemispheric WM lesions are only seen in 30-50% of patients. Large, confluent 
lesions with a ‘spilled ink’ appearance or a ‘spindle-like’ shape, following along WM 
tracts, are frequent (see Figure II.8-B) (Barnett et al., 2014). The temporary 
accumulation of water due to AQP4 channels disruption has been suggested as a 
possible cause for the large, diffuse and often ‘vanishing’ lesions observed 
(Cabrera-Gomez and Kister, 2012; Nakamura et al., 2009; Pittock et al., 2006a). In 
case of tumefactive, demyelinating lesions, the absence of Gd-enhancement may 
be more specific for seropositive NMOSD than MS (Ikeda et al., 2011). 
Corticospinal tract lesions are another characteristic MRI finding; these can be uni- 
or bilateral, are often extensive and follow the pyramidal tracts, via the posterior limb 




Figure II.8. Examples of brain lesions in neuromyelitis optica spectrum disorder. A: Acute, 
heterogeneous, “fluffy” lesions in the corpus callosum on a FLAIR scan. B: Lesions with a 
“spilled ink” appearance along the white matter tracts on a diffusion-weighted scan, 
suggestive of vasogenic oedema. C, D: FLAIR (left) and Gadolinium-enhanced T1-weighted 
(right) scans showing large, extensive hemispheric lesions with typical patchy enhancement 
pattern and blurred margins. Sources: A: (Barnett et al., 2014); B, C, D: (Kim et al., 2012). 
 
While callosal involvement is also frequently seen in MS, the appearance of lesions 
in this area differentiates the two conditions. A ‘marbled pattern’ in the corpus 
callosum is a typical feature of NMOSD, formed by a number of smaller lesions in 
close proximity and of varying intensities (see Figure II.8-A) (Nakamura et al., 2009; 
Pittock et al., 2006b). Another possible presentation consists in lesions lining the 
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lateral ventricles, and involving the entire thickness of the splenium in a typical ‘arch 
bridge’ pattern (Kim et al., 2012, 2010). 
Non-specific T2 lesions “in dots or patches” are frequent in the subcortical or deep 
WM, brainstem and cerebellum (Kim et al., 2015). Cystic lesions, or T1-hypointense 
areas with the aforementioned ‘black hole’ appearance, are also seen (Ito et al., 
2009). NMOSD lesions tend to be more destructive compared to MS plaques, with 
possible destruction of all cellular compartments, including axons, in addition to 
demyelination (Misu et al., 2013). At 7T, small, T2-hyperintense WM lesions were 
observed to have different characteristics from typical MS lesions: not restricted to 
venules, and without a hypointense edge (Kister et al., 2013b; Sinnecker et al., 
2012). 
Gd-enhancing lesions may appear during the acute stage, and remain as areas of 
T1-hypointensity or disappear entirely upon follow-up, suggesting heterogeneity in 
the underlying pathological processes (Cabrera-Gomez and Kister, 2012). Overall, 
Gd-enhancement is rare. The most prominent and specific feature is a ‘cloud-like’, 
patchy enhancement pattern, caused by multiple adjacent lesions with blurred 
margins (see Figure II.8-C&D). This pattern can be seen in 90% of patients with 
positive contrast enhancement, and it has been suggested it can differentiate 
between MS and NMOSD patients almost perfectly (Ito et al., 2009). Linear 
enhancement of the lining of the latera ventricles, in a ‘pencil-like’ shape, is also 
seen (Kim et al., 2015). 
Lesions can be clinically silent (Kim et al., 2016a), or result only in ‘subtle’ 
symptoms that may resolve in periods of quiescence (Pittock et al., 2006a). New 
lesions do not seem to develop between relapses (Matthews et al., 2015), but 
asymptomatic lesions may appear during ON or myelitis attacks (Kim et al., 2016a). 
Brainstem lesions are common, associated with NMO-IgG seropositivity, and 
frequently result in multiple clinical symptoms (Barnett et al., 2014). Medullary 
lesions, mainly affecting the central GM and contiguous with upper cervical lesions, 
are associated with intractable hiccups and nausea (Cabrera-Gomez and Kister, 
2012). Hypothalamic lesions are common to both NMOSD and MS (Ito et al., 2009), 
may be linked with narcolepsy-like hypersomnia and behavioural changes (Barnett 
et al., 2014; Pittock et al., 2006b; Viegas et al., 2009), and appear independently of 
other parenchymal lesions (Poppe et al., 2005). Lesions in the frontal, parietal and 
occipital lobes have been linked with cognitive impairment (Barnett et al., 2014). 
Other clinical symptoms linked with focal pathology may include trigeminal 
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neuralgia, vertigo, dysphagia, aphasia, hemiparesis, ataxia, facial weakness or 
sensory loss (Asgari et al., 2013b). 
In the spinal cord, the main feature is the presence of LETM, defined as a 
transverse inflammatory lesion extending over at least 3 vertebral segments. Cord 
lesions in NMO can be located in the upper thoracic region or more frequently in the 
cervical cord, and may be contiguous with the brainstem (Asgari et al., 2013b; 
Cassinotto et al., 2009). Typical lesions have an irregular appearance, with bright, 
spotty T2 hyperintensity and the same “patchy” enhancement pattern that occurs in 
the brain, and can stretch over 4-7 segments (Nakamura et al., 2008). As these are 
rarely seen in MS, and visible on conventional MRI, lesion type and length are 
useful in differentiating the two (Krampla et al., 2009). 
The central GM is frequently involved in the acute stage (Nakamura et al., 2008), in 
contrast with preferential involvement of the dorsal and lateral WM in MS. 
Characteristic MRI findings include central T2-hyperintensity of the cord, visible on 
axial scans. Ring enhancement is commonly seen in NMOSD cord lesions (in about 
a third of patients that present with cord involvement), although this can also occur 
in MS, albeit more rarely (Zalewski et al., 2016). T1-hypointensity, necrosis and 
cavity formation are other features seen in NMOSD not typical of MS (Barnett et al., 
2014; Cassinotto et al., 2009; Nakamura et al., 2008). 
Despite LETM being the most specific MRI finding in adults with NMOSD, ‘short’ 
TM, defined as a T2-hyperintense lesion extending less than 3 vertebral segments, 
can also arise. During a first episode of myelitis, 14-14.5% of NMOSD patients 
present with short TM as opposed to LETM, whether or not myelitis is the heralding 
manifestation of the disease (Flanagan et al., 2015; Huh et al., 2017). A first myelitis 
episode presenting with short TM is most commonly followed by the occurrence of 
LETM. Because this presentation is atypical in NMOSD, and more commonly seen 
in MS, it can lead to delays in diagnosis and treatment (Flanagan et al., 2015). 
Moreover, lesion length is known to evolve over time, and thus appearance at the 
time of a single MRI may not suffice to classify the lesion as short or longitudinally 
extensive TM. Cord swelling can occur during the acute phase, and lesions can 
grow over a period of days (Asgari et al., 2013a). Lesions can subsequently be 
broken down following treatment with steroids, resolve into multiple shorter lesions 
during remission (Asgari et al., 2013b; Cassinotto et al., 2009), or disappear entirely 
on conventional imaging (Collongues et al., 2011). Cord atrophy is frequent and 
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severe, especially focally at sites of previous lesions; the patterns of atrophy 
particular to NMOSD will be discussed in Chapter V.  
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Chapter III. Intra-scanner reliability of 
mcDESPOT in healthy older adults 
 
In this chapter we present a single-site study on the test-retest reliability of several 
quantitative metrics (myelin water fraction, and longitudinal and transverse 
relaxation times) derived from a mcDESPOT protocol, in healthy adults aged over 
50 years old at three time points over one month. 
 
Disclaimer: This study made use of the National Institute for Health Research 
(NIHR) Wellcome Trust King's Clinical Research Facility (CRF) MRI scanning 
facilities. The views expressed are those of the authors and not necessarily those of 
the UK National Health Service (NHS), the NIHR or the UK Department of Health. 
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Multicomponent Driven Equilibrium Single Pulse Observation of T1 and T2 
(mcDESPOT) is a relaxometry-based technique that allows whole-brain, voxel-wise 
determination of several quantitative parameters related to tissue microstructure, 
including the longitudinal and transverse relaxation times T1 and T2, and the myelin 
water fraction (fM). As a quantitative method yielding biologically stable and 
putatively platform-independent values, assessment of reproducibility is paramount. 
In this chapter we investigate the intra-scanner reliability of several parameters 
output by mcDESPOT8 at 3 Tesla (T). We present results from a scan-rescan study 
in healthy adults between 50 and 75 years old at three time points on a single 3T 
scanner, using intraclass correlation coefficient (ICC) and coefficient of variation 
(CV) measures to assess within-subject reliability at the voxel and region of interest 
(ROI) level for T1, T2 and fM. 
                                                
8 mcDESPOT technically refers to the multicomponent acquisition and processing technique. 
Here we use mcDESPOT to refer to the complete protocol from which both single-and 
multicomponent analyses can be carried out, using the appropriate corrections schemes for 
high-field acquisitions: High-Speed Incorporation of RF Field Inhomogeneities (HIFI) (Deoni, 




III.2.1. Concept of reliability 
In research concerned with quality assurance of magnetic resonance imaging (MRI) 
measurements, the following terms: repeatability, reliability, reproducibility, 
accuracy, precision, are often used interchangeably, or accompanied by conflicting 
definitions. The aim of the present study was to determine whether quantitative 
measurements from mcDESPOT on the same stable subjects, under the same 
conditions, are consistent, as a prerequisite for its use in cross-sectional and 
longitudinal investigations. Thus here, we are concerned with reliability and 
precision, which are related but distinct concepts. 
For an intuitive understanding of the concepts of accuracy and precision, the 
‘bullseye metaphor’ is often employed, with the following two illustrative examples: 
several marks centred around the middle of a target but with a large spread (high 
accuracy, low precision), and several marks close together but off-centre (high 
precision, low accuracy). Assessing the accuracy of a measurement necessitates 
comparing observations with its ‘true’ value, therefore requiring a gold standard 
measurement to be performed, or an objective truth to be known a priori, e.g. in 
phantoms or using histological validation. Since this is rare in human imaging, we 
are often more concerned with precision (Tofts, 2003b), i.e. how ‘close together’ 
repeated measurements are compared to the quantity measured. Precision can be 
measured with the CV, or ratio of the standard deviation of a measurement to the 
mean. 
The psychometric definition of reliability is the ratio of subject variability, to subject 
variability plus measurement error (Streiner et al., 2015). With a perfect, highly 
precise instrument, repeated measurements of the same stable quantity would yield 
identical measures; any variation would be attributed to measurement error. 
However, in a real-world context, reliability is also related to the information value of 
a measurement as it enables discrimination between subjects or groups (Streiner 
and Norman, 2006). According to this definition, an instrument that yields the same 
measurement for a supposedly heterogeneous group of subjects, tested several 
times and yielding perfectly identical measures between trials, will have poor 
reliability, since inter-subject variability is low (even though the error may be low or 
null). Examples of the relationship between sample variance and reliability are 





Figure III.1. Three examples of test-retest data with varying degrees of reliability, and how 
they relate to commonly used statistical measures: the coefficient of variation (CV) and 
intraclass correlation coefficient (ICC). Each symbol type represents a subject, with five 
repeat measurements across time on the x-axis. In all cases we assume the “true” value for 
each subject to be the average of all their repeat measurements (i.e. assuming perfect 
accuracy). Case 1 (left): high between-subjects variance, and low within-subject variance. 
The inter-subject variance is much greater than the intra-subject variance, hence would yield 
low CVs and very high ICC. Case 2 (middle): low within- and between-subjects variance. 
According to the ‘classic’ definition (Streiner et al., 2015), reliability is poor because 
information gained about subject differences is null. This scenario would result in good CVs, 
but a poor ICC, as this instrument applied to this particular population cannot be relied upon 
to discriminate between subjects. Case 3 (right): low between-subjects variance, high 
within-subject variance, yielding poor reliability overall. In this experimental situation the 
variance between repeat measurements is similar to, or greater than the variance between 
subjects, which would produce high CVs and a low ICC. From (Vavasour et al., 2006). 
 
 
Reproducibility in imaging studies often refers to the agreement of measures taken 
at different sites, with the aim of assessing compatibility between identical scanners, 
different models from the same vendor, or different systems. In the present study, 
we are concerned with the test-retest reliability of a measurement, i.e. the 
consistency between scan-rescan acquisitions. Intuitively, this means how much we 
can trust that repeated measurements of the same subject will yield consistent 
measures, that error measurement is small, and that therefore any differences 
measured between subjects and/or time points are due to a true effect. Assessing 
the reliability of a measurement on a single platform is a first step towards 
establishing its cross-platform reproducibility; if different platforms are assumed to 
be reliable, then the presence of systematic bias across sites is easier to account 
for. Obtaining stable, precise measurements is necessary to draw information on 
 
78 
differences between groups, pool together datasets from different centres, or follow 
individuals across several time points. The latter may include longitudinal studies 
that follow the same subjects over time (e.g. developmental studies, clinical trials), 
or use several time points to compare different conditions (e.g. intervention studies). 
 
III.2.2. Previous work 
mcDESPOT is a quantitative technique that, in theory, yields measures that are 
platform-independent. As mcDESPOT is being increasingly used in developmental 
research in cohort studies necessitating several time points, and multi-centre 
studies are becoming commonplace, information on the reliability of the technique is 
required. 
While no study to date has focused on assessing the protocol’s reliability, several 
published methodological papers have included assessments of inter-scanner 
reproducibility and intra-subject reliability, which are summarized in Table III.1. 
Overall, estimates for intra-site reliability (employing both voxelwise and ROI 
approaches) are good for T1 and fM, and slightly worse for T2, although all studies 
bar one were performed at 1.5T, and all had very small sample sizes (1-9 subjects 
maximum for repeat measurements). We further these efforts in the current project, 
the first to directly address intra-scanner reliability in a larger sample and at several 
time points. 
Of note, we only present here studies that address scanner and acquisition 
variation. Investigations into the stability and precision of the mcDESPOT algorithm 
itself are also an area of investigation (Lankford and Does, 2013). It has however 
been shown to be robust under the right conditions (mainly: adequate signal-to-
noise ratio (SNR); choice of appropriate bounds; use of three-pool model and 
appropriate field corrections schemes) (Deoni and Kolind, 2015). 
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Table III.1. Studies addressing the intra- and/or inter-scanner reproducibility of DESPOT or mcDESPOT-derived parameters. 
Study Field strength 
Sequence, 





1 WM phantom 
4 scans 
Scan-rescan CV for T1: 6.4% 










7 HC (3 F, 22-34y ) 
All scanned twice at 
each of 3 sites 
4 scanned 3 times at 
site 1, 3 scanned 3 
times at site 2 
Mean whole-brain voxelwise CVs: 
T1: 6.4 ± 0.52% 
T2: 7.9 ± 0.71% 
Voxelwise paired t-tests for scan vs. rescan: no significant 
difference (p > 0.1). 
No differences in whole-brain histogram distributions overall 
(Kolmogorov-Smirnov test). 
Mean voxelwise CV: 
T1: 6.8 ± 0.67% 
T2: 8.3 ± 0.92% 
No significant difference 
voxelwise (p > 0.1). 










9 HC (6 F, 23-41y) 
All scanned twice (5 
at site 1, 4 at site 2) 
7 subjects scanned 
at 2 sites  
All within 1 week 
Voxelwise paired t-tests for scan vs. rescan (normalized, 
smoothed maps): no significant difference (p > 0.1). 
CVs across 3 GM ROIs (thalamus, putamen, globus 
pallidus): ~7-10% 
CVs across 4 WM ROIs (genu, body, splenium of corpus 
callosum, frontal WM): ~4-8% 
No significant difference 
voxelwise for site 1 vs. 2 
(p > 0.1). 
CVs across ROIs in GM: 
~8-11% 










5 HC (4 F, 23-35y) 
2 scans within 3 
months 
Scan-rescan CV across the entire cervical spinal cord. 
T1: mean 0.9% (range 0.4-1.7%) 
T2: 6% (1.5-13.3%) 














7 HC, 9 PPMS 
2 scans within 2 
weeks 
Scan-rescan CV for mean fM within each tissue type: 
In HC – GM: 7.9%; WM: 3.8% 
In PPMS – NAGM: 14.3%; NAWM: 4.7% 
TBSS at each time point; voxelwise CV between each 
skeleton pair. 
Median CV (range) across skeleton for HC: 5% (3.5-6.5%) 
For PPMS: 5.8% (4.5-7.5%). 
Visual inspection of CVs on TBSS skeleton showed uniform 












1 HC (M, 24y) 
5 scans over 5 weeks 
Mean voxelwise CV within 5 ROIs (frontal, occipital, 
cerebellar WM, thalamus): 5-6.5% 
N/A 
Studies are listed in chronological order. When exact values are not given in the original publication, estimated values derived from plots are reported here. 
CV: coefficient of variation. fM: myelin water fraction. GE: General Electric. GM: grey matter. HC: healthy control. M/F: male/female. N/A: Not Applicable. 
NAGM: normal-appearing GM. NAWM: normal-appearing WM. PPMS: primary progressive multiple sclerosis. ROI: region of interest. TBSS: tract-based 
spatial statistics. T: Tesla.  WM: white matter. y: years old.
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III.2.3. Choice of sample 
When testing reliability in human subjects, the chosen sample should be 
representative of the larger population that the instrument under investigation is to 
be applied to, especially when statistical techniques are used that make use of the 
group variance, as is the case with the ICC. The use of a heterogeneous sample is 
often recommended to obtain meaningful statistical estimates (Portney and 
Watkins, 2009), as reliability may be underestimated if the inter-subject variance is 
lower in the control group used for reliability assessment than in a future patient 
group (Tofts, 2003a). 
For most applications in adult populations and, in the present case, with regards to 
application to demyelinating diseases, we posit that reliability measures collected 
among an older group are likely to be more representative of data acquired as part 
of clinical studies or trials, for several reasons. One, older subjects are more likely 
to exhibit motion during scanning, which leads to artefacts and decreased image 
quality. Two, the robustness of preprocessing pipelines is likely to diminish in 
ageing brains as ventricular and sulcal enlargement, demyelination and non-
specific focal lesions are known to occur even in healthy subjects. Three, we expect 
a wider range of biological variation in people over 50 than in younger ‘super-
controls’, while still being a more homogeneous population than a patient group,  
and thus representing  a compromise between under- and over-estimation of 
reliability. By selecting participants nominally aged 50-75, we hoped to test the 
reliability of the protocol under conditions resembling those observed in clinical 





Sixteen healthy, right-handed participants (8 males, aged 51-72, mean age = 59 ± 7 
years) were recruited via recruitment circulars at King’s College London and a local 
Third Age University. Participants had no known neurological abnormalities or pre-
existing conditions and were mentally and physically healthy, as determined by self-
report. The study was approved by the King’s College London Psychiatry, Nursing 
and Midwifery Research Ethics Sub-Committee (approval number: PNM/12/13-58) 
and written informed consent was obtained from all subjects. 
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Participants were scanned on a GE 3.0T Discovery MR750 at the NIHR Wellcome 
Trust King’s Clinical Research Facility, King’s College Hospital. Collection of 
mcDESPOT data was part of a larger study (‘Serial Assessment of Good Ageing’ – 
SAGA) that aimed to assess reproducibility of several structural and functional MRI 
sequences in healthy older adults. The mcDESPOT sequence was situated at 
around the one-hour mark into an hour-and-a-half scanning session. Participants 
were scanned three times on the same scanner at baseline, 1 week (range 2-10, 
median 7 days) and 4 weeks (range 20-38, median 28 days), as no significant 
global changes in relaxation times were expected to occur within this time frame. 
 
MRI acquisit ion 
The protocol consisted of nine spoiled gradient recalled (SPGR) images at different 
flip angles (α), one inversion recovery SPGR (IRSPGR) image, and eight balanced 
steady-state free precession (bSSFP) images with phase-cycling at 0° and 180° for 
correction of B0 inhomogeneity, all acquired in sagittal orientation. The 12-channel 
head portion of a head/neck/spine coil was used for signal reception. Total 
acquisition time was under 15 minutes. Repetition (TR), echo (TE), and inversion 
times (TI) below are in milliseconds (ms). 
SPGR: TR/TE = 8/3.6; α = [2, 3, 4, 5, 6, 7, 9, 13, 18]°; matrix size = 128 x 128 x 
102; voxel size = 1.7 mm3 isotropic. 
IR-SPGR: TR/TE = 8/3.6; TI = 450; α = 5; matrix size = 220 x 110 x 88, 
reconstructed to 220 x 220 x 88; voxel size = 1 x 1 x 2 mm. 
bSSFP: TR was dependent on the specific absorption rate, which is determined by 
the scanner based on subject weight and ‘coil loading’ (itself dependent on the 
participant’s exact position within the scanner). This meant variability between 
participants and in a few cases sessions, ranging between 3.66-4.03 ms (mean 
3.82). The actual TR for each subject, at each session, was collected from the 
image header and used for analysis. TE = TR/2; α = [12.4, 16.5, 21.62, 27.8, 34.0, 





I I I .3.2.1.  Preprocessing 
Preprocessing steps were carried out using FMRIB’s Software Library (FSL) (Smith 
et al., 2004). 
In order to create mcDESPOT maps, the 26 images that compose the protocol 
need to be motion-corrected. Here we describe a combined motion correction and 
inter-session registration scheme that was found to perform well on the current 
dataset while only resampling each image once. All linear registrations were 
performed with FSL’s Linear Image Registration Tool (FLIRT), using a mutual 
information cost function, 6 degrees of freedom (DOF) unless otherwise specified, 
and sinc interpolation. 
1) Within each session, the SPGR 18° was chosen as a reference image as it 
possesses good grey/white matter contrast – an important feature for 
successful registration using FLIRT (Jenkinson and Smith, 2001). 
2) For each subject, all three SPGR 18° images were co-registered to a mid-
space by deriving the average transform from co-registration between the 
three time points. This procedure is similar to the one used in the FSL tool 
Structural Image Evaluation, using Normalization, of Atrophy (SIENA) for 
registering several time points for the same subject (Smith et al., 2002). 
3) All remaining SPGR scans and the IR were registered to the SPGR 18° in 
this mid-space. Registration of the IR scan used 12 DOF, as this was found 
to perform better by accommodating the different acquisition resolution of 
this image. 
4) The SSFP images represent a different problem; due to banding artefacts, 
failure of registration is more frequent. A two-step procedure was therefore 
implemented. Within each SSPF phase cycle (8 images), the lowest flip 
angle image (12.4° – the one with the least amount of banding appearing 
across the brain) was registered to the SPGR 18° in mid-space. Then, for 
each phase cycle, the remaining SSFP scans were registered to the 
corresponding SSFP in mid-space.  
Following brain extraction using FSL’s Brain Extraction Tool (BET) (Smith, 2002), 





I I I .3.2.2.  Creating maps 
The implementation of the mcDESPOT calculation algorithm that was used here is 
part of the Quantitative Imaging Tools (QUIT) suite9. The processing pipeline for 
single- and multi-component DESPOT analysis consists in the following four steps, 
which follow the procedure described in II.2, except where noted below. 
1) Run DESPOT1-HIFI processing, to obtain B1 map. 
2) Run DESPOT1 processing, using the B1 map from step 1, to obtain T1 map. 
When only two SPGR flip angles are acquired, DESPOT1 and the HIFI 
extension default to linear least squares (LLS) fitting. Use of a nonlinear LLS 
algorithm is made possible by acquisition of more than two SPGR flip angles 
– here, nine. Theoretically, given the adequate SNR of SPGR scans at 3T, 
the nonlinear LLS algorithm affords higher precision and accuracy (Chang et 
al., 2008). 
3) Run DESPOT2-FM processing, using the T1 and B1 maps from step 2, to 
obtain off-resonance (f0) and T2 map. A nonlinear optimization method is 
used. 
4) Run mcDESPOT processing, with previously obtained B1 and f0 maps. This 
produces final estimates of all parameters, including fM. 
 
I I I .3.2.3.  Post-processing 
Tissue-type segmentation and ROIs were obtained for each subject. To achieve 
this, the mid-space image created above (by averaging each subject’s three co-
registered SPGR 18°) was used as a target image. Nonlinear transforms from each 
subject’s target to the MNI152 structural template10 (Evans et al., 1997) were 
derived with FSL’s Nonlinear Image Registration Tool (FNIRT) (Andersson et al., 
2007), using the default scheme optimized for normalization of a T1-weighted scan. 
The following standard-space ROIs were selected: 
- ROIs for the caudate, putamen and thalamus were extracted from the MNI 
structural atlas10. 
                                                
9 Details and code can be found at: http://github.com/spinicist/QUIT. 




- Bilateral spherical ROIs in the frontal white matter (WM) were hand-drawn 
on the MNI152 template. 
- ROIs in the genu, body, and splenium or the corpus callosum were hand-
drawn on the MNI152 brain, based on region identification from the John 
Hopkins University DTI-based WM atlas11 (Hua et al., 2008). 
- Corticospinal tract (CST) and optic radiation (OR) masks were obtained 
from the Jülich histological atlas12 (Eickhoff et al., 2007). 
The ROI masks were transformed from standard to mid-space using the inverse of 
each subject’s nonlinear transform, and thresholded at visually determined levels 
before binarizing. 
Tissue-type segmentation was performed on each subject’s average mid-space 
SPGR 18o image using FSL-FAST (Zhang et al., 2001), with partial volume 
estimation (PVE). Cerebrospinal fluid (CSF), grey matter (GM) and WM masks 
were created from the PVE maps, using conservative thresholds in order to exclude 
voxels with partial volume effects. The aforementioned CSF masks were used to 
exclude non-brain voxels where appropriate. Additionally, brainstem and 
cerebellum masks were obtained from the MNI and Harvard-Oxford subcortical 
atlases10, respectively, and used to mask out infratentorial areas (e.g. for the CST 
and WM masks). Example ROIs are shown in Figure III.2. 
 
                                                
11 JHU-WhiteMatter-labels-2mm atlas: 
http://neuro.debian.net/pkgs/fsl-jhu-dti-whitematter-atlas.html 





Figure III.2. Example regions of interest, overlaid on an SPGR image. A: corpus callosum 
genu, splenium (yellow), body (orange). B: optic radiations. C: corticospinal tracts. D: frontal 
white matter (red), putamen (blue), caudate (pink), thalamus (purple), corpus callosum genu 
and splenium (yellow). E: white matter mask. F: eroded, ‘conservative’ white matter mask. 
 
 
III.3.3. Reliability assessment 
Overview 
Our aim was to assess test-retest reliability of parameter maps. In the following 
sections, example figures from representative participants are displayed, along with 
tables presenting group average metrics. We present voxelwise (histogram, CV 
maps) and ROI-specific results (CVs and ICC for mean parameter values). Bilateral 
ROIs were analysed separately in case asymmetrically distributed artefacts were 
present. Statistical analysis was conducted in R version 3.3.2 (R Core Team, 2017). 
 
Coefficient of variation 
The CV is a measure of variability that corresponds to the ratio of the standard 
deviation to the mean of a sample: 
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CV = standard	deviationmean ∗ 100 
Some caution must be exercised in interpretation of the CV. It is sensitive to the 
quantity being measured, i.e. it will near infinity when the mean is close to zero, and 
cannot be computed for a variable with a negative mean. 
CVs can be computed voxelwise, or on an ROI basis. CV maps enable visualization 
of spatial patterns of variability. An ROI-based approach, ubiquitous in research 
(e.g. tracking changes in segmented lesions over time) is likely to be more reliable, 
since the SNR will be higher when the measure is the average, or median, of many 
voxels. 
CV maps were created for each subject by computing the CV voxelwise across 
sessions. We present CV maps for visual inspection, summary metrics of voxelwise 
reliability, and average CVs within the chosen ROIs. 
Although interpretation of CV should be case-specific and based on the variable of 
interest, Duval et al. considered scan-rescan CVs < 10% to be good values for 
quantitative MRI metrics (Duval, 2016). 
 
Intraclass correlation coefficient 
The ICC is a measure of reliability that was originally used in the social sciences for 
determining agreement between raters or judges. Since every article that describes 
the ICC mentions the ‘confusion’ surrounding both its implementation and 
interpretation, in neuroimaging as in other fields, it must be used carefully when 
dealing with test-retest data, when the raters are, in fact, multiple scanning 
acquisitions. In its simplest form, it is summarized by Tofts (Tofts, 2003a) as: 
ICC = variance	between	subjectsvariance	between	subjects+	variance	within	subjects	 
It can therefore be described as the proportion of variance that can be attributed to 
the phenomenon of interest, once instrument variability (measurement error) is 
taken out (Fleiss, 1999).  
The ICC is based on variance estimates, and thus a proper ANOVA model must 
first be defined. In the present case, a two-way mixed model was chosen, with 
subjects treated as random effects and sessions as fixed, measuring absolute 
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agreement between repeated measures. Moreover, we are interested in the 
reliability of a single measurement (i.e. reliability as it applies to a measurement 
made at a single time point, not the average of two or more scanning sessions). 
This design corresponds to an ICC(3,1) according to the nomenclature defined by 
Shrout and Fleiss (Shrout and Fleiss, 1979), the recommended metric for test-retest 
reliability assessment (Portney and Watkins, 2009). In order to measure absolute 
agreement, the error variance (representing the interaction between subjects and 
sessions, or measurement error for each data point (McGraw and Wong, 1996)) is 
added to the denominator representing the total variance in the equation above 
(Lewis-Beck et al., 2004). 
Fleiss proposed the following interpretation of ICCs: poor below .40, “fair to good” 
between .40 and .75, and excellent above .75 (Fleiss, 1999). 
ICC calculations were made using ICC, part of the psych package in R. 
 
III.4. Results 
III.4.1. Example data 
Example of an acquired protocol is shown in Figure III.3. Representative slices 




Figure III.3. Example of a mcDESPOT acquired protocol. Flip angles are indicated below each image; for full acquisition parameters, see III.3.1. IR-SPGR: 
inversion recovery SPGR. pc: phase cycle. SPGR: spoiled gradient recalled. bSSFP: balanced steady-state free precession.
90 
 
Figure III.4. Representative maps for one subject at baseline, 1 and 4 weeks. Subject 
shown is a 55-year-old male. fM: myelin water fraction. (m)s: (milli)seconds.  
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III.4.2. Absolute measurements 
Average values, across all three sessions and subjects, are presented in Table 
III.2. Data for each ROI, at each time point are shown in Figure III.10, Figure III.11 
and Figure III.12 at the end of this chapter. 
 
Table III.2. mcDESPOT values for each parameter averaged across subjects and sessions. 




Left 1362.99 ± 54.97  60.23 ± 3.88  0.062 ± 0.02 
Right 1388.84 ± 44.41  63.12 ± 6.2  0.055 ± 0.015 
Putamen 
Left 1297.28 ± 66.86  58.94 ± 5.04  0.091 ± 0.031 
Right 1339.18 ± 62.4  63.79 ± 6.32  0.07 ± 0.023 
Thalamus 
Left 1229.85 ± 48.13  56.36 ± 3.59  0.119 ± 0.026 





Genu 849.07 ± 37.04  34.44 ± 3.57  0.275 ± 0.012 
Body 897.67 ± 34.06  38.46 ± 2.79  0.273 ± 0.01 
Splenium 873.4 ± 36.91  43.81 ± 3.39  0.273 ± 0.01 
Frontal 
Left 879.12 ± 41  40.37 ± 3.44  0.248 ± 0.016 
Right 893.86 ± 41.6  42.98 ± 3.59  0.243 ± 0.02 
Corticospinal 
tract 
Left 920.36 ± 31.88  49.12 ± 3.06  0.247 ± 0.011 
Right 922.47 ± 32.82  50.72 ± 2.77  0.252 ± 0.009 
Optic  
radiation 
Left 899.13 ± 40.04  41.14 ± 3.19  0.266 ± 0.013 
Right 922.81 ± 41.14  47.05 ± 3.5  0.254 ± 0.012 
Average ± standard deviation across subjects. fM: myelin water fraction. ms: milliseconds. 
 
III.4.3. Voxelwise reliability 
Histograms 
To visualise the frequency distributions of intensity values within the calculated 
maps, whole-brain histograms were created with the following specifications. 
- T1: 30 bins between 0 and 3000 ms for T1, whole-brain 
- T2: 20 bins between 0 and 200 ms for T2, whole-brain 
- fM: : 35 bins between 0 and 0.35, within WM only 
We present data from two representative subjects for each session, and a 
comparison between the two in Figure III.5. 
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Coefficient of variation maps 
Example CV maps for two subjects are shown in Figure III.6. 
Mean CVs were calculated across all voxels for T1 and T2, and within the WM for fM. 
Due to the expected high variability in GM in fM in cortical areas we only report 
voxelwise CVs for WM. Average ± standard deviation across the whole group are 
presented in Table III.3. 
 
Table III.3. Voxelwise reliability for all three parameters. 
 Voxelwise coefficient of variation (%) 
 T1  T2  fM 
Whole-brain 3.66 ± 0.59  13.17 ± 2.40  - 
White matter 2.60 ± 0.61  10.37 ± 2.51  11.51 ± 4.38 
‘Core’ white matter 2.04 ± 0.38  8.21 ± 2.16  9.02 ± 1.99 
Average ± standard deviation across subjects. fM: myelin water fraction. 
 
III.4.4. ROI-specific reliability 
CV and ICC results for selected ROIs are presented in Table III.4. The distribution 
of individual CVs are visualized in Figure III.7, Figure III.8 and Figure III.9. 
Inspection of the ROIs-wise CVs plot showed no apparent bias towards better or 
worse reliability within left vs. right regions.
93 
 
Figure III.5. Example parameter histograms for two subjects. In the first two columns, histograms for each of the three scans are overlaid, showing near-
perfect agreement for all three parameters. In the last column, average across the three sessions for each subject are overlaid, showing visible differences in 
distributions. Histograms are normalized by the total number of voxels considered (therefore the y-axis on each plot is a fraction). Subject 1: female, 53 years 




Figure III.6. Example coefficient of variation maps, across the three time points, for two 
subjects. Subject 1: female, 53 years old. Subject 2: male, 69 years old. 
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Table III.4. Reliability metrics for T1, T2, and myelin water fraction across three time points. 
   T1  T2  fM 




Left 1.08 ± 0.74 0.91  5.88 ± 4.96 0.26  14.83 ± 7.91 0.69 
Right 1.39 ± 1.16 0.75  6.22 ± 6.30 0.42  17.61 ± 8.55 0.59 
Putamen 
Left 0.96 ± 0.47 0.96  3.64 ± 2.10 0.80  11.08 ± 5.37 0.87 
Right 1.28 ± 0.83 0.90  3.77 ± 1.62 0.85  15.00 ± 8.49 0.85 
Thalamus 
Left 1.10 ± 0.63 0.90  3.57 ± 2.39 0.65  8.69 ± 4.85 0.81 




Genu 1.18 ± 0.91 0.90  5.63 ± 5.15 0.60  2.67 ± 2.06 0.58 
Body 1.00 ± 0.51 0.92  6.07 ± 2.97 0.45  2.28 ± 1.52 0.58 
Splenium 1.01 ± 0.45 0.94  3.53 ± 2.60 0.74  1.98 ± 0.93 0.74 
Frontal 
Left 1.18 ± 0.70 0.92  4.39 ± 2.60 0.71  4.05 ± 2.17 0.66 
Right 1.30 ± 0.69 0.91  4.25 ± 2.09 0.75  4.06 ± 3.37 0.72 
Corticospinal 
tract 
Left 1.03 ± 0.62 0.89  3.09 ± 1.40 0.76  2.40 ± 1.51 0.68 
Right 0.88 ± 0.35 0.93  3.31 ± 1.47 0.67  2.69 ± 1.64 0.50 
Optic radiation 
Left 0.88 ± 0.63 0.94  2.99 ± 1.62 0.83  1.53 ± 1.17 0.88 
Right 0.85 ± 0.46 0.95  2.67 ± 1.51 0.85  2.80 ± 1.54 0.65 





Figure III.7. Coefficients of variation for T1 across three sessions. Data points outside of boxplot whiskers are outliers, defined as being beyond 1.5 
interquartile range of each quartile. CC: corpus callosum. CST: corticospinal tract. L/R: left/right. OR: optic radiation.   
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Figure III.8. Coefficients of variation for T2 across three sessions. Data points outside of boxplot whiskers are outliers, defined as being beyond 1.5 
interquartile range of each quartile. CC: corpus callosum. CST: corticospinal tract. L/R: left/right. OR: optic radiation.  
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Figure III.9. Coefficients of variation for fM across three sessions. Note the large range (0-40%) to accommodate the high CVs in grey matter, while CVs in 
white matter are mostly under 5%. Data points outside of boxplot whiskers are outliers, defined as being beyond 1.5 interquartile range of each quartile. CC: 
corpus callosum. CST: corticospinal tract. fM: myelin water fraction. L/R: left/right. OR: optic radiation.
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III.5. Discussion 
III.5.1. Reliability of T1 
T1 values were in the 1200-1350 ms range for GM, and 850-900 ms range across 
WM regions. 
These values are overall lower than previous estimates using DESPOT1-HIFI, 
reported as ~1500-1600 ms in deep grey matter structures and ~1100 ms in WM 
(Deoni, 2007). In an experiment at 3T using saturation recovery, Wansapura et al. 
reported an average value of 1331 ms (range 1283-1392) in GM structures, and 
832 ms (range 827-838) across WM ROIs (Wansapura et al., 1999). 
Our results are reasonably in line with these values, although T1 in both GM and 
WM appear slightly underestimated here. A possible explanation for this 
discrepancy is that inadequate B1 correction will result in inaccurate calculated T1 
values, which may be the case since visual inspection of B1 maps showed relatively 
high deviation between prescribed and transmitted flip angle. 
Average CV within WM was very low for T1 (< 3% on average across subjects), and 
CV maps show uniformly high reliability across the brain. Reliability was equally 
good in both GM and WM, with ROI-wise CVs around 1% and ICCs consistently > 
0.90, denoting excellent reliability in the studied sample. 
 
III.5.2. Reliability of T2 
We report mean T2 values between 55-63 for GM, and 35-50 for WM structures. 
Using a multiple spin-echo approach, Wansapura et al. measured values around 
98-132 (mean 110) for GM structures, and 74-84 (mean 80) in WM. Deoni (Deoni, 
2009a) reported the following T2 values using DESPOT2-FM (values given are 
range across four healthy volunteers): frontal WM: 48-53, thalamus: 70-76, 
putamen: 66-72, caudate: 78-86. The values in the present study, for the same 
ROIs as Deoni et al., are consistently lower (frontal WM: mean ~41, thalamus: ~56, 
putamen: ~61, caudate: ~61). 
Overall, T2 values here are lower in both GM and WM compared to previous studies 
using either DESPOT or other methods. DESPOT2 is known to provide lower T2 
estimates compared to traditional methods, due to magnetization transfer (MT) 
effects in tissue that arise due to short RF pulses used to achieve steady state in 
the bSSFP acquisition (Crooijmans et al., 2011). 
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CVs were low for T2: between 3-6.5% for all structures, in line with previous 
reliability studies using DESPOT2 (see Table III.1). However, ICCs were overall 
only moderate, both for GM (range 0.26-0.85) and WM (range 0.45-0.76). ICCs 
showed great variability across ROIs, but also for the same structures between left 
and right hemispheres. Voxelwise estimates were moderately good, with a mean 
voxelwise CV of ~13% across the whole brain, ~10% in WM. 
 
III.5.3. Applications of T1 and T2 mapping 
DESPOT1&2 have high efficiency, defined as accuracy over scan time, rivalled only 
by that of MR fingerprinting (Deoni et al., 2003; Ma et al., 2013). 
The excellent reliability of T1 maps using DESPOT1-HIFI shown here, both 
voxelwise and using an ROI approach, supports the use of the technique for 
several research applications, examples of which are listed hereafter. 
T1 is strongly related to water content, and has been used in the study of multiple 
sclerosis (Neema et al., 2007) and epilepsy (Deoni, 2010). T1 in the cerebral cortex 
has been suggested to reflect in large part myelin content (Lutti et al., 2014), 
although this interpretation has been criticized (MacKay and Laule, 2016). T1 maps 
have also been used to improve segmentation estimates of particular structures 
(Deoni et al., 2007; Deoni and Catani, 2007) and to yield reliable tissue-type volume 
estimates (Deoni et al., 2008b). T2 is influenced by iron content, and therefore also 
has applications in the study of neurological conditions, such as Parkinson’s 
disease and Alzheimer’s disease (Brass et al., 2006).  
Relaxation time mapping is not limited to neuroimaging, and has applications in 
imaging of tissue throughout the body, i.e. heart, muscle, cartilage, breast and 
prostate tumours, etc. Another application is synthetic imaging, which refers to the 
creation of computer-generated structural images given chosen acquisition 
parameters and relaxometry data. Using this method, an effectively infinite range of 
images can be created at different T1/T2 weightings, the advantage being images 
free of artefacts, and the possibility of generating many different contrasts from a 
single acquisition (i.e. an economy of scanner time). An example is shown in Deoni 
et al. (Deoni et al., 2006), although preliminary research has shown limited 
advantages compares to conventional images in terms of diagnostic utility (Blystad 
et al., 2012). 
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III.5.4. Reliability of fM 
We observed, as expected, very low fM values in the deep grey matter, slightly 
higher (~0.12-0.14) in the thalamus (of mixed GM/WM content), and the highest 
values in the callosal ROIs (~0.27) compared to other WM ROIs (0.24-0.25). 
These values are higher than those usually observed with other methods (Alonso-
Ortiz et al., 2015), a known phenomenon possibly also due in part to the influence 
of MT effects described above in III.5.2. While these would be expected to yield 
higher fM values, an experiment showed minimal effect using a two-pool model (J. 
Zhang et al., 2015). However, these interactions have not been assessed with the 
three-pool model used here, and thus, their influence cannot be ruled out. 
CV maps showed better voxelwise reliability within WM than GM. Reliability in GM 
was moderate, with CVs between 7-18%, and ICCs ranging between 0.59-0.87. In 
WM, CVs were low (all < 4.5%), and ICCs were moderate to good (0.50-0.74). 
As noted above, CVs depend on the absolute quantity being measured; values will 
be higher for lower mean, and fM in GM structures will therefore necessarily yield 
higher CVs compared to WM. Additionally, in simulations under a variety of 
conditions, accuracy and precision of fM were better for higher values (Deoni and 
Kolind, 2015). Results are in line with those from previous studies, which showed 
ROI-based CVs of 7-10% in GM, 4-8% in WM as reported in Table III.1. 
Investigations into other MWI methods have yielded comparable, or higher 
estimates of intra-site reliability (Arshad et al., 2017; Meyers et al., 2013; Nguyen et 
al., 2016), although the use of different methodologies (acquisition time and 
efficiency, statistical estimates of reliability) preclude direct comparisons. However, 
the mcDESPOT protocol presents other advantages in terms of spatial coverage 
and acquisition time. 
 
III.5.5. Generalizability to other populations 
Previous studies have reported consistency across subjects for values obtained in 
specific structures, which, in a homogeneous population, is suggestive of good 
precision. In the present sample however, we expect more heterogeneity, due to 
factors like age and education which are known to have an effect, but the 
trajectories of which have not yet been characterized in large-scale studies 
(MacKay and Laule, 2016). An index like the ICC is appropriate, when used in 
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conjunction with within-subject CVs, to inform on measurement error relative to the 
variance of the particular sample under investigation. However, because of this, the 
generalizability of the presented statistical results to other populations is limited. 
Given the recent applications of mcDESPOT in infants and children to study 
neurodevelopment, separate assessment of reliability in these populations would be 
useful, as additional problems may arise when scanning young populations, from 
data quality (potential for motion), to the biological (lower myelin content), to 
analysis challenges in post-processing non-adult brains (e.g. dearth of appropriate 
atlases), which would affect reliability. 
 
III.6. Conclusion 
As a well-supported marker of myelination (see II.1.3), fM mapping has been used in 
studies of neurodevelopment and has the potential to be a clinically useful tool in 
MS research. We conducted a single-site 3T study of mcDESPOT at three short-
term time points using healthy subjects aged 50 and over, in order to represent 
population variability in a patient population. Voxelwise reliability was excellent for 
T1, and within acceptable range for T2 and fM. ROI-based results were excellent for 
T1, and good for T2 and fM (ICCs within the 0.5-0.8 range). 
We show here that reliable estimates of fM, T1 and T2 can be obtained using 
mcDESPOT, and that it is therefore suitable for single-centre longitudinal 
assessments. Knowledge of the reliability of mcDESPOT overall, and in specific 
ROIs, informs the choice of analysis methods in projects using a similar protocol, 
and impacts on the interpretation of the results. Several of the ROIs that were 
assessed here were used in a project comparing fM and T1 values in the brain in 
patients compared with healthy subjects, which we report on in the next chapter. 
With the multiplication of multi-site studies, data on the inter-scanner reproducibility 
of various protocols across vendors and scanners in the brain and cord would be 
valuable. 
 
III.7. Additional information 
Boxplots for all T1, T2 and fM values at the three time points are included hereafter in 





Figure III.10. T1 values by region of interest across the three sessions. Data points outside of boxplot whiskers are outliers, defined as being beyond 1.5 
interquartile range of each quartile. CC: corpus callosum. CST: corticospinal tract. L/R: left/right. ms: milliseconds. OR: optic radiation. ROI: region of interest. 





Figure III.11. T2 values by region of interest across the three sessions. Data points outside of boxplot whiskers are outliers, defined as being beyond 1.5 
interquartile range of each quartile. CC: corpus callosum. CST: corticospinal tract. L/R: left/right. ms: milliseconds. OR: optic radiation. ROI: region of interest. 





Figure III.12. Myelin water fraction values by region of interest across the three sessions. Data points outside of boxplot whiskers are outliers, defined as 
being beyond 1.5 interquartile range of each quartile. CC: corpus callosum. CST: corticospinal tract. fM: myelin water fraction. L/R: left/right. OR: optic 
radiation. ROI: region of interest. WM: white matter.
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Chapter IV. Subcortical pathology and 
relationship with cognitive performance 
in neuromyelitis optica spectrum disorder 
 
In this chapter, we investigate subcortical pathology in an NMOSD group compared 
with healthy controls. We report volumetric measures and quantitative indices in the 
thalamus and several white matter regions, and assess the relationship of thalamus 
pathology to a measure of information processing speed in a subset of subjects. 
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Brain involvement is a recognized and documented feature of neuromyelitis optica 
spectrum disorder (NMOSD), informed by a growing number of advanced imaging 
and histopathology studies. However, due in part to the recent redefinition of the 
currently used diagnostic criteria and the rarity of this clinical population, several 
questions remain regarding the characterisation of cerebral pathology and its 
clinical correlates. 
Cognitive impairment is found in over half of relapsing-remitting multiple sclerosis 
(MS) patients (Chiaravalloti and DeLuca, 2008), and has been linked with grey 
matter (GM) damage, in particular cortical thinning, demyelination, and thalamic 
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pathology (Messina and Patti, 2014). The prevalence of cognitive impairment is 
thought to be slightly lower in NMOSD, although select deficits are found in nearly 
half of patients. As cortical damage is limited in NMOSD, currently available 
evidence suggests that subcortical pathology may play a greater role; this theory is 
consistent with the pattern of deficits typically found in this group (Blanc et al., 2012; 
Hyun et al., 2016). 
As a second point of interest, the presence of diffuse brain pathology in NMOSD is 
a point of contention in the field, and only inconsistently found across advanced 
magnetic resonance imaging (MRI) studies and methods. Specifically, the presence 
of diffuse myelin loss outside of lesions, and outside typically involved regions, is 
debated. Similarly, despite thalamic atrophy being a relatively frequent finding, the 
underlying tissue damage in this structure has not been well characterised and its 
origin is unknown. Due to its high number of reciprocal connections with other 
structures, the thalamus may be particularly vulnerable to downstream damage to 
focal lesions throughout the brain, and especially within the white matter (WM) (Su 
et al., 2016). The literature pertaining to these observations will be reviewed herein. 
Informed by the MS literature, and by studies suggesting a possible subcortical 
origin to cognitive impairment in NMOSD, we focus here on damage to NMOSD 
WM and thalamus. We investigate thalamic atrophy and quantitative parameters as 
indices of tissue integrity using a multicomponent Driven Equilibrium Single Pulse 
Observation of T1 and T2 (mcDESPOT) protocol, and explore whether diffuse WM 




NMOSD predominantly affects the optic nerves and spinal cord, although damage 
to the brain is becoming recognized as an important and clinically significant 
feature. Here we review the use of advanced imaging to describe brain involvement 
in NMOSD and differentiate it from MS. We first describe the nature of pathology in 
the cerebral GM and WM, before summarising current evidence for the brain 
substrates of cognition in NMOSD. 
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IV.2.1. Cortical pathology 
Although cortical lesions are rarely found in NMOSD, which has been proposed as 
a possible differentiating feature from MS (see II.4.6), some degree of involvement 
of the cortical GM has been found with advanced MRI. 
There is great discrepancy among findings using both voxel-based morphometry 
(VBM) and global measures of cortical volume, which are summed up below. 
Using VBM, Matthews et al. found no significant reduction in cortical volume in 
NMOSD compared to healthy controls (HC) (Matthews et al., 2015). Regional 
reductions in GM density and volume limited to primary sensory, motor, and visual 
cortices are frequently observed (Cai et al., 2017; Calabrese et al., 2012; Liu et al., 
2014; Pichiecchio et al., 2012). Atrophy in the frontal and temporal regions has also 
been reported (Duan et al., 2012; Wang et al., 2015). 
Kim et al. found widespread cortical thinning, but regional atrophy in motor, 
sensory, and visual areas only when including only patients without brain lesions, or 
patients with a disease duration < 3 years (Kim et al., 2016b). Consistent with 
previous studies that only found atrophy of these areas, this results suggests that 
retrograde degeneration is the main feature responsible for cortical volume loss at 
early stages of the disease or in the absence of direct brain involvement. 
However, von Glehn et al. found widespread cortical atrophy, especially but not 
limited to the motor, sensory and visual areas, and mention that despite the likely 
interpretation as Wallerian degeneration and axonal damage, primary tissue 
damage due to cortical inflammation cannot be ruled out (von Glehn et al., 2014). 
Pache et al. also found widespread, multifocal atrophy, although there results failed 
to remain significant when corrected for multiple comparisons (Pache et al., 2016). 
Another finding challenging the hypothesis of retrograde damage as the only cause 
of focal GM atrophy is the observation of regional volume loss in the auditory cortex 
(Cai et al., 2017). 
Rocca et al. found abnormalities in the normal-appearing GM (NAGM), using 
magnetisation transfer ratio (MTR) and diffusion tensor imaging (DTI)-derived mean 
diffusivity (MD) parameters, that were unrelated to the presence and extent of focal 
brain and cord abnormalities. They proposed several possible explanations for this 
observation: the presence of discrete GM lesions not seen on conventional 
imaging; increased sensitivity to age-related changes or perturbations of global 
cortical metabolism; and possible retrograde neuronal degeneration due to cord 
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and optic nerves impairment, despite the lack of correlation between lesional and 
diffuse pathology detected in their study (Rocca et al., 2004b). 
A subsequent study found normal MTR and MD parameters in the NAGM, failing to 
replicate Rocca et al.’s findings, but instead found reduced fractional anisotropy 
(FA) in the cortical NAGM (Pichiecchio et al., 2012). Increased MD has been 
measured in the parietal and occipital cortices (Yu et al., 2006) and frontal and 
temporal cortices (Qian et al., 2016), possibly attributed to neuronal loss. 
Neuropathological examinations have indeed shown that cortical neuronal loss is 
not limited to areas connected with the optic radiations (OR) or corticospinal tract 
(CST) (Saji et al., 2013), and it has been suggested that the prominent and 
widespread astrogliosis and neuronal pathology observed in the cortex post-
mortem cannot be entirely attributed to retrograde degeneration from axonal 
transection in the optic nerves and spinal cord, or to downstream WM lesions 
(Popescu et al., 2010). However, no evidence of widespread cortical demyelination 
has been found thus far (Popescu et al., 2010). Kim et al. have proposed altered 
glutamate metabolism as a possible cause for the observed cortical changes in the 
absence of demyelination, although this remains a hypothesis (Kim et al., 2016b). 
Overall, regional atrophy is most often seen in sensory and motor cortices. More 
widespread changes are only infrequently observed, and the heterogeneity in these 
findings may be influenced by the impact of disease duration and focal brain 
involvement. The use of exploratory statistical thresholds in some of these studies 
must also be noted (Duan et al., 2012; Pache et al., 2016). In addition, the impact of 
the number and severity of optic neuritis attacks across patients has been shown to 
be a potential confound, and may explain some discrepancies in the reported 
results regarding focal volume loss (Sanchez-Catasus et al., 2015). 
 
IV.2.2. White matter pathology 
When global tissue compartment volume is considered, WM atrophy is a consistent 
finding in NMOSD (Blanc et al., 2012; Chanson et al., 2013; Qian et al., 2016). One 
study suggested that WM atrophy is broadly distributed: focal atrophy was observed 
using FreeSurfer in several regions connected to the optic nerves and spinal cord 
(optic chiasm, brainstem, pre- and postcentral gyri which are connected to the 
CST), as well as in areas that are not (cerebellum, corpus callosum (CC)), and in 
the frontal, parietal and temporal WM (Calabrese et al., 2012). 
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Investigations using MR spectroscopy have shown normal ratios of n-
acetylaspartate (NAA), choline and myo-inositol, putative markers of axonal loss, 
inflammation and gliosis respectively (Aboul-Enein et al., 2010; Bichuetti et al., 
2008b; Pichiecchio et al., 2012). Only a single study found a mild increase in 
choline, in the absence of changes in NAA, suggesting the presence of “subtle 
metabolic changes” (Duan et al., 2017). Another study using MR elastography 
found reduced ‘tissue softening’ in the WM in the absence of atrophy, which the 
authors attribute to a non-specific change in tissue integrity possibly linked with 
astrocyte death or neurodegeneration, favouring the hypothesis of a diffuse disease 
process independent from focal damage and distinct from ageing (Streitberger et 
al., 2016). 
Using DTI, abnormal MD and FA have been found in regions within the WM 
connected with the spinal tracts and optic nerves, such as the CST and OR, while 
parameters in areas not connected to these tracts, such as the cingulum and CC, 
were normal relative to controls (Yu et al., 2008, 2007, 2006). 
Abnormalities in the OR have been confirmed via several observations of reduced 
FA (Jeantroux et al., 2012; Kimura et al., 2014; Pache et al., 2016; Pichiecchio et 
al., 2012), increased MD (Zhao et al., 2012), and increased apparent diffusion 
coefficient (reflecting “cellular size and integrity”) (Jeantroux et al., 2012). 
Observations of lower FA in the posterior limbs of the internal capsule (Jeantroux et 
al., 2012), borderline significant reduction in the cerebral peduncle (Pache et al., 
2016), and reduced MD in the medulla oblongata and internal capsule (Zhao et al., 
2012), often in the absence of abnormalities in other regions, suggests damage 
restricted to visual and motor pathways. Additionally, significant correlations have 
been found between diffusion parameters in the CST and OR with the pyramidal 
and visual functional systems scores, respectively (Yu et al., 2008). DTI 
abnormalities have been noted in the CC (He et al., 2011b; Kimura et al., 2014; 
Zhao et al., 2012). 
Across studies, FA appears as the parameter most sensitive to the detection of 
diffuse abnormalities, as it can be reduced even in the absence of MD or MTR 
abnormalities (Pichiecchio et al., 2012). This suggests that the use of other 
techniques may bring complementary information. 
More recently, a limited number of studies have used myelin water imaging (MWI) 
to evaluate WM demyelination with increased specificity. Using gradient and spin-
echo MWI (GRASE), decreased myelin water fraction has been measured in the 
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OR (Manogaran et al., 2016b) and CST (Manogaran et al., 2015), consistent with 
previous DTI investigations. Using a semi-quantitative MWI technique (ViSTa; see 
II.1.3.7), reductions in normal-appearing WM (NAWM) myelin water fraction have 
been found, as well as local changes in the OR, CST, CC, periventricular WM and 
centrum semiovale. However, these differences were not apparent when using 
multi-echo T2 MWI measures in the same sample (Jeong et al., 2017). 
Abnormal structural connectivity in WM networks was shown in one study using DTI 
data and graph theory analysis, with regional inefficiency being found in the default-
mode, sensorimotor and visual systems. The authors hypothesized that these 
alterations may be due to reorganisation following cord or optic nerves injury, but 
favoured the idea that these changes may be due to widespread, diffuse pathology 
(Liu et al., 2012a). 
Unsurprisingly, recent studies at higher field strength and with greater sample sizes 
are those that tend to find more evidence for the presence of occult damage in the 
NAWM (Zhao et al., 2012), and some authors have argued that the increased 
sensitivity of techniques like tract-based spatial statistics (TBSS), and increased 
sample sizes, allow for previously unseen widespread damage beyond the CST 
and OR to be observed (Liu et al., 2012b). However, even subsequent studies 
using TBSS have reported the absence of abnormalities across the whole WM 
skeleton, reporting normal DTI and diffusional kurtosis metrics (Qian et al., 2016), 
and normal mcDESPOT-derived myelin water fraction (Matthews et al., 2015). 
 
IV.2.3. Thalamus pathology 
IV.2.3.1.  Neuroanatomy and function 
The thalamus is a subcortical deep GM (DGM) structure adjacent to the lateral and 
third ventricles, and is composed of several nuclei: relay, association, and 
unspecific (Jacobson and Marcus, 2011). The thalamus receives information from 
motor structures, sensory input from peripheral receptors (retina, auditory systems), 
projects onto the corresponding cortical areas, and connects subcortical nuclei 
within the same hemisphere. Functionally, it serves as a relay for sensory and 
motor information, and is broadly involved in perception and cognition, as well as 
higher order and integrative functions (sleep regulation, ocular motility, posture, 
memory, emotion, consciousness, awareness and attention) (Minagar et al., 2013). 
Animal, electrophysiological, and lesion studies have shown a role of the thalamus 
113 
in memory, executive function, attention, inhibition, and decision-making, planning 
and response selection, response monitoring, spatial perception and visuo-motor 
coordination (Mitchell et al., 2014). 
In health, there is heterogeneous evidence for age-related MRI-assessed thalamic 
atrophy (Walhovd et al., 2005). Thalamic volume loss may be linear with age 
(Walhovd et al., 2005), but gender-independent (Sullivan et al., 2004). Thalamic 
atrophy may occur earlier, and more severely, than whole brain volume loss; 
cognitive performance (assessed via measures of the speed of information 
processing, and executive function) was correlated with thalamic volume, when 
correcting for intracranial volume and brain size, in subjects under 61 years old 
(Van Der Werf et al., 2001). 
 
IV.2.3.2.  Thalamic pathology in NMOSD 
A limited number of studies have reported inconsistent evidence for both the 
presence and absence of atrophy and microstructural abnormalities in the thalamus 
in NMOSD, which we summarize below. These studies have used both voxelwise 
(e.g. voxel-based morphometry (VBM)) and region of interest (ROI)-based 
approaches (e.g. FreeSurfer, FSL-FIRST). 
Some studies have reported the absence of thalamic pathology compared to HC. 
Normal thalamic volumes have been found using VBM, FSL-FIRST and FreeSurfer 
(Duan et al., 2012; Finke et al., 2016; Pache et al., 2016), and in one study, no 
significant change was seen in thalamic volume in NMOSD over one year 
(Matthews et al., 2015). Normal MD and FA in the thalamus have been observed 
using DTI (Finke et al., 2016; Yu et al., 2006), as well as normal MTR (Pichiecchio 
et al., 2012). One study reported no evidence of iron deposition in the DGM in 
NMOSD brains using susceptibility-weighted angiography, in contrast to what is 
usually seen in MS (Chen et al., 2012). 
On the opposite hand, a number of studies have detected thalamic atrophy in 
NMOSD compared to HC (Chanson et al., 2013; Liu et al., 2015a). Atrophy has 
been reported in the absence of thalamic lesions (Calabrese et al., 2012), and in 
the presence of otherwise normal DGM volumes (Hyun et al., 2016). Some studies 
have found relationships between brain lesion load and thalamic atrophy, 
suggesting that atrophy in this region may be secondary to the effect of lesions 
causing axonal degeneration (Hyun et al., 2016; Wang et al., 2015). In one of these 
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studies, thalamic volumes were normal compared to HC in the subset of NMOSD 
subjects with no brain lesions (Hyun et al., 2016). Some studies have found atrophy 
limited to the right thalamus only (Su et al., 2016; Wang et al., 2015). One study 
reported a correlation between Expanded Disability Status Scale (EDSS) score and 
thalamic volume (Hyun et al., 2016). 
Investigations using DTI-derived indices have yielded inconsistent findings. 
Reduced MD was found in the thalamus in patients in period of remission, and 
higher FA in both stable and remitted patients compared to controls (Zhao et al., 
2012). Contrarily, one study reported reduced FA and increased MD, that were not 
correlated with thalamic volume loss (Liu et al., 2015a). Qian et al. also found 
increased MD, but normal mean kurtosis in the thalamus, indicating ‘tissue 
heterogeneity’ (Qian et al., 2016). Of note, these authors remark on the lower 
reliability of directional DTI metrics in GM, mentioning that MD may be a more 
robust measure when applied to a structure with relatively low myelin content like 
the thalamus – but making the discrepancies in findings with this metric all the more 
puzzling. Reduced thalamic ‘stiffness’ has also been found using MR elastography, 
presumably denoting loss of structural integrity, even in the absence of atrophy 
(Streitberger et al., 2016). 
The two most prevalent explanations for the origins for thalamic pathology in 
NMOSD that have been proposed are: 1) a primary degenerative process, possibly 
due to the vicinity of this structure to the ventricles, where aquaporin-4 (AQP4) 
protein expression is high; 2) a secondary process due to axonal transection in the 
rest of the brain, especially in the WM (Hyun et al., 2016; Su et al., 2016). 
 
IV.2.3.3.  Functional abnormalit ies of thalamic networks 
Abnormal functional activity at rest was found in one patient group using measures 
of regional homogeneity (Liang et al., 2011) and amplitude of low frequency 
fluctuation (Liu et al., 2011). Changes were observed in networks supporting 
cognition, visual and motor systems, for which the thalamus acts as a ‘relay point’. 
These may reflect compensatory mechanisms to support the visual and motor 
systems following structural damage, which may in turn be a potential cause for the 
neuropsychological deficits reported in this population (Liu et al., 2011). 
Hyperactivation of the thalamus at rest has been reported, possibly to preserve 
visual and motor function in injured systems (Liu et al., 2011). However, another 
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study found no resting-state abnormalities involving the thalamus, purportedly 
denoting “intact thalamic function” even in the presence of atrophy and 
microstructural damage assessed with DTI (Liu et al., 2015a). 
 
IV.2.3.4.  Differentiating between MS and NMOSD with thalamic 
volume 
The thalamus, along with the basal ganglia, is extensively involved in MS, and has 
been recognized as an “early sensor” of brain pathology in the disease (Absinta et 
al., 2016). Thalamic pathology, and in particular volume loss, is a known predictor 
of disease progression even in the relapsing stage (Rocca et al., 2010), and linked 
to cognitive impairment. Thalamic pathology accumulates on “a background of” the 
age-related atrophy described above, and has been described as a “barometer of 
diffuse neuropathological damage in MS”, due to numerous connections with 
cortical and subcortical GM structures (Minagar et al., 2013). 
Studies comparing MS and NMOSD cohorts often find atrophy in relapsing-
remitting MS (RRMS), but absent or milder atrophy in NMOSD, following the typical 
‘MS > NMOSD > HC’ pattern seen in most studies regarding the severity of 
observed abnormalities. Thus, thalamic atrophy has been proposed as a 
differentiating feature between these patient groups with potential clinical diagnostic 
usefulness (Duan et al., 2012; Liu et al., 2015a; Matthews et al., 2015). Matthews et 
al. devised a discriminant function based on thalamic and normalized brain volume, 
which successfully separated RRMS and NMOSD subjects with 89.5% sensitivity 
and 92.9% specificity (Matthews et al., 2015). Using machine learning, Eshaghi et 
al. found that thalamic atrophy was the most discriminating measure, and the best 
predictor of disease status among other GM volumetric variables, and along with 
WM lesion volume, could be used to classify MS and NMOSD patients with 74% 
accuracy (Eshaghi et al., 2016). 
 
IV.2.4. Brain substrates of cognitive impairment in NMOSD 
Neuropsychological deficits in several domains can generally be found in over half 
of NMOSD patients (Blanc et al., 2008; Saji et al., 2013; N. Zhang et al., 2015). 
‘Core deficits’ in attention and information processing speed (IPS) have consistently 
been found across Chinese, Japanese, French, Brazilian and Argentinian cohorts; 
deficits in verbal fluency, working and long-term memory, and emotional face 
116 
processing have also been reported (Blanc et al., 2008; Cardona et al., 2014; Kim 
et al., 2016c; Liu et al., 2015b; Saji et al., 2013). Studies comparing NMOSD and 
matched MS subjects have suggested an overall similar pattern of cognitive 
impairment, and no relationships have been found with disease duration, EDSS, or 
the presence of abnormalities on conventional MRI (Blanc et al., 2008; He et al., 
2011b; Saji et al., 2013; Vanotti et al., 2013). Because most studies evaluate 
patients during remission, the effects of acute, attack-related inflammation and 
oedema are unlikely to account entirely for the observed deficits (N. Zhang et al., 
2015). Therefore, a number of studies have aimed to investigate the substrates of 
cognitive impairment in NMOSD. 
In MS, cortical thinning, focal lesions and demyelination have been linked with 
abnormal cognitive function (Calabrese et al., 2009; Filippi et al., 2010; Kutzelnigg 
and Lassmann, 2006). In NMOSD, cortical lesions are more rare, and atrophy 
findings are generally limited to visual and motor cortices (see IV.2.1). Moreover, 
the absence of cortical demyelination suggests a different aetiology to cognitive 
impairment in NMOSD (Popescu et al., 2010). 
There is limited evidence for relationships between cortical MRI measures and 
cognition in NMOSD. He et al. linked impaired IPS and executive control with DTI 
metrics (MD and FA) in the anterior cingulate cortex and adjacent medial prefrontal 
cortex (He et al., 2011b). A relationship between GM volume reduction in the 
medial prefrontal cortex and working memory was also reported by another group 
(Wang et al., 2015). Conversely, Liu et al. reported cortical thinning limited to the 
visual cortex, and found no relationship between scores on the Paced Auditory 
Serial Addition Test (PASAT) and cortical thickness (Liu et al., 2014). In another 
study, regional atrophy was not linked with any cognitive scores, despite 
widespread cortical thinning. The authors postulate that deficits in IPS and working 
memory, functions which require wider cortical involvement and rely on cortico-
cortical connections via long WM tracts, may be due to WM involvement, which 
they did not evaluate. They also suggest that the lack of focal cortical involvement 
may explain the relative preservation of function in a measure of delayed memory 
observed in their sample (Kim et al., 2016b). 
It has been proposed that the pattern of cognitive deficits observed in NMOSD is 
consistent with a ‘subcortical’ pattern of neurocognitive impairment (Blanc et al., 
2012), typical of inflammatory disorders and characterised by a relative sparing of 
the cortex, greater WM involvement, and causing deficits in the aforementioned 
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domains: slowing of IPS, executive dysfunction, and attentional deficits, while 
language ability and visuoperceptual deficits are relatively preserved13 (Filley, 
2012). Consistent with this hypothesis, the presence of WM atrophy is well-
documented (see IV.2.2). In one study, WM volume loss was more severe in 
NMOSD subjects with vs. without cognitive impairment compared to HC. Patients 
with cognitive impairment showed greater global and focal WM atrophy (in the 
frontal and parietal lobes, CC, cerebellum, brainstem, optic chiasm and CST), while 
no global or focal GM atrophy was observed (Blanc et al., 2012). One study found 
abnormal MD and FA in the CC, linked with several cognitive measures (He et al., 
2011b). 
In the absence of widespread cortical pathology, and consistently with the above 
described theory, the question has been raised as to whether thalamic atrophy may 
contribute to cognitive impairment, as is seen in MS (Ciccarelli, 2012). Memory 
performance has been linked with GM volume reduction in the right thalamus 
(Wang et al., 2015), and WM volume adjacent to the thalamus has been linked with 
phonemic fluency (Blanc et al., 2012). Liu et al. found a correlation between 
reduced FA in the thalamus and PASAT-2 scores (Liu et al., 2015a). In one study, 
thalamic atrophy was only found in cognitively impaired NMOSD subjects, and not 
in a cognitively preserved group; moreover, thalamic volume was positively 
correlated with a global index of cognitive function (Hyun et al., 2016). 
 
IV.2.5. Study aims 
IV.2.5.1.  Summary of current evidence 
• Cortical pathology is less extensive in NMODS than in MS. Regional atrophy 
seems mostly related to retrograde degeneration from optic nerves and spinal 
cord lesions, although there may be some degree of NAGM damage not 
confined to these areas. 
• WM atrophy is a frequent finding. Most studies looking at the NAWM have used 
DTI, and investigations using quantitative metrics of myelin content are few. The 
body of literature suggests secondary damage related to focal optic and spinal 
                                                
13 Interestingly, in a separate project involving a wider group of NMOSD patients, only a subset of 
whom also underwent MRI for research purposes and are included in this study, subjects showed 
overall slowed cognitive processing but relative sparing of verbal fluency [data not shown]. 
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pathology, as in the cortex, rather than inflammatory or degenerative processes 
in the brain. The existence of “chronic and diffuse neurodegeneration” remains 
unproven (Kawachi and Lassmann, 2017). 
• In the thalamus, assessments of atrophy and microstructural parameters 
provide conflicting findings regarding the prevalence, severity, and nature of 
abnormalities. Thalamic atrophy is found more frequently than in other DGM 
structures, and is generally less severe than in MS. Its sensitivity to the 
secondary effects of focal brain pathology, and preliminary evidence regarding 
relationships with clinical measures (EDSS, cognitive tests), suggests that even 
subtle thalamic pathology may have functional relevance. 
• Cognitive impairment in NMOSD may follow a typically ‘subcortical’ pattern, with 
deficits in IPS and attention being most frequently observed. Cortical atrophy 
appears unrelated to cognitive performance, and the absence of cortical 
demyelination suggests a different aetiology than in MS. There is some 
evidence for the involvement of both WM and thalamic abnormalities in 
cognitive impairment in NMOSD. 
 
IV.2.5.2.  Research questions and hypotheses 
Here we aimed to investigate subcortical pathology in the NMOSD brain using MWI, 
in order to answer the following questions. 
1) Are MWI-derived parameters sensitive to abnormalities in the cerebral 
NAWM of NMOSD subjects compared to HC? 
2) Can abnormalities of the thalamus be detected using these parameters, and 
are they related to focal WM pathology? 
3) Are either of these features related to cognitive performance? 
We used measures of volume, myelin content, and quantitative relaxation time T1, 
acquired with a mcDESPOT protocol, in the NAWM and thalamus, in an NMOSD 
group compared to matched HC. First, we report tissue-compartment volumes to 
assess the presence of atrophy. We report measures of thalamic volume, as well as 
multicomponent relaxometry parameters relating to tissue microstructure, to 
investigate the presence and characteristics of thalamic pathology. We also 
correlate these measures to determine whether thalamic pathology can be related 
to the extent of focal and/or diffuse WM damage. Finally, we aim to explore (in a 
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subset of patients) whether these parameters are related to cognitive performance, 
by assessing relationships between quantitative MRI metrics and a measure of IPS. 
We used the Symbol Digit Modalities Test (SDMT), a highly sensitive task that is 
widely used in MS research, as well as nearly all of the studies on cognition in 
NMOSD cited above. 
We hypothesized that WM atrophy and NAWM abnormalities would be present; that 
thalamic atrophy and abnormal parameters would be found in the NMOSD group 
compared to controls; that thalamus pathology would be related to WM pathology, 
in the form of either focal abnormalities (lesion load) or more subtle damage to the 
NAWM; and that these indices would be related with cognitive performance. 
 
IV.3. Methods 
IV.3.1. Population characteristics 
NMOSD participants were recruited from the MS and NMO clinic at the University of 
British Columbia in Vancouver, Canada. Patients were diagnosed according to the 
2015 criteria14 (Wingerchuk et al., 2015). A HC group was selected based on age 
and gender from an available database. Two NMOSD subjects were excluded at 
the time of analysis: one for being significantly older than the rest of the sample (70 
years old), and one who displayed an unusually large lesion in the right temporal 
WM, rendering most measures biased and potentially meaningless. In total, 19 
NMOSD subjects and 21 HC were included (see Table IV.1). 
Nearly all patients were receiving immunosuppressant or immunomodulatory 
treatment. Seven were on mycophenolate mofetil, six on azathioprine, one on 
rituximab, one on mitoxantrone, one on prednisone, and two were receiving 
combinations thereof (one on prednisone and azathioprine, one on mycophenolate 
mofetil and rituximab). One was unmedicated. 
                                                
14 Of note, two of the subjects originally included in this cohort had their diagnosis revoked: one was 
subsequently diagnosed as RRMS, and one as brain inflammation of unknown aetiology, which 
speaks of the difficulty in differentiating and diagnosing this condition in the clinical setting. These 
subjects’ data were not used in this project. 
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Table IV.1. Population characteristics for healthy controls and NMOSD subjects. 
 HC NMOSD 
N 21 19 
Age, years (mean ± SD, range) 42 ± 7 (28-56) 43 ± 10 (24-60) 
Sex, M:F 6:15 6:13 
Disease duration, years (mean ± SD, range) N/A 6.2 ± 4.1 (0.5-14) 
EDSS (median ± IQR, range) N/A 3.5 ± 2.25 (1-6) 
Aquaporin-4 antibody seropositivity (n, %) N/A 9 (47%) 
EDSS: Expanded Disability Status Scale. HC: healthy controls. IQR: inter-quartile range. 
NMOSD: neuromyelitis optica spectrum disorder. N/A: not applicable. SD: standard 
deviation. 
 
IV.3.2. Data acquisition 
IV.3.2.1.  MRI acquisit ion 
All participants were scanned on a 3.0T Philips Achieva MRI scanner (Best, the 
Netherlands) using an 8-channel head coil. Acquired scans included three-
dimensional (3D) T1-, T2-weighted, and fluid-attenuated inversion recovery (FLAIR) 
scans, and a mcDESPOT protocol (Deoni et al., 2008a) that consisted in seven 
spoiled gradient recalled (SPGR) scans, one inversion recovery SPGR (IRSPGR) 
scan, and seven balanced steady-state free precession (bSSFP) scans with phase-
cycling at 0° and 180° for correction of B0 inhomogeneity. All were acquired in 
sagittal orientation. Repetition (TR), echo (TE), and inversion times (TI) below are in 
milliseconds, voxel sizes in millimetres (mm). 
3D T1-weighted fast field echo: TR/TE = 6.2/3; matrix size = 256 x 256 x 200; 
voxel size = 1 x 1 x 1.6 mm; reconstructed to 320 x 320 x 200, 0.8 mm3 isotropic. 
3D T2-weighted spin echo: TR/TE = 2500/363; matrix size = 256 x 256 x 200; 
voxel size = 1 x 1 x 1.6 mm; reconstructed to 320 x 320 x 200, 0.8 mm3 isotropic. 
3D FLAIR: TR/TE = 8000/337; TI = 2400; matrix size = 256 x 256 x 200; voxel size 
= 1 x 1 x 1.6 mm; reconstructed to 320 x 320 x 200, 0.8 mm3 isotropic. 
SPGR: TR/TE = 6.5/3.6; α = [2, 3, 4, 6, 9, 13, 18]°; matrix size = 128 x 128 x 92 
mm; voxel size = 1.7 mm3 isotropic. 
IR-SPGR: TR/TE = 6.5/3.2; TI = 450; α = 5°; matrix size = 128 x 128 x 92; voxel 
size = voxel size = 1.7 x 1.7 x 3.4 mm, reconstructed to 1.7 mm3 isotropic. 
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bSSFP: TR/TE = 5.8/2.9; α = [7, 11, 15, 19, 24, 30, 47]°; matrix size = 128 x 128 x 
92; voxel size = 1.7 mm3 isotropic. 
 
IV.3.2.2.  Cognitive testing 
A subset of NMOSD subjects (n = 12) received the SDMT, a timed pen-and-paper 
test. It is a quickly administered substitution task where participants are required to 
match numbers to symbols using a reference key, completing as many symbol-digit 
matches as possible, without skipping one, within 90 seconds. An example of the 
task sheet is shown in Figure IV.1. The score is calculated as the number of correct 
matches, and therefore better performance is reflected by a higher score. This test 
measures IPS, and is widely used as a screening tool with high sensitivity to 
cognitive impairment that has been shown to be independent of education level in 




Figure IV.1. Example task sheet for the Symbol Digit Modalities Test. The top row is the 
‘key’ of corresponding symbol and digits. The bottom two rows are the task stimuli to be 
‘decoded’ by the participant, with a training set of 10 items delimited by the vertical line in 
the middle row. (Actual test is under copyright; image shows an equivalent setup for 
illustrative purposes.) Source: (Langdon et al., 2012). 
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IV.3.3. Image processing 
All structural processing was performed on the SPGR 13° scan using tools from 
FMRIB’s Software Library (FSL) version 4.8 (Smith et al., 2004). 
 
IV.3.3.1.  Lesion identif ication 
Lesions were identified using T1-weighted and FLAIR2 images and in-house 
software. 
FLAIR2 (‘FLAIR-squared’) refers to the process of multiplying a T2-weighted scan by 
a FLAIR scan to obtain a hybrid image with T2 contrast where cerebrospinal fluid 
(CSF) appears dark, and lesion brightness is increased (Wiggerman et al., 2016). 
This serves to increase conspicuity of lesions. NMOSD subjects’ T2-weighted and 
FLAIR scans were linearly co-registered, when necessary, to create FLAIR2 
images. Examples of scans from one subject can be seen in Figure IV.2. 
 
 
Figure IV.2. Example of FLAIR2 image for lesion segmentation for a subject with 
periventricular lesions. From left to right: T2-weighted, FLAIR, FLAIR2 image, and overlaid 
lesion mask in blue. This subject (52 years old, female, aquaporin-4 antibody negative, 
disease duration 6 years, EDSS 2.5) presents with several T2-hyperintense periventricular 
lesions and has a lesion load of 4104.19 mm3 (4.10 millilitres). 
 
The software used to segment lesions is a semi-automated region-growing tool; a 
point in each lesion is manually identified, and the lesioned area is expanded to the 
surrounding voxels using a specified intensity threshold, which can be adjusted 
interactively so that the mask can be ‘grown’ or ‘shrunk’ to fill the lesioned area. 
Lesions were drawn on the FLAIR2 image, with concurrent information gleaned from 
the T1-weighted image, referring back to the individual FLAIR and T2-weighted 
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scans when required. Two subjects had missing data: one was missing the FLAIR 
scan, and one only had the T1-weighted scan. For these subjects, lesions were 
assessed based on the available scans. The lesion masks obtained were reviewed 
by an experienced neurologist. 
Lesions masks drawn in FLAIR2 space were transferred to mcDESPOT space using 
the SPGR 13° as a reference. FSL’s Linear Image Registration Tool (FLIRT) 
(Jenkinson et al., 2002) was used with 6 degrees of freedom (DOF) from the T2- to 
the T1-weighted scans, and the T1-weighted scan to the SPGR, and the two 
transforms concatenated to obtain a final unique transform to transpose the lesion 
masks into SPGR space. 
 
IV.3.3.2.  Tissue-class volume estimation using SIENAX 
Tissue class volumes were estimated using the FSL tool for cross-sectional 
Structural Image Evaluation, using Normalization, of Atrophy (SIENAX) (Smith et 
al., 2002) on the SPGR 13° scan. After initialization with robust brain extraction 
(Smith, 2002), SIENAX uses linear registration to register to MNI152 space, in order 
to derive a scaling factor used to correct the obtained raw volumes for head size. 
The tissue compartment classification is based on the FAST algorithm (Zhang et 
al., 2001), including bias field correction and partial volume estimation. Lesion 
masks were included in the pipeline. The following volume measures were 
obtained: GM, WM, ventricular CSF, cortical GM, and lesion. We calculated 
subcortical GM volume by subtracting the cortical from the total GM volume. 
 
IV.3.3.3.  mcDESPOT analysis 
In order to ensure compatibility with other datasets as part of a larger study, 
mcDESPOT preprocessing was performed according to a predetermined pipeline in 
which all images are registered to the SPGR 13° scan using FLIRT, with 6 DOF, 
using a correlation ratio cost function and trilinear interpolation. 
Voxelwise mcDESPOT analysis was performed to create single-component 
T1 relaxation time and fM maps, using a three-pool model and with the version of the 
algorithm described in II.2.4.2 as per Deoni et al. (Deoni et al., 2013). 
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IV.3.3.4.  Segmentation of white matter regions 
FAST segmentation (Zhang et al., 2001) was carried out on the SPGR 13°	to obtain 
WM masks. These were eroded by two voxels using a 3D kernel to avoid voxels 
with partial volume effects, and lesion masks were subtracted to create 
conservative NAWM masks. All masks were visually checked for quality assurance. 
Mean fM and T1 were calculated within whole NAWM. We also compared fM and T1 
in specific tracts: OR, CST, CC, and frontal WM. Regions were obtained by warping 
standard space masks, including hand-drawn regions and regions derived from the 
Jülich histological atlas (OR, CST) and John Hopkins WM atlas (CC), in the same 
procedure as described in Chapter III. Example ROIs can be seen in Figure III.2. 
WM lesion load was obtained by calculating the volume of the overlapping lesion 
and WM masks, and normalized using the SIENAX-derived scaling factor. 
 
IV.3.3.5.  Thalamic segmentation 
Thalamic segmentation was performed on the SPGR 13° scan using FIRST 
(Patenaude et al., 2011), and the obtained volumes were normalized for intracranial 
volume using a scaling factor derived using SIENAX, as noted above. FIRST uses 
shape deformation from a-priori models made from a library of manually segmented 
healthy and pathological brains. Boundary correction is performed to classify voxels 
overlapping between adjacent structures (e.g. left and right thalami) depending on 
probability. Presence or absence of thalamic lesions was assessed systematically 
by looking at overlap of lesion masks with the thalamic masks. 
ROIs were created in the left and right thalamus by eroding the segmented masks 
by two, voxels in order to avoid partial volume effects. Thalamic segmentation and 
ROI masks are shown in Figure IV.3. 
Exploratory comparison between left and right thalamic volumes in the HC group 
revealed a significant difference, with the right thalamus being on average 2.13% 
smaller than the left (paired t-test, p < 0.001). To assess whether this effect was 
consistent across both groups, an asymmetry index was calculated as the ratio of 
the difference between left and right, to the average volume. Because this ratio did 
not significantly differ between the groups (p = 0.1), volumetric and quantitative 




Figure IV.3. Example thalamic masks and quantitative maps with overlaid regions of 
interest for: a) a healthy control, 46 years old, female; b) a neuromyelitis optica spectrum 
disorder subject, 48 years old, female, disease duration 7 years, EDSS 1. The masks used 
to collect quantitative metrics are slightly eroded compared to the volume mask to avoid 
partial volume effects. fM: myelin water fraction. ms: milliseconds. SPGR: (T1-weighted) 
spoiled gradient recalled. 
 
IV.3.4. Statistical analysis 
Statistical analysis was conducted in R version 3.3.3 (R Core Team, 2017). Group 
comparisons were performed using Student’s t-test. As lesion load was found to 
have a non-normal distribution, the relationships between this measure and 
thalamic metrics were assessed using Spearman’s rank correlation coefficient. 
Multiple regression analysis was used to test whether thalamic metrics could predict 
SDMT score in the NMOSD subgroup, with age as a covariate. All tests were 




IV.4.1.1.  Sample description 
The NMOSD and HC groups did not significantly differ in age (p = 0.8). In the 
NMOSD group, all but two subjects had detectable brain lesions. Among those with 
lesions, all had lesions in the WM, apart from one subject whose focal abnormalities 
were restricted to the right thalamus. 
 
IV.4.1.2.  Volumes 
Tissue-compartment-specific volumes for NMOSD and HC, and results from group 
comparisons performed using Student’s t-test are presented in Table IV.2, and 
shown in Figure IV.4. 
 
Table IV.2. Tissue compartment volumes. 
Volumes (cm3) HC NMOSD % diff. p 
   Whole-brain 1715.42 ± 77.18 1578.68 ± 116.27 -7.97% < 0.001*** 
   Cortical GM 563.08 ± 39.9 568.98 ± 69.16 +1.05% 0.747 
   Subcortical GM 131.04 ± 13.32 133 ± 17.10 +1.68% 0.655 
   WM 1021.230 ± 64.87 876.45 ± 45.10 -14.18% < 0.001*** 
   vCSF 26.76 ± 13.43 41.27 ± 21.18 +54.21% 0.016* 
   Lesions N/A 2.55 ± 3.44 N/A N/A 
   Lesions in WM N/A 1.97 ± 2.60 N/A N/A 
All volumetric measures, including white matter (WM) lesion volume, are normalized with 
respect to intracranial volume. cm: centimetre. fM: myelin water fraction. GM: grey matter. 
HC: healthy controls. ms: milliseconds. NMOSD: neuromyelitis optica spectrum disorder. 
N/A: not applicable. vCSF: ventricular cerebrospinal fluid. WM: white matter. % diff.: percent 
difference of NMOSD relative to HC. *Significant at p < 0.05; ***at p < 0.001. 
 
There were highly significant reductions in whole-brain and WM volume (both p < 
0.001), as well as an increase in ventricular CSF volume (p = 0.016) in NMOSD 
compared to HC. There were no significant differences between the groups in 




Figure IV.4. Group comparison between SIENAX-derived normalized volumes. Data points 
outside of boxplot whiskers are outliers, defined as being beyond 1.5 interquartile range of 
each quartile. GM: grey matter. HC: healthy controls. mm: millimetres. NMOSD: 
neuromyelitis optica spectrum disorder. vCSF: ventricular cerebrospinal fluid. WM: white 
matter. *Significant at p < 0.05; ***at p < 0.001. 
 
 
IV.4.1.3.  WM regions 
Group averages and differences in fM and T1 between WM ROIs are reported in 
Table IV.3, and shown in Figure IV.5. 
Across all NAWM, fM was reduced by 2.96% in the NMOSD group compared to HC, 
although this did not reach statistical significance (p = 0.068). There was a 
significant increase of 2.15% in T1 (p = 0.02). 
T1 was increased in NMOSD in the frontal, CST, OR and total NAWM, while fM was 
only reduced in NMOSD in the frontal WM and OR. Metrics in the CC differed only 
at a trend level of significance for both parameters (both p < 0.1).  
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Figure IV.5. Myelin water fraction and T1 across white matter regions of interest. Data points outside of boxplot whiskers are outliers, defined as being beyond 
1.5 interquartile range of each quartile. CC: corpus callosum. CST: corticospinal tract. fM: myelin water fraction. HC: healthy controls. ms: milliseconds. 
NAWM: normal-appearing white matter. NMOSD: neuromyelitis optica spectrum disorder. OR: optic radiation. WM: white matter. *Significant at p < 0.05; **at 
p < 0.01.
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Table IV.3. fM and T1 values for white matter regions of interest. 
 HC NMOSD % diff. p 
fM     
   Frontal WM 0.218 ± 0.013 0.208 ± 0.16 -5.06% 0.047* 
   CST 0.200 ± 0.007 0.195 ± 0.007 -2.52% 0.077 
   OR 0.233 ± 0.013 0.221 ± 0.017 -5.17% 0.037* 
   CC 0.226 ± 0.009 0.220 ± 0.010 -2.63% 0.070 
   Total NAWM 0.218 ± 0.009 0.212 ± 0.012 -2.96% 0.068 
T1 (ms)     
   Frontal WM 1051.87 ± 36.26 1089.72 ± 42.90 +3.94% 0.005** 
   CST 1131.31 ± 27.57 1155.09 ± 20.06 +2.10% 0.010** 
   OR 1028.66 ± 37.79 1074.44 ± 47.38 +4.45% 0.008** 
   CC 1040.08 ± 36.98 1058.17 ± 28.55 +1.73% 0.098 
   Total NAWM 1067.71 ± 31.53 1090.69 ± 30.31 +2.15% 0.024* 
Subjects with lesions in specific regions were excluded on a region of interest basis. Three 
NMOSD subjects had lesions in the frontal white matter; two in the corpus callosum; six in 
the optic radiations; eight in the corticospinal tract. CC: corpus callosum. CST: corticospinal 
tract. fM: myelin water fraction. HC: healthy controls. ms: milliseconds. NAWM: normal-
appearing white matter. NMOSD: neuromyelitis optica spectrum disorder. OR; optic 
radiations. WM: white matter. % diff.: percent difference of NMOSD relative to HC. 
*Significant at p < 0.05; **at p < 0.01. 
 
 
IV.4.1.4.  Thalamus metrics 
Four NMOSD subjects had small unilateral thalamic lesions (one left, three right). 
Thalamic volumes and quantitative parameters are reported in Table IV.4, and 
shown in Figure IV.6. 
The NMOSD group had on average lower thalamic volumes compared to HC, 
although this did not reach significance (-5.35%, p = 0.08). There were no 
significant differences in either fM or T1 within the thalamus between the groups 
(both p > 0.05). 
Scatter plots showing relationships with WM lesion load are shown in Figure IV.7. 
There were no significant correlations between WM lesion load and thalamic 
volume (Spearman’s rho = -0.29, p = 0.2), nor between WM lesion load and 
thalamic fM (rho = 0.2, p = 0.5) or T1 (rho = -0.44, p = 0.06). 
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Table IV.4. Thalamic quantitative metrics. 
Thalamic 
parameters HC NMOSD % diff. p 
   Volume (cm3) 11.77 ± 0.95 11.14 ± 1.24 -5.35% 0.084 
   fM 0.126 ± 0.007 0.124 ± 0.012 -1.86% 0.457 
   T1 (ms) 1505.86 ± 47.96 1514.57 ± 65.14 +0.58% 0.636 
Thalamic volume is normalized with respect to intracranial volume. Metrics are shown 
averaged between left and right. cm: centimetre. fM: myelin water fraction. HC: healthy 
controls. ms: milliseconds. NMOSD: neuromyelitis optica spectrum disorder. % diff.: percent 
difference of NMOSD relative to HC. 
 
 
Figure IV.6. Group differences in normalized thalamic volume, thalamic fM and T1 between 
healthy controls (HC) and neuromyelitis optica spectrum disorder (NMOSD) subjects. Data 
points outside of boxplot whiskers are outliers, defined as being beyond 1.5 interquartile 
range of each quartile. fM: myelin water fraction. mm: millimetres. ms: milliseconds. 
 
 
Figure IV.7. Scatter plots between white matter lesion volume and thalamic metrics in the 
neuromyelitis optica spectrum disorder group, all scaled to intracranial volume. None of the 
correlations assessed were significant (all p > 0.05). fM: myelin water fraction. mm: 
millimetre. ms: milliseconds. WM: white matter. 
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IV.4.1.5.  Relationships with SDMT score 
Relationships between SDMT and thalamic quantitative parameters (volume, fM and 
T1) are shown in Figure IV.8. 
 
 
Figure IV.8. Scatter plots between SDMT score and thalamic metrics: normalized thalamic 
volume, average thalamic fM and T1 in a subset of neuromyelitis optica spectrum disorder 
subjects (n = 12). A higher SDMT score reflects better performance. Significant results from 
univariate linear regressions are shown. fM: myelin water fraction. SDMT: symbol digit 
modalities test. 
 
Exploration of variables while setting up the multiple regression analysis revealed 
that fM and T1 were highly related (Pearson’s r = -0.77, p < 0.001), violating the 
assumption of non-collinearity between independent variables. Univariate linear 
regressions showed that T1 significantly explained a higher amount of variance in 
SDMT score (R2 = 0.60, p = 0.002) than fM (R2 = 0.36, p = 0.02), therefore fM was 
not included in the regression model. Thalamic volume was not related to either fM 
(r = -0.07, p = 0.8) or T1 (r = 0.01, p = 0.9). 
Multiple regression analysis showed a significant overall effect of thalamic metrics 
on SDMT score when controlling for age (adjusted R2 = 0.51, p = 0.04). However, 
neither age (p = 0.6) nor thalamic volume (p = 0.8) significantly contributed to the 
model, and therefore T1 was retained as the sole predictor of SDMT score. 
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IV.5. Discussion 
IV.5.1. Summary of findings 
We used MWI to investigate abnormalities in the NAWM and the thalamus in an 
NMOSD group compared to HC. Regional analysis of quantitative parameters 
revealed abnormal fM, and elevated T1 in several selected ROIs: fM was reduced in 
the frontal WM and OR, and T1 was increased in the frontal WM, OR, CST and total 
NAWM in NMOSD compared to controls. Indices in the CC were normal. Thalamic 
volume, fM and T1 did not differ between NMOSD and HC, and in the NMOSD 
group, these metrics were unrelated to WM lesion load. Assessing relationships 
between thalamic variables and SDMT score while controlling for age, T1 emerged 
as a strong predictor of performance. 
 
IV.5.2. Volumetric measures 
Volumetric analysis showed a similar pattern to that seen in the literature, with 
significant WM atrophy and preserved GM volumes. The absence of cortical 
atrophy is expected and in line with most previous studies, that only find distributed 
regional volume loss  in select areas. Of note, the large difference in ventricular 
CSF volumes reflects a high variance in the NMOSD group (i.e. some subjects 
having severe ventricular enlargement). One study using VBM of the ventricular 
CSF compartment found that enlargement of the third ventricle was especially 
severe compared to controls. Tissue loss due to periependymal inflammation has 
been brought up as a possible explanation for this observation (Schneider et al., 
2016). 
 
IV.5.3. NAWM pathology 
IV.5.3.1.  Possible aetiology 
There is mounting, if inconclusive, evidence for the presence of diffuse 
demyelination in NAWM; its detection appears to depend in part on the technique 
used. Jeong et al. used ViSTa and GRASE MWI to compare a range of ROIs 
between seropositive NMOSD and HC subjects (Jeong et al., 2017). They found 
that ViSTa was more sensitive than ‘conventional’ MWI in detecting group 
differences; this however raises the question of the specificity of this more recent, 
non-quantitative technique to demyelination as opposed to other pathological 
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substrates. Preliminary work comparing mcDESPOT with GRASE in MS and 
NMOSD has suggested that the latter may be more sensitive to group differences 
(Kolind et al., 2015a), which requires further investigation. 
Using a quantitative, myelin-specific technique, we bring further evidence that 
demyelination can be observed outside of lesions. We observed abnormal 
parameters in areas where secondary damage is expected (OR, CST), however, 
the presence of abnormalities in areas where other influences may be at play (CC, 
frontal WM) remains unclear. Alterations in T1 were observed in more regions than 
fM; when considering the whole NAWM as an ROI, only T1 was abnormal. We 
confirm some robust findings in the literature showing relative preservation of CC 
integrity, and abnormalities in the OR and CST. Significant demyelination in the OR 
has been shown before, including with two different MWI techniques (Jeong et al., 
2017; Manogaran et al., 2016a). 
The greater sensitivity of T1 to detect group differences in these regions suggests 
that, when present, demyelination is unlikely to be the main pathological process, 
and that changes in water content and/or axonal pathology may underlie the diffuse 
abnormalities seen in the brain. In support of this, Liu et al. found abnormal MD and 
radial diffusivity parameters, but normal FA in the NAWM, and raised the possibility 
of the presence of ‘low-grade’ damage, possibly due to an increase in intracellular 
water content, astrocytic pathology, or antibody-mediated cellular injury (Liu et al., 
2012b). 
Disruption of AQP4 channels may lead to disturbances in cerebral water 
homeostasis, but the relationship between this process and MRI metrics is 
unknown, and the influence of water content changes in brain tissue specific to 
NMOSD pathology on MRI parameters remains to be examined. Therefore, 
techniques such as absolute water content measurement, and markers of axonal 
damage and loss (e.g. g-ratio, neurite orientation dispersion measures) used in 
combination may hold promise for the assessment of diffuse WM damage, and to 
determine whether a primary pathological process can explain the abnormalities 
observed in regions putatively less susceptible to secondary damage (CC, frontal 
WM). Using multi-echo T2 relaxometry data to obtain absolute measures of water 
content, preliminary work has shown increases in water content in the NAWM 
(Vavasour et al., 2016), which would be an interesting measure to explore in 
conjunction with MWI. 
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IV.5.3.2.  Corpus callosum 
A number of the studies cited above report abnormalities of the CC (He et al., 
2011b; Zhao et al., 2012), which in MS has known susceptibility to axonal damage 
following lesions throughout the WM, via secondary degeneration of commissural 
fibres (Evangelou, 2000). Despite inconsistent findings, it has been proposed that 
DTI indices in the CC could help differentiate between RRMS and NMO (Yu et al., 
2007). While we did not assess callosal atrophy, we found normal fM and T1 values 
in this structure (although both of these results could be considered borderline 
significant at p < 0.1). The severity of pathology in the CC has been proposed as a 
differentiating feature between MS and NMOSD, which is supported by the present 
observation. 
 
IV.5.4. Thalamus findings 
IV.5.4.1.  Structural damage 
The absence of significant thalamic atrophy is in line with other studies using FIRST 
(see IV.2.3). The present results provide complementary evidence that tissue 
integrity in this structure may be preserved, or only subject to subtle alterations, in 
NMOSD.  
One study found increased FA and decreased MD in the thalamus of NMOSD 
subjects, which the authors suggest may be consistent with "increased myelination 
and axonal packing" (Zhao et al., 2012). They raise the hypothesis of a possible 
compensatory effect from damage to other regions, or to the surrounding white 
matter; however, this has not been consistently replicated (Finke et al., 2016; Liu et 
al., 2015a). We found normal myelin content in the thalamus, and no relationship of 
fM to WM lesion load. Although not yet extensively studied, in MS, demyelination of 
DGM structures has been found to be related to cortical, but not WM demyelination 
(Minagar et al., 2013); therefore, normal fM would be consistent with the lack of 
cortical demyelination found in NMOSD. Normal microstructural parameters 
suggest that thalamic demyelination may not be the main feature underlying the 
abnormalities reported in the DTI literature. Further multimodal investigations into 
the type of tissue damage driving the loss of thalamic volume observed in some 
studies would shed light on this. 
The vicinity of the thalamus to the ventricles, a region of high AQP4 expression, 
has been invoked as reason it may be vulnerable to AQP4-antibody attacks (Hyun 
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et al., 2016; Su et al., 2016), suggesting that abnormalities may be due to a direct 
pathological process, and not just secondary damage. However, previous 
investigations have shown a relationship with lesion volume (excluding subjects 
with thalamic lesions), which is evidence towards a secondary origin of thalamic 
pathology as it would result from distal lesions in thalamic tracts. In MS, it has been 
proposed that lesions in the thalamocortical WM could cause retrograde damage to 
the thalamic nuclei (Henry et al., 2009), and thalamus volume has been linked with 
T2 lesion volume in RRMS (Duan et al., 2012; Shiee et al., 2012). In this study, we 
found thalamic parameters to be unrelated to WM lesion load. However, the lack of 
spread in lesion load in the current sample may be a limiting factor. 
 
IV.5.4.2.  Influence of demographic factors 
Thalamic atrophy has been an inconsistent finding in previous studies. The present 
investigation used a Canadian group of mixed ethnicity and AQP4 antibody status. 
Some authors have remarked that studies in Asian populations tend to find thalamic 
atrophy, while those in Caucasian groups do so less often (Hyun et al., 2016). 
Although the distinction regarding a distinct ‘Asian optic-spinal MS’ and NMOSD is 
generally regarded as outdated, and the differences are as likely to be due to 
differences in analysis methods, centre-dependent therapeutic options, and 
genuine heterogeneity in cohorts as they are attributable to race, the differing 
prevalence of NMOSD based on ethnicity suggests these discrepancies may be 
grounded in real phenotypic differences, although this remains to be examined 
(Finke et al., 2016). 
Fan et al. found reduced thalamic volumes in seronegative, but not in seropositive 
subjects compared to HC, and suggested that AQP4-antibody-negative NMOSD 
could represent a ‘halfway phenotype’ between MS and NMO (Fan et al., 2017). 
 
IV.5.4.3.  Thalamic segmentation 
Regarding volume measurements, segmentation of the thalamus can be 
complicated by its mixed grey and white matter content, which gives it a ‘blurry’ 
delineation on T1-weighted images and may lessen the precision of volume 
estimates. When it came to ROI measurements, conservative masks were used in 
order to prevent contamination by ventricular CSF. 
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Only one study has looked at regional variations in thalamic parameters, 
segmenting the structure into functionally distinct subregions; all subregions were 
consistently affected with respect to volume loss, reduced FA and increased MD 
(Liu et al., 2015a). However, Pache et al. found reduced FA in the posterior 
thalamic radiations but normal thalamic volumes, using an ROI approach (Pache et 
al., 2016). Using TBSS, Pichiecchio et al. found reduced FA in the OR extending 
into the thalamic lateral geniculate nuclei, part of the optic pathways, in patients 
with a history of optic neuritis (Pichiecchio et al., 2012). 
Therefore, it is possible that subregional differences may exist; thalamus 
parcellation may afford additional information, as would voxelwise assessment of 
volume and quantitative parameters, which may reveal localized changes not 
detectable with whole-ROI measures. The use of T1 maps has been proposed to 
improve segmentation of thalamic nuclei, based on an a priori atlas (Traynor et al., 
2011), which may be an interesting extension to the current study, although this 
would require images with higher resolution than were available here. Other 
advanced methods for segmenting the thalamus have been proposed, based on 
structural connectivity assessed with diffusion tensor imaging (Behrens et al., 
2003). 
 
IV.5.4.4.  Relationship of thalamic metrics with cognitive 
performance 
We found relationships between both fM and T1 with SDMT score in an NMOSD 
group. T1 and fM are intrinsically correlated (De Santis et al., 2014), due to the 
influence of macromolecules on longitudinal relaxation; however, T1 emerged as 
the strongest predictor of performance, even in the absence of significant 
differences with a control group. Associations between indices of thalamic 
pathology and cognitive scores have previously been reported (Blanc et al., 2012; 
Wang et al., 2015), and the present finding provides further evidence that this 
structure may be linked with cognitive impairment in NMOSD. 
It is likely, as is frequent in neurological populations, that other causes or mediating 
factors contribute to cognitive slowing than a purely organic aetiology. No studies 
have so far found links between cognitive impairment and depression in NMOSD 
(Blanc et al., 2008; He et al., 2011a; Saji et al., 2013). A link with sleep 
abnormalities is possible; thalamic neurons are involved in sleep regulation, and 
thalamic atrophy (right-lateralized only) has also been linked with disturbances in 
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slow wave sleep (Su et al., 2016). The interaction of sleep, depression, and their 
impact on cognitive disturbances are unknown, and further studies are needed to 
address this in the context of NMOSD. 
 
IV.5.5. General limitations 
IV.5.5.1.  Population 
Kim et al. remarked that the heterogeneity of results obtained in investigations of 
the brain in NMOSD may be attributable to the following causes: discrepancy in 
diagnostic criteria employed; proportion of seropositive subjects, and presence of 
brain lesions (Kim et al., 2016b). 
All but two subjects included in this study had detectable brain lesions. Despite the 
presence of some subjects with short disease durations, all NMOSD subjects had 
an EDSS ≥ 1, ensuring at least some degree of disease evolution. Moreover, the 
group included a balance of AQP4 antibody-positive and negative subjects. While 
reflecting the broad spectrum of NMOSD disease in a real-world setting is 
interesting, it could be argued that research should focus on seropositive cases in 
order to better identify the pathological features of the disease. We did not assess 
the influence of serostatus on results, although exploration of the results did not 
show differences between these subgroups [data not shown]. (This negative result 
should of course be viewed in the context of the small group sizes, as well as the 
resulting differences in other clinical characteristics in the subgroups, after 
subdividing by seropositivity.) 
Myelin oligodendrocyte glycoprotein (MOG) antibodies are found in 21-33% of 
AQP4-IgG-negative NMOSD cases, although MOG-immunoglobulin (MOG-IgG) 
seropositivity is not specific to NMOSD (Sato et al., 2014; van Pelt et al., 2016). Of 
particular relevance to the present study, one group noted the higher prevalence of 
deep grey matter lesions in a MOG-IgG-positive sample compared with AQP4-IgG-
positive NMOSD subjects (Kitley et al., 2014b). Here, the presence of MOG 
antibodies was not assessed, and thus we could not ascertain the proportion of 
these patients in our sample nor compare and contrast their characteristics to HC 
and AQP4-IgG-positive subjects. 
Sample size is an evident issue common to research in rare disorders, and 
especially for the cognitive data presented here. Another general limitation, as 
noted by Pache et al., is that chronically ill patients on polypharmacotherapies are 
 138  
likely to show various structural changes when compared to matched “super-
controls” in research studies (Pache et al., 2016). 
 
IV.5.5.2.  Defining cognitive performance 
Defining individual patients as cognitively impaired vs. preserved requires 
normative data, or ranking performance compared to a control population. This can 
be done by determining cut-off values based on deviation from normalized 
performance on one or an assortment of cognitive tests, in comparison with a 
control group assessed concurrently, or using literature-derived normative values. 
However, in MS research, the separation of patients in two groups (impaired vs. 
non-impaired) based on cut-off values on one or several tests, or on the number of 
tests within a battery meeting a certain cut-off point, has been criticized as 
disregarding which domains cognitive impairment manifests in (Levin et al., 2017). 
The definition of “cognitive phenotypes”, and the potential of such classification in 
improving detection of cognitive impairment and therefore the efficacy of treatment 
and remediation strategies, has been highlighted as a priority in the field of 
cognitive rehabilitation (Sumowski et al., 2018). 
The SDMT, considered the most sensitive method of measuring information 
processing speed (IPS), is itself related to broader cognitive functioning, which has 
a high impact on activities of daily living in MS (Benedict et al., 2017). IPS is 
thought to be the main domain underlying impaired performance in other domains, 
such as executive function and working memory (Leavitt et al., 2014), and plays a 
greater role than working memory impairment in explaining general information 
processing deficits in MS patients (DeLuca et al., 2004). Slowed IPS also underlies 
difficulties in planning ability in a problem-solving context (Tower of London task) 
(Owens et al., 2013), and SDMT score has been linked with automobile driving 
performance in MS patients (Schultheis et al., 2010). 
This score can therefore be regarded as a measure of cognitive performance rather 
than impairment. In MS, it is strongly associated with brain atrophy, T2 lesion 
volume (Rao et al., 2014) and thalamic atrophy (Batista et al., 2012). There is 
strong support for its use above other tests in clinical practice (Benedict et al., 
2002; Langdon et al., 2012), and it has recently been suggested as a replacement 
for the PASAT in MS clinical trials (Benedict et al., 2017), due to its ease of 
administration and rating, and its strong psychometric profile in terms of sensitivity 
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and construct validity (Sonder et al., 2014). Here, we were interested not in defining 
cognitive impairment, or even impaired IPS, as a discrete category, but in probing 
subtle changes in performance. We therefore employed the SDMT as a measure of 
cognitive slowing. 
Additional information on performance in other cognitive domains, such as 
attention, memory or visuospatial perception, would without a doubt be valuable. A 
self-contained battery designed for use in MS, such as the Brief International 
Cognitive Assessment for MS (BICAMS; (Langdon et al., 2012)), would offer the 
advantage of providing normative values based on demographic characteristics. 
Other available batteries designed for use with MS populations include the Brief 
Repeatable Battery of Neuropsychological tests (BRB-N) and the Minimal 
Assessment of Cognitive Function in MS (MACFIMS), which take 45 and 90 
minutes respectively (Langdon, 2011). A range of neuropsychological tests have 
been used in previous studies of NMOSD (see IV.2.4), with the BRB-N battery 
appearing most frequently (Eizaguirre et al., 2017). However, these tools have not 
yet been validated for use in NMOSD. The SDMT forms part of these three 
batteries, and the BICAMS panel echoed previous recommendations that when 
time or other constraints should limit assessment to a single test, the SDMT should 
be used, which motivated the choice of this measure in the present study (Sepulcre 
et al., 2006). 
Other limitations of the cognitive assessment performed here include the lack of 
cognitive data for HC. Cognitive testing for some subjects was not done at the time 
of scanning, a major limitation to the precision of this analysis. In addition, 
longitudinal studies tracking the evolution of cognitive performance over time, in 
relation to attacks and MRI activity, would be useful. 
 
IV.5.5.3.  Lesion segmentation 
It should be noted that the FLAIR2 method is experimental, and has only been fully 
evaluated for the assessment of MS lesions. The different characteristics of 
NMOSD lesions may lead to different contrast and thus appearance on FLAIR2, and 
this would require validation. In this project, it was meant to be an aid to lesion 
identification, in conjunction with other images. 
Moreover, lesion assessment was performed by trained, but not expert, assessors, 
the aim being to isolate gross areas of focal pathology. While masks were reviewed 
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by an expert neurologist, the focus was on preventing false positives, and it is a 
possibility that some smaller, or less conspicuous lesions were missed. However, 
the purpose of lesion identification here was to measure WM lesion load, to mask 
out lesions from NAWM, and to identify lesions within specific ROIs. Therefore, we 
do not anticipate great impact of false positive or negatives in lesion detection to be 
a major factor in any of the results (i.e. lesions small enough to be missed would 
not have a major impact on the measurements performed here). 
 
IV.6. Conclusion 
We investigated quantitative indices of myelin content and T1 relaxation time in 
NMOSD compared to HC. We found abnormal metrics in the OR and CST, 
consistently with previous literature findings, as well as in the frontal MW, a region 
where secondary demyelination would not typically be observed. Metrics in the CC 
were normal. The borderline significance of some results raises the question of the 
sensitivity of the metrics used to the tissue abnormalities in NMOSD in these 
regions. Because T1 revealed a greater number of significant differences relative to 
the HC group, we hypothesize that changes in water content, rather than severe 
demyelination, are responsible for the differences observed. We also observed 
relationships between quantitative metrics of tissue integrity in the thalamus and a 
measure of IPS, even when those parameters were normal compared to controls 
and in the absence of atrophy. This result provides encouraging evidence for the 
association of thalamic pathology and cognitive performance in NMOSD.  
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Chapter V. Longitudinal cervical cord 
myelin water imaging in multiple 
sclerosis and neuromyelitis optica 
spectrum disorder 
 
In this chapter, we present a longitudinal study of the cervical spinal cord in multiple 
sclerosis and neuromyelitis optica spectrum disorder using myelin water imaging. 
We collected mcDESPOT at baseline and one-year follow-up in matched controls 
and patients, in the absence of clinical relapses. We aimed to compare measures 
of cord volume and myelin water fraction at both time points, to assess the 
presence of abnormalities in normal-appearing and lesioned areas of the cord, as 
well as atrophy and changes in myelin content over time. 
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Spinal cord pathology is a feature of both neuromyelitis optica spectrum disorder 
(NMOSD) and relapsing-remitting multiple sclerosis (MS). While subclinical disease 
activity has been described in MS using quantitative magnetic resonance imaging 
(MRI) measures, current evidence suggests that neurodegeneration is absent 
between relapses in NMOSD. However, most of the evidence comes from brain 
studies, and only a limited number of studies have investigated cord pathology in 
NMOSD using advanced MRI. 
 143  
A previous longitudinal study using a range of quantitative MRI metrics in the brain 
showed a lack of nonfocal damage in an NMOSD group at baseline, as well as 
stability over one year, but evidence of widespread abnormalities and ongoing 
neurodegeneration in a relapsing-remitting MS group (Matthews et al., 2015). 
Following up on this project, we investigated cervical cord atrophy and myelin 
integrity in clinically stable NMOSD and MS subjects compared to healthy controls. 
All participants were scanned using a multicomponent Driven Equilibrium Single 
Pulse Observation of T1 and T2 (mcDESPOT) protocol at baseline, and after one 
year in the absence of relapses. We collected measures of cervical cord volume, as 
well as myelin water fraction (fM) within lesioned and non-lesioned areas. We aimed 
to assess myelin content in the cord outside of lesions in the patient groups, as well 
as the presence of detectable changes in these metrics over time. 
 
V.2. Background 
V.2.1. Disease progression in MS and NMOSD 
NMOSD is a relapsing autoimmune disease of the central nervous system that, due 
to similar clinical and neurological features, was long thought to be a rare variant of 
MS (Wingerchuk et al., 2015). Since the discovery of a highly specific antibody 
(Jarius and Wildemann, 2010), and the advent of serum testing to aid differential 
diagnosis, it is now considered a separate entity (Weinshenker, 2007). Serum 
antibodies to the aquaporin-4 water channel protein (AQP4-Ab), found on astrocytic 
foot processes, are detectable in a high proportion of patients (Pandit et al., 2015). 
AQP4 is expressed throughout the brain, and is found in particularly high 
concentration in the optic nerve and spinal cord, in line with the observed frequency 
of pathology in these regions in NMOSD (Pittock et al., 2006b). 
Unlike in MS, which can present as a relapsing-remitting disease with secondary 
conversion to a progressive phase, or as progressive from onset (Compston and 
Coles, 2008), conversion to a progressive phase is extremely rare in NMOSD 
(Aboul-Enein et al., 2013; Cabre et al., 2009; Collongues et al., 2014, 2010). 
Clinical disability is accrued as a consequence of damage sustained during 
relapses, whereas clinical disability scores in MS increase more steadily during the 
progressive phase (Collongues et al., 2011; Wingerchuk et al., 2007a). Current 
clinical and neuroimaging evidence suggests that subclinical disease activity does 
not occur between attacks in NMOSD (Wingerchuk et al., 2007b), contrary to what 
is observed in MS (Filippi and Agosta, 2010; Matthews et al., 2015). However, it 
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has been suggested that NMOSD attacks are so severe that the resulting sequelae 
hide the subtler changes that may accrue over time as a result of progressive 
axonal deterioration following relapse-related inflammation (Wingerchuk et al., 
1999). 
 
V.2.2. Imaging the cervical cord 
The cervical cord is the portion of the spinal cord at the neck level. Anatomical 
locations of the cord can be labelled relative to the vertebral bones; the cervical 
cord corresponds to vertebral levels C1 to C7. It is 10-12 centimetres (cm) long, 
around 1 cm in diameter, and occupies about two thirds of the space in the spinal 
canal (Jacobson and Marcus, 2011). Morphological measures of the cord include 
volume and cross-sectional area (CSA) measurements, grey and white matter (GM, 
WM) areas and their ratio. These measurements vary across segments, although 
the cervical cord is relatively homogeneous in the rostro-caudal direction compared 
to the lower cord sections (Fradet et al., 2014). 
There are several challenges to imaging the cervical cord, due to its small size, its 
high sensitivity to motion artefacts from the cardiac and respiratory cycles, and 
magnetic susceptibility effects due to the interface of air, tissue, and bone; 
however, recent technical efforts have endeavoured to translate the wide array of 
techniques available for brain imaging to the cord (Stroman et al., 2014), including 
myelin water imaging (MWI). 
Wu et al. first implemented multi-echo T2 (MET2)-based MWI in the cervical cord in 
vivo, and showed good reproducibility (Wu et al., 2006). A similar protocol was 
subsequently applied to the cervical and thoracic portions of the cord (Minty et al., 
2009), and used in primary progressive MS subjects to demonstrate reduced 
myelin water fraction at the C2/C3 level, and continued decrease over two years 
(Laule et al., 2010). MacMillan et al. found differences in MET2-derived myelin 
water fraction at the C5 level between younger and older healthy adults (MacMillan 
et al., 2011). 
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Figure V.1. mcDESPOT protocol in the cervical spinal cord. a) Cervical cord myelin water 
fraction (fM) map for a healthy volunteer, with axial cross-sections at the C2 and C5 levels 
where the characteristic grey matter ‘butterfly’ is visible. b) Axial sections of fM maps from 
seven healthy volunteers at the C2 level. Source: (Kolind and Deoni, 2011); inset from 
Gray’s Anatomy (Mancall and Brock, 2011). 
 
mcDESPOT is a quantitative MWI method with high sensitivity for the estimation of 
myelin content (Deoni et al., 2008a). Kolind and Deoni first implemented the 
protocol in the cervical cord (Kolind and Deoni, 2011). They showed good reliability 
for fM estimates with the whole cervical cord taken as a region of interest, with an 
average coefficient of variation of 2.6% (range 0.6-5.7% across five healthy 
volunteers, scanned twice within 3 months), which compared favourably to the 
scan-rescan repeatability of other MWI methods. The axial resolution of 1 mm2 also 
allowed for the visualization of GM and WM, with good contrast (Figure V.1). Only 
one study so far has used mcDESPOT in the cord in clinical research, to show that 
fM in primary progressive MS patients was reduced by 11% compared to controls, 
and correlated with ambulatory and manual dexterity scores (Kolind et al., 2015b). 
 
 146  
V.2.3. Cervical cord pathology in MS and NMOSD 
Cord pathology is present in 80-90% of relapsing-remitting MS cases, with the 
cervical cord being a preferential site of involvement; demyelinating cord lesions 
are most often seen in the lateral and dorsal WM columns (Gass et al., 2015). In 
NMOSD, the main feature of cord pathology is the presence of longitudinally 
extensive lesions, spanning three or more vertebral segments, that favour the GM 
(Nakamura et al., 2008). 
Cord lesions in NMOSD are characterised by abnormal diffusion metrics, reflecting 
greater tissue injury compared with MS lesions (Klawiter et al., 2012; Rivero et al., 
2014). Abnormally low myo-inositol (normalized to creatine) levels have been 
measured in the upper cervical cord, proposed to reflect astrocytic dysfunction 
within lesions, a process thought to play a major role in the pathogenesis of the 
disease by contributing to oligodendrocyte dysfunction and eventually secondary 
demyelination (Ciccarelli et al., 2013). Abnormal magnetization transfer (Benedetti 
et al., 2006; Filippi et al., 1999; Rocca et al., 2004a) and diffusion parameters 
(Jeantroux et al., 2012; Pessôa et al., 2012; Qian et al., 2011; Rivero et al., 2014) 
have been observed in the cervical cord, suggesting the presence of inflammatory 
processes, demyelination and axonal pathology. 
However, very few studies have differentiated between lesional and normal-
appearing spinal cord tissue (NASCT). Abnormal mean diffusivity and 
perpendicular diffusivity parameters in the NASCT have been attributed to 
inflammation and demyelination, respectively (Qian et al., 2011). In another study, 
altered diffusion parameters were found in WM tracts in regions up- or down-stream 
of focal lesions in both diseases, while tracts not directly adjoining lesions were 
affected in MS, but not in NMOSD (Klawiter et al., 2012). Diffuse damage in 
unaffected tracts can be attributed to MS lesions not visible on standard imaging 
(e.g. those below the imaging resolution), diffuse damage, or distal effects of 
regions outside the cervical cord. Moreover, some of the abnormalities observed in 
brain may be secondary to cord pathology (Calabrese et al., 2012; Rocca et al., 
2004b; Saji et al., 2013). 
Overall, focal cord pathology in NMOSD is considered more aggressive; secondary 
degenerative processes in WM tracts may be common to both diseases (Klawiter et 
al., 2012). To date, no longitudinal advanced imaging study has assessed whether 
changes in NASCT occur in NMOSD outside of clinical relapses. 
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V.2.4. Rationale for this study 
V.2.4.1. Previous work 
In a recent multimodal investigation, Matthews et al. built upon the theory that 
occult damage in relapsing-remitting MS results from subclinical disease 
progression, rather than being merely secondary to focal pathology. They 
hypothesized that in NMOSD, evidence of disease activity between relapses would 
be absent, despite more severe relapse-related damage (Matthews et al., 2015). 
Advanced MRI surrogate markers of neurodegeneration, including regional atrophy 
measures, diffusion and MWI metrics in the brain were investigated over one year 
in clinically stable MS and aquaporin-4 antibody-positive NMOSD patients. 
Their results showed evidence of widespread non-lesional abnormalities in the MS 
group only, using several MRI parameters including volumetric measures, MWI and 
diffusion tensor imaging. NMOSD non-lesional cerebral tissue was found to be 
similar to controls, except for abnormalities in the optic radiations, in relation with 
the high prevalence of previous optic neuritis in this group. No evidence of disease 
progression was seen in the NMOSD group, while several measures in the MS 
group showed changes over one year suggestive of subclinical disease activity, 
including the mcDESPOT-derived fM in major WM tracts. 
 
V.2.4.2. Study aims 
In this study, we extend this work to the cervical spinal cord in a subset of the same 
cohort, including aquaporin-4 antibody-positive NMOSD, relapsing-remitting MS 
subjects, and matched healthy controls. Participants were scanned at baseline and 
one-year follow-up using mcDESPOT. We obtained measures of cervical cord 
volume and fM, a surrogate marker of myelin content, differentiating between 
lesional and normal-appearing portions of the cord, to investigate cross-sectional 
differences and changes over time in patients and controls. We aimed to 
characterise normal-appearing and lesional cervical cord pathology at baseline, and 
to assess whether evidence of degenerative changes could be detected over one 
year in either patient group. 
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V.3. Methods 
V.3.1. Study design and population characteristics 
This study was approved by the South East Hampshire NHS Research Ethics 
Committee. 15 antibody-positive NMOSD patients, 15 relapsing-remitting MS 
patients, and 17 sex and age-matched healthy controls were recruited from the 
NHS Neuromyelitis Optica Highly Specialized Service in Oxford, UK. All participants 
gave written informed consent before taking part. 
All NMOSD subjects were receiving immunosuppressant medication: 7 were on 
azathioprine, 2 on methotrexate, 1 on prednisone, and 5 on combinations thereof. 
The majority of MS subjects were on disease-modifying therapies (DMTs): 6 on 
Copaxone, 3 on beta-interferons, and 1 on low-dose naltrexone; 5 were not 
receiving treatment. 
A subset of 8 NMOSD, 11 MS and 14 controls completed a follow-up scan after one 
year. All patients had been relapse-free for at least 6 months prior to the baseline 
scan, and none experienced a relapse between baseline and follow-up. 
EDSS assessments were performed at both time points by a neurologist. There are 
varying definitions of what constitutes significant clinical deterioration using this 
scale. A commonly agreed upon definition in MS clinical trials is a change of 1 point 
if baseline score is £ 5.5, and 0.5 if baseline is ≥ 5.5, although a cut-off of 6 has 
also been recommended (Healy et al., 2013; Meyer-Moock et al., 2014). 
 
V.3.2. MRI acquisition 
Participants were scanned on a 3T MRI scanner (Siemens MAGNETOM Verio, 
Erlangen, Germany) using a custom-built neck coil. 
The mcDESPOT protocol was acquired sagittally, and covered the whole cervical 
cord with 0.9 x 0.9 x 1.8 mm voxels, reconstructed to 0.9 mm3 isotropic  (Kolind and 
Deoni, 2011). Acquisition time was 22 minutes. Data consisted in a series of eight 
spoiled gradient echo (SPGR) scans over a range of flip angles (α), an inversion 
recovery-prepared SPGR scan for correction of B1 inhomogeneity (Deoni, 2011), 
and eight balanced steady-state free precession scans (bSSFP). Repetition (TR), 
echo (TE), and inversion times (TI) below are in milliseconds. 
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SPGR: TE/TR = 2.7/6.1 ms; α = [2.25, 4.5, 6.75, 9, 11.25, 13.5, 15.75, 18]°. 
IR-SPGR: TE/TR = 2.7/6.3 ms; TI = 450 ms; α = 5°. 
bSSFP: TE/TR = 2.3/4.6 ms; α = [5.625, 11.25, 16.875, 22.5, 28.125, 33.75, 
39.375, 45]°, acquired over two phase-cycling patterns (0° and 180°) to correct for 
off-resonance effects (Deoni, 2009a). 
An axial T2-weighted multi-echo gradient echo sequence (voxel size: 0.7 x 0.7 x 3 
mm, TE/TR = 17/470 ms, 30 slices with the uppermost slice at the superior border 
of C2), a sagittal T1-weighted magnetization-prepared rapid gradient echo (voxel 
size: 1 x 1 x 0.9 mm, TE/TR = 3.59/2300 ms, α = 9°), and a sagittal T2-weighted 
turbo spin echo sequence (voxel size: 0.6 x 0.6 x 3 mm, 15 slices, TE/TR = 67/4590 
ms) were acquired for lesion identification. 
 
V.3.3. Image analysis 
V.3.3.1. Cord segmentation 
For each subject, an SPGR image from the mcDESPOT protocol with good contrast 
between tissue and cerebrospinal fluid (α = 9°) was used for preprocessing. The 
spinal cord was segmented using PropSeg (De Leener et al., 2014), a semi-
automated propagation-based method from the Spinal Cord Toolbox15 (SCT) (De 
Leener et al., 2017). Each subject’s SPGR was warped to the MNI-Poly-AMU 
template (Fonov et al., 2014). The inverse transform was then applied to the 
template in order to obtain vertebral level segmentation in subject space (see 
Figure V.2). 
                                                
15 Details on the software can be found at: http://sourceforge.net/projects/spinalcordtoolbox 
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Figure V.2. Cord segmentation and vertebral level identification using the Spinal Cord 
Toolbox. A semi-automated binary segmentation method (PropSeg) is first applied to a 
structural T1-weighted scan. A nonlinear transform from atlas to subject space is then 
applied to the MNI-Poly_AMU atlas. The labelling of vertebral segments, from C1 to C7, 
enables isolation of normal-appearing and lesioned areas of the cord. 
 
 
V.3.3.2. Lesion identif ication 
Lesions were identified on the patients’ anatomical scans by an experienced 
radiologist blinded to diagnosis, primarily based on the sagittal T2-weighted scan 
with additional information gleaned from the sagittal T1 and axial T2-weighted scans. 
The assessment was done for both baseline and follow-up concurrently. Spinal 
levels were identified as normal-appearing or lesioned. For small lesions located at 
a disc level, both adjoining segments were considered lesioned. 
Using the segmentation and labelling procedure described above, separate masks 
were created including only segments marked as either normal-appearing or 
lesioned. An example of a lesioned tissue mask is shown in Figure V.3. 
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Figure V.3. Procedure for segmentation of lesioned areas. a) Example of a T2-hyperintense 
lesion at the C4 level in a multiple sclerosis subject (female, 28 years old, EDSS 2), and b) 
an extensive lesion from C1 to C4 in a neuromyelitis optica spectrum disorder (NMOSD) 
subject (female, 39 years old, EDSS 3.5). c) Example of a T2-hyperintense lesion in a 
(different) NMOSD subject at the C1/C2 level (left), and corresponding cord segmentation 
on an SPGR image from the mcDESPOT protocol (right). The area at the C1/C2 level was 
categorized as lesioned (in red), and the remaining portion of the cord as preserved tissue 
(in green). 
 
V.3.3.3. Volume measurements 
Cord length from the top of C1 to the bottom of C7 was calculated using the SCT, 
which determines the centerline of the segmented volume and corrects it for cord 
orientation. Cord volume, normalized by length, was measured on the SPGR scan. 
Volumes were collected in cubic millimetres, and cervical cord length in millimetres, 
therefore normalized volumes are reported in square millimetres (mm2). This 
corresponds to the average cross-sectional area (CSA) of the cord, despite not 
being a direct measurement of this metric. 
 
V.3.3.4. Myelin water fraction measurements 
Visual quality control of individual images from mcDESPOT acquisition showed no 
significant nonlinear deformations between scans (see V.5.4.1 for discussion of 
motion). Images were linearly registered within-subject to the reference SPGR scan 
with FSL-FLIRT (Jenkinson et al., 2002), using trilinear interpolation. Individual 
linear registration strategies were employed to ensure optimal co-registration for 
each volume when necessary (e.g. masking/weighting of relevant portions of the 
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region of interest; two-step registration using an intermediate image for bSSFP 
images with banding artefacts, etc.). 
fM maps were calculated with a three-pool model (Deoni et al., 2013), and manually 
edited by an observer blinded to group and time point to exclude voxels where 
partial volume effects in the acquired images led to artificially very low computed 
values. Visual inspection was performed on all images to ensure the quality of co-
registration. Median fM values were collected within the whole cervical cord for 
controls, and within NASCT and lesioned tissue separately for patients, using the 
masks described above. 
 
V.3.4. Statistical analysis 
Non-parametric tests were chosen due to small sample sizes, the presence of 
outliers, and after visual inspection showed that MRI variables were not normally 
distributed. 
Percent changes between baseline and follow-up metrics were calculated for each 
subject. Differences between patient groups were evaluated using the Mann-
Whitney U test, and between the three groups using the Kruskal-Wallis test. Post 
hoc comparisons following a significant omnibus test (α = 0.05) were conducted 
with the Mann-Whitney U test. 
Within-group differences were assessed using paired Wilcoxon’s signed rank tests. 
We tested cross-sectional differences between NASCT and lesional segments 
within each patient group, and changes over time within each group and tissue 
type. 
Results were not corrected for multiple comparisons, due to the exploratory nature 
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V.4. Results 
Subject characteristics are summarized in Table V.1. There was no significant 
difference in age between the three groups (p = 0.6). Both patient groups had 
equivalent disease duration (p = 0.6). The NMOSD group had a higher median 
Expanded Disability Status Score (EDSS) (p = 0.03). 
Summary baseline and longitudinal MRI metrics, and group comparisons are 
displayed in Table V.2. 
 
Table V.1. Population characteristics for the cross-sectional sample. 
 Controls MS NMOSD p 
N (sex) 17 (4M) 15 (4M) 15 (3M) - 
Age (years) 54 (19-76) 41 (22-68) 45 (20-76) 0.586 
Disease duration 
(months) - 72 (24-254) 60 (12-186) 0.589 
Baseline EDSS - 2 (0-5) 4 (2-7.5) 0.033* 
Lesioned segments 
per subject - 5 (0-7) 3 (0-7) 0.098 
Number of subjects 
with NASCT - 11 13 - 
Number of subjects 
with ≥ 1 lesion - 14 13 - 
Values are reported as median (range) unless specified otherwise. Group comparisons are 
performed with the Kruskal-Wallis test. Where only pairwise MS vs. NMOSD comparisons 
are appropriate, results from the Mann-Whitney U test are reported. *Significant at p ≤ 0.05. 
EDSS: Expanded Disability Status Scale. M: male. MS: multiple sclerosis. NASCT: normal-
appearing spinal cord tissue. NMOSD: neuromyelitis optica spectrum disorder. 
 
V.4.1. Cross-sectional 
V.4.1.1. Lesion identif ication 
At baseline, in the MS group, a total of 67/105 segments (65%) were identified as 
containing lesioned tissue. Four MS subjects had lesions spanning the whole 
cervical cord, and one had no detectable lesions. In the NMOSD group, a total of 
47/105 segments (45%) contained lesions. Two NMOSD subjects had lesions 
spanning the whole cord, and two had none. The number of lesional segments per 
subject did not differ significantly between groups (p = 0.1) (see Table V.1). The 
distribution of lesions along the cord is shown in Figure V.8. 
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V.4.1.2. Cord volume 
Normalized cord volumes for each group can be seen in Figure V.4. 
Compared to controls, both the MS (on average -6.5%, p = 0.1; not significant) and 
NMOSD (-12.5%, p = 0.009) groups had smaller volumes. The difference between 
MS and NMOSD was not significant, despite NMOSD having smaller volumes on 





Figure V.4. Cervical cord volumes at baseline and over time. Cross-sectional: normalized 
cord volume at baseline. Right-hand axis shows percent difference of each data point from 
the control group average. Longitudinal: percent change over one year. Dotted line 
represents 0% change from baseline. Data points outside of boxplot whiskers are outliers, 
defined as being beyond 1.5 interquartile range of each quartile. *Significant at p ≤ 0.05, **p 
≤ 0.01. MS: multiple sclerosis. NMOSD: neuromyelitis optica spectrum disorder. 
 155  
V.4.1.3. Myelin measurements 
Example maps are shown in Figure V.5, and fM measurements at baseline in 
Figure V.6. 
fM was significantly reduced in the NASCT for both MS (on average -9.66%, p = 
0.03) and NMOSD (-9.8%, p = 0.002) compared to controls. fM in lesioned areas 
was also reduced in both MS (-14.9%, p = 0.002) and NMOSD (-16.4%, p < 0.001). 
Neither NASCT nor lesioned tissue fM differed between MS and NMOSD. There 




Figure V.5. Example myelin water fraction (fM) maps for three subjects, overlaid on a T1-
weighted SPGR scan. a) Healthy control: female, 26 years old. b) Multiple sclerosis subject: 
male, 35 years old, Expanded Disability Status Scale (EDSS) 2, disease duration of 4 years, 
with lesions at the C1 and C2 levels. c) Neuromyelitis optica spectrum disorder subject: 
female, 41 years old, EDSS 3.5, disease duration of 2 years, with a lesion at the C2/C3 
level. White lines represent upper and lower limits for cord segments identified as lesioned. 
Reduced fM is visible in lesions and along the length of the cord for both patients. 
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Table V.2. Baseline and longitudinal spinal cord MRI measures. 
 Within-group  Between groups 
 









Cross-sectional         
Normalized volume (mm2) 70.6 ± 8.1 66.6 ± 7.2 60.4 ± 15.6  0.023* 0.105 0.009** 0.202 
NASCT fM 0.159 ± 0.017 0.148 ± 0.016 0.149 ± 0.015  0.006** 0.025* 0.002** 0.820 
Lesioned tissue fM - 0.140 ± 0.023 0.138 ± 0.035  < 0.001*** 0.002** < 0.001*** 0.706 
NASCT vs. lesioned tissue fM† - .846 .322  - - - - 
Longitudinal         
Change in volume 
% diff. -1.4 ± 3.4% -2.0 ± 5.2% -6.4 ± 3.1%  
0.026* 0.809 0.013* 0.020* p 0.194 0.206 0.016*  
Change in 
NASCT fM 
% diff. -0.9% ± 7.0% -7.3 ± 5.2% +5.8 ± 10.2%  0.005** 0.020* 0.095 0.002** 
p 0.626 0.016* 0.109  
Change in 
lesioned tissue fM 
% diff. - -1.4% ± 7.6 +3.1% ± 10.5 
 
0.201 - - - 
p 0.322 0.297  
Values reported are median ± interquartile range. Baseline values and percent change in magnetic resonance imaging (MRI) metrics over time, and group 
differences are presented. *Significant at p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. †Within-group paired Wilcoxon signed-rank test. fM: myelin water fraction. MS: 
multiple sclerosis. NASCT: normal-appearing spinal cord tissue. NMOSD: neuromyelitis optica spectrum disorder. NS: non-significant. mm: millimetres. % 
diff.: percent difference. 
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Figure V.6. Myelin water fraction for the cross-sectional sample, by group and 
tissue type. Right-hand axis shows percent difference of each data point from the 
control group average. 
 
Figure V.7. Percent changes in median myelin water fraction by group and 
tissue type over one year. Dotted line represents 0% change from 
baseline. 
Data points outside of boxplot whiskers are outliers, defined as being beyond 1.5 interquartile range of each quartile. *Significant at p ≤ 0.05, **p ≤ 0.01, ***p ≤ 
0.001. MS: multiple sclerosis. NASCT: within normal-appearing spinal cord tissue. NMOSD: neuromyelitis optica spectrum disorder. fM: myelin water fraction. 
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V.4.2. Longitudinal 
Because only a subset of participants had data available at follow-up, additional 
information regarding baseline metrics for the longitudinal subset can be found in 
Table V.3 at the end of this chapter. Reasons for drop-out included geographical 
and scheduling conflicts, technical difficulties during scanning, as well as a few of 
the patients feeling unwell at the time of appointment. The results observed at 
baseline overall held true for the subset of subjects who took part in the longitudinal 
part of the study. 
 
V.4.2.1. Changes in EDSS 
In the MS group, three subjects had an increase of 0.5 points on the EDSS, and 
two subjects a decrease of 0.5 points; all of them had a baseline score £ 4.5. In the 
NMOSD group, one subject had a one-point decrease from 7.5 to 6.5, and one had 
an 0.5-point increase from 5.5 to 6. Depending on the criteria chosen for the 
definition of significant clinical deterioration outlined above in V.3.1, this last subject 
is the only one that showed a significant increase in disability at follow-up, although 
this person did not experience a clinical relapse. 
 
V.4.2.2. Lesions 
None of the subjects developed any new lesions between baseline and follow-up.  
Within the longitudinal MS sample (n = 11), a total of 47/77 segments (61%) 
contained lesions. One subject had no lesions, therefore lesional analysis included 
10 patients; 3 had entirely lesioned cords, therefore NASCT analysis only included 
8 patients. Within the NMOSD group, 23/56 segments (41%) were counted as 
lesioned. All 8 subjects had some degree of NASCT tissue, and one had no 
lesions, therefore 7 patients were included in lesional analysis. Details are shown in 
Figure V.8. The number of lesioned segments did not differ between groups (p = 
0.2). 
 
V.4.2.3. Volume changes 
Changes in cord volume are shown in Figure V.4. Median volume change did not 
differ between controls (-1.4%) and MS (-2.0%) (p = 0.8). Volume loss in NMOSD 
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was -6.4%, significantly greater than in either controls (p = 0.01) or MS (p = 0.02). 
Volume change was significant within the NMOSD group over time (p = 0.02). 
 
V.4.2.4. Changes in myelin water fraction 
Changes in fM in NASCT and lesioned tissue are shown in Figure V.7. 
We report, for NASCT and lesioned tissue separately, change within-group (i.e. 
baseline vs. follow-up values within each sample) as well as comparisons between 
groups. 
In NASCT fM, only the decrease in the MS group was significant (p = 0.02). fM in the 
control and NMOSD groups remained stable over time. Between groups, there was 
a greater reduction in the MS group (-7.3%) compared to controls (-0.9%, p = 0.02) 
and NMOSD (+5.8%, p = 0.002). There was no difference between controls and 
NMOSD. 
In lesioned tissue, the MS group showed a median decrease of -1.42%, and the 
NMOSD group increased by +3.05%, although neither of these within-group 
changes was significant. A Kruskal-Wallis test revealed that there was no 
significant difference between change in NASCT in controls and change in lesioned 
tissue for either patient group. 
 
V.5. Discussion 
V.5.1. Summary of findings 
Cross-sectionally, NMOSD subjects had significantly lower cervical cord volume 
than controls. fM in lesioned and non-lesioned segments was significantly reduced 
in MS and NMOSD compared to controls, to a similar extent in both groups. 
Longitudinally, volume loss was only significant in the NMOSD group. fM decreased 
within NASCT in the MS group, but remained stable in NMOSD. There was no 
significant change in myelin content in lesioned segments over time in either group. 
These observations, their implications and limitations are discussed below. 
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V.5.2. Volume differences and atrophy 
Using normalized cervical cord volume, we observed (non-significantly) smaller 
values in MS compared to controls; no change occurred in this group over time. 
This result is likely due to a lack of statistical power with the present sample size. 
As a potential confounding factor, the presence of inflammation and oedema are 
known to influence cord volume in relapsing-remitting MS, and have been observed 
to cause cord expansion, potentially offsetting pathological changes (Klein et al., 
2011). However, although non-significant, the observed median volume loss of 2% 
in the MS group is well within the expected range, which has been estimated at 
1-5% per year using CSA measurements (Gass et al., 2015). 
The NMOSD group had smaller cord volume at baseline, and showed significant 
volume loss (median -6.4%) over one year. In Matthews et al.’s investigation, 
including many of the same subjects, no difference was found between NMOSD 
and controls when looking at normal-appearing cord volume at the C1/C2 level, 
excluding slices that contained a lesion. By choosing a measure that would reflect 
the extent of damage to the entire cervical cord, including lesioned tissue, we were 
able to detect volume loss in NMOSD compared to controls both cross-sectionally 
and over time. This suggests that the group differences observed here may be 
driven by volume loss at lesion sites, and delayed focal atrophy. In contrast, while a 
significant difference was found by Matthews et al. between MS and controls when 
looking at normal-appearing upper cord volume, the difference in whole cervical 
cord volume was not significant here, suggesting that focal volume loss plays a 
lesser role than in NMOSD. 
These results are consistent with previous literature findings that volume loss is 
more severe in NMOSD than in relapsing MS (Liu et al., 2015c; Weier et al., 2015), 
and suggest that atrophy occurs over time in a process driven by tissue loss at 
lesion sites. Global and focal atrophy is in fact known to occur in NMOSD in relation 
with the extent and intensity of lesions (Cassinotto et al., 2009; Krampla et al., 
2009). In contrast, focal atrophy is unrelated to cervical cord lesion load in 
relapsing-remitting MS (Evangelou et al., 2005; Lukas et al., 2013). 
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V.5.3. Myelin water fraction measurements 
V.5.3.1. fM is reduced in lesioned areas in MS and NMOSD 
In this study, we segmented the cervical cord into spinal levels and isolated 
segments identified as containing a lesion on standard clinical T2-weighted scans. 
Lesioned segments had lower fM compared to controls in both MS and NMOSD, but 
there was no difference between patient groups, and no longitudinal changes in 
these areas. 
There were no within-group differences between NASCT and lesional areas for 
either MS or NMOSD, which may be explained by the observed extent of damage 
to NASCT in both groups, as well as the varying proportion of NASCT tissue within 
segments counted as lesioned. 
While observing comparably lower fM in MS and NMOSD lesions may indicate 
similar degrees of demyelination in the affected segments, it is likely that the 
identified lesions may be of different sizes, types, and at different stages, especially 
given the heterogeneity of lesion types in NMOSD (Misu et al., 2013). The large 
spread of values within each group would corroborate this; moreover, the 
proportion of lesioned tissue included in any segment may vary (see V.5.4.1). 
Further exploration of quantitative differences in metrics within segmented lesions 
would be of interest, as would tract- or tissue compartment-specific assessments. 
Recent advancements are making high-resolution MWI in the cervical cord feasible 
in acceptable times; gradient-echo and spin-echo (GRASE) MWI has been 
demonstrated (Ljungberg et al., 2016), and preliminary results have been presented 
with an alternative mcDESPOT protocol providing high-resolution axial slices 
(Ljungberg et al., 2017). 
 
V.5.3.2. fM is reduced in NASCT in MS and NMOSD 
We observed lower fM in the NASCT in both MS and NMOSD groups compared to 
controls. The presence of diffuse abnormalities in the MS cervical cord is well-
documented (Gass et al., 2015); these may be attributed to lesions not visible on 
conventional MRI (e.g. below the imaging resolution), distal effects of damage to 
regions outside the cervical cord, or a more diffuse disease process. 
A similar finding in NMOSD is more surprising, given that diffuse damage is only 
seldom observed in the brain in NMOSD (for further discussion, refer back to 
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Chapter IV), although the presence of NASCT damage has been noted previously 
(Klawiter et al., 2012; Qian et al., 2011). As in MS, the influence of secondary 
degeneration processes due to focal damage is likely, given the extent and 
prevalence of cervical cord lesions in this sample. Alternatively, the abnormalities 
observed in NASCT may be the consequence of previous focal abnormalities, 
resolved at the time of scanning. Complete or partial resolution of lesions is 
possible, and lesions may break up during periods of remission, leading to a 
marbled appearance (Asgari et al., 2013b; Krampla et al., 2009; Lalan et al., 2012). 
In this case, it would therefore be possible that previous lesion sites may have a 
normal appearance on conventional imaging, but with residual reduction in myelin 
content, to which MWI is sensitive. These findings bring further evidence for the 
presence of demyelination outside of areas of focal damage in NMOSD. 
 
V.5.3.3. fM decreases over t ime in MS NASCT only 
After one year, we measured a decrease in fM in non-lesional areas in the MS 
group. Interestingly, this phenomenon was not seen in NMOSD. Given comparable 
degrees of demyelination in the cord at baseline, the differences observed between 
MS and NMOSD groups over time seem to reflect distinct inflammatory and 
neurodegenerative processes (Kawachi and Lassmann, 2017). 
One possible explanation for this observation in MS would be the formation of new 
demyelinating lesions, undetected on the clinical scans available. However, 
patients in this cohort were relapse-free over the course of the study, and while new 
spinal cord lesions in MS can be silent (Barkhof, 2002), this is thought to be a rare 
occurrence (Filippi et al., 2016). Notwithstanding, recent work has shown improved 
lesion detection at 7T compared to 3T in the MS cord (Dula et al., 2016), and thus 
the development of small, undetected lesions cannot be ruled out. 
Alternatively, a significant loss of myelin content in the MS cord, in clinically stable 
patients and without the appearance of new lesions, may reflect ongoing 
demyelination due to secondary degeneration, especially given the extent of focal 
pathology in this sample. However, since subjects in the present study were 
relapse-free for a minimum of 6 months before enrolment, any lesion-related 
secondary changes would have in all probability already occurred at the time of 
baseline scan, and would not show further worsening over the subsequent year. 
Moreover, if demyelination secondary to focal lesions were the main process at 
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play, it is likely that similar changes would have been observed in the NMOSD 
group, which was not the case. 
While chronic inflammatory demyelination is characteristic of progressive disease 
(Zeis et al., 2007), our findings are consistent with the hypothesis of a primary 
neurodegenerative process in MS, which has been proposed before (Stys et al., 
2012), as well as with the results of the preceding investigation in brain in the same 
sample. 
Additionally, the relatively high change in fM observed (median -7.3%) is likely 
influenced by several factors such as time to last relapse, treatment effects, 
distance to and extent of focal pathology (including outside of the imaged area), 
etc. The heterogeneity of these factors in the current sample is reflected in the 
variance seen in this variable. Laule et al. observed a decrease of 10% over two 
years in the cord in primary progressive subjects (Laule et al., 2010). Although in 
relapsing-remitting MS, the same neurodegenerative processes are not expected, 
changes of this magnitude are possible, especially considering the already reduced 
fM in NASCT at baseline. Moreover, even for those subjects who experience a 
greater decrease during the observation period, this process is not expected to be 
linear over time. 
The observed increase in NASCT fM in NMOSD warrants discussion, despite not 
being a statistically significant result. Remyelination in diffusely abnormal areas is a 
possibility, although unlikely. This would be corroborated by the fact that fM in 
lesions also tends to increase (non-significant; to be interpreted with caution), and 
some lesions are known to heal at least partly, indicating that some degree of repair 
is possible (Asgari et al., 2011; Benedetti et al., 2006). 
This observation could also be a by-product of volume loss in lesions, and by 
extension in normal-appearing areas: where necrotic tissue is lost, a greater 
relative amount of healthy tissue remains, producing the observed increase in fM. 
Volume loss in the cord, driven by shrinkage of lesioned areas, may lead to 
changes in fM in preserved areas, presuming a constant amount of myelin. 
Alternatively, fM being the ratio of myelin water to total water content, elevated water 
content at baseline (possibly due to cystic change or oedema in relation to the 
disruption of water homeostasis characteristic of NMOSD) could, when returning to 
normal during a period of quiescence, lead to increased fM at follow-up. However, 
given that all subjects in this study were relapse-free for 6 months before baseline, 
and the likely variation in time to last relapse within the NMOSD group, delayed 
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ongoing atrophy is a more likely explanation for the observed increase in fM. All of 
these hypotheses imply that myelin content does not decrease over one year in 
NMOSD, in stark contrast to MS. 
Interestingly, a recent study observed smaller cord volumes in NMOSD subjects 
with no history of transverse myelitis or detectable cord lesions, albeit to a lesser 
degree than subjects with cord pathology, but comparably to MS subjects (Ventura 
et al., 2016). While the authors raise the possibility of a diffuse pathological process 
occurring in the cord, our results do not appear to support this hypothesis. Another 
possibility is that of the occurrence of a transient inflammatory episode culminating 
neither in clinically detected myelitis nor in overt focal pathology, that would be 
responsible for tissue damage and loss, in parallel or in addition to shrinkage of 
lesions in NMOSD. 
 
V.5.4. Methodological considerations 
V.5.4.1. Influence of motion 
The mcDESPOT protocol is composed of steady-state scans, which are intrinsically 
relatively insensitive to motion (Chavhan et al., 2008). Cervical cord movement is 
greatest in the ‘up-and-down’ direction, affected by cardiac pulsation; therefore, 
acquisition was done with read-out in the superior-inferior direction so as to 
minimize motion artefacts in the direction in which they are most severe. Natural 
motion in the anterior-posterior direction has previously been assessed at 0.25-0.5 
mm (Figley et al., 2008). At the current voxel size (0.9 x 0.9 mm in-plane), any 
blurring in the data would be at an acceptable level. mcDESPOT acquisition results 
in 25 separate collected scans; thus, individual acquisition time is relatively short 
which serves to limit noise from intrascan motion. 
 
V.5.4.2. Methods for cord volume measurement 
A number of metrics and normalization approaches have been proposed for the 
assessment of cervical cord atrophy. The most widely used measure is CSA at the 
C2/C3 level, due its relative robustness to motion artefacts, and because it has 
been found to be representative of overall spinal cord atrophy; however, it requires 
appropriate axial resolution (Tench et al., 2005b). Another proposed metric, the 
mean upper cervical cord area (MUCCA; (Daams et al., 2014)), consists in 
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measuring volume in the uppermost portion of the cord (i.e. usually at the C1-C2 or 
C2-C3 level) and normalizing by length, similar to the approach used here. Whole 
cervical cord volume, employed in the present work, has been found similarly 
effective to C2/C3 volume in terms of revealing group differences in MS, and has 
the added benefit of taking into account tissue loss due to focal damage along the 
extent of the cord (Zivadinov et al., 2008). 
Possible normalization factors have been investigated before and include, but are 
not limited to, height, body-mass index, intracranial volume, number of acquired 
slices, and length of individual segments or portions of the cord (Oh et al., 2014). 
We chose here to normalize by cord length. While the choice of one approach over 
the other is still a matter of debate, these metrics have been found to be highly 
correlated (Healy et al., 2012), and both studies cited above mention normalization 
by cord length as the recommended approach. 
To ensure the validity of this measure in the present sample, average CSA at the 
C2/C3 level was also collected using the SCT, which measures the area of the 
segmented cord on each slice over the chosen volume, and corrects it for cord 
orientation. Using the larger baseline dataset, normalized volume showed excellent 
correlation with average CSA at the C2/C3 level, within each of the HC, MS, and 
NMOSD groups (Pearson’s correlation coefficient: all r > 0.93, p < 0.001). The 
group differences reported above were also preserved [data not shown]. This 
contributes to guaranteeing high confidence in the presented results, regardless of 
methodological approach to atrophy measurement. 
We obtained a median normalized cord volume (equivalent to average CSA across 
C1-C7) of 70 mm2 in the control group. Cord area decreases at the C5-C7 levels 
compared to higher segments, thus averaged across the whole cord, this result is 
naturally slightly smaller compared to most reported estimates of CSA at C2/C3 
(Tench et al., 2005a). The choice of including or excluding edge voxels is also 
known to affect volume estimation; the PropSeg method only provides a binary 
segmentation, and does not provide estimates of partial volume effects. The choice 
of performing manual editing, in order to create conservative masks for fM 
measurement, may also have had an impact. Nevertheless, this result is in line with 
measurements obtained in other studies that used the same method in healthy 
subjects (De Leener et al., 2014; Ventura et al., 2016). 
When used for longitudinal assessment of cord atrophy, all the methods mentioned 
above rely on using cord segmentation to collect measures of area or volume at 
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each time point, and comparing the obtained metrics. In the brain, methods have 
been developed that rely on within-subject registration between two time points, 
such as FSL-SIENA (Smith et al., 2002) or the brain boundary shift integral (BBSI; 
(Freeborough and Fox, 1997)). These methods use registered data from two time 
points to compute either distance or difference in intensity between voxels at the 
tissue interface, and afford greater reproducibility and power to detect group 
differences compared to segmentation-based approaches (Moccia et al., 2017). An 
implementation of the BBSI technique has recently been developed for use in the 
cord (Prados Carrasco et al., 2016), and may lead to more precise estimates of 
atrophy for use with longitudinal data; further work is expected in this area. 
 
V.5.4.3. Segmentation of lesions 
An important limitation of the current approach lies in the segmentation of lesioned 
areas, which include varying proportions of NASCT, and are therefore lesioned 
areas and not purely lesioned tissue. While this approach enables isolation of 
NASCT, it does not constitute lesion segmentation per se, and thus limits the 
specificity of this measure to lesional pathology. This may contribute to explain the 
lack of significant baseline differences between NASCT and lesioned areas in each 
patient group, as would be expected, although the observed extent of damage to 
NASCT areas is another contributing factor. 
It is worth also noting that despite the fact that NMOSD cord pathology is usually 
more severe than in MS, in this study, the MS group had on average more affected 
segments than the NMOSD group, although this difference was not significant in 
the smaller follow-up subset (see Table V.3). While possible that the extent of cord 
pathology may by chance be greater in this particular MS sample, this is 
compounded by the fact that the number of segments considered lesioned does not 
represent the extent of lesions in itself, as well as the fact that some subjects from 
both disease group had lesions in the brainstem and thoracic portion of the spine 
that may have had up- and downstream effects (which we did not assess 
systematically). 
V.5.4.4. Variations in myelin content along the cord 
The ratio of white and grey matter, and consequently myelin concentration and thus 
fM, are known to vary along the length of the cord (Fradet et al., 2014; Kolind and 
Deoni, 2011; Minty et al., 2009). In order to exclude lesions from normal-appearing 
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tissue analysis, we excluded cord segments identified as lesioned on T2-weighted 
scans, and compared preserved areas of the cord at different spinal levels. 
However, the distribution of lesions across cord levels was relatively uniform within 
and between each disease group (see Figure V.8), thus mitigating possible bias in 
comparing unmatched regions that are expected to vary in myelin content. Distance 
of normal-appearing segments from lesion sites, as well as lesion type, length and 
age are all parameters that would warrant attention in further investigations of 
secondary degeneration processes in both diseases. 
 
V.5.4.5. Treatment effects 
Half of the MS and all of the NMOSD subjects were on immunomodulatory and 
immunosuppressant treatments, respectively. While all patients were in remission 
for the duration of the study, DMTs are likely to mediate background inflammatory 
activity, and thus may affect volume and changes in myelin content compared to 
patients not currently on treatment. However, discussions on the effects of DMTs 
on spinal cord pathology in the current context remain speculative. Characterisation 
of the influence of volume changes (i.e. atrophy) on the fM measurements would 
also be of interest to allow description of the relationship between possible volume 
loss and changes in myelin content. 
 
V.5.4.6. Sample size 
Limitations to this study also include the small sample size, especially for the 
longitudinal sample, and the resulting heterogeneity in age and clinical profiles 
within the patient groups, including in DMTs. Results should therefore be regarded 
as preliminary, and warrant replication in larger samples. 
 
V.6. Conclusion 
In this study, we aimed to ascertain whether evidence of cervical cord atrophy and 
demyelination could be seen in stable relapsing-remitting MS and NMOSD 
subjects. Using MWI, we found that measures of myelin content are similarly 
reduced in MS and NMOSD compared to controls in cervical spinal cord lesions 
and in normal-appearing tissue. 
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At one-year follow-up, there was a significant decrease in NASCT fM in the MS 
group. This observation suggests that chronic changes occur in the absence of new 
detectable lesions, bringing further evidence that occult activity occurs in MS tissue, 
either due to secondary degeneration following lesions, or to lesions appearing 
below the imaging resolution of clinical scans. Detection of a significant change 
over a short period supports the use of cervical cord fM as a potential imaging 
marker of ongoing neurodegeneration in MS. Particularly, this measure may 
constitute a valuable imaging outcome in clinical trials in progressive disease. 
In contrast, despite ongoing loss of volume in the NMOSD cervical cord, likely 
driven by lesions, and diffuse damage at baseline comparable to that seen in MS, 
no significant change in myelin content was seen in NMOSD. Instead, fM showed a 
(non-significant) tendency to increase in normal-appearing areas, which could 
result from the observed reduction in volume while actual myelin content remained 
stable. This observation suggest that the NASCT is not subject to further 
degeneration, lending new evidence to the idea that subclinical disease activity is 
not a feature of NMOSD, and supporting the observation that disease progression 
is absent clinically. 
Evaluations of the effects of the location and extent of focal cord pathology in both 
disease groups are required before making assumptions about the pathological 
substrates of these observations. Recent technical developments will allow 
collection of mcDESPOT in the cervical cord with reduced coverage, but higher 
resolution in the axial plane, which will enable tract-specific assessments and 
differentiation between the up- vs. downstream effects of focal damage, as well as 
enhance the precision of lesional measurements. 
Finally, these results support the use of longitudinal MWI for the assessment of 
pathological changes in the cervical cord in demyelinating diseases. Further 
longitudinal investigations should address the link between such changes and 
progression of disability in order to establish its potential use as a clinically relevant 
marker of pathology.   
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V.7. Additional information 
Included here are a diagram showing the distribution of lesioned cervical cord 
segments cervical cord level for each patient group in Figure V.8, and summary 





Figure V.8. Repartition of lesions by cervical segment for the cross-sectional and 
longitudinal sub-samples. The proportion of subjects out of each group for whom each 
segment was considered as lesional is shown. In the follow-up subset, three MS subjects 
had lesions covering the whole cervical cord, and one had none. In the NMOSD group, one 
subject had no lesions. The number of lesioned segments by subject did not differ between 
groups (p = 0.2). MS: multiple sclerosis. NMOSD: neuromyelitis optica spectrum disorder. 
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Table V.3. Population characteristics and MRI metrics at baseline for the longitudinal sub-sample. 
 Within-group  Between groups 









Demographics         
N (sex) 14 (3M) 11 (3M) 8 (0M)  - - - - 
Age (years) 51 (26-76) 41 (28-62) 46 (27-76)  0.613 - - - 
Disease duration (months) - 54 (26-156) 65 (24-186)  - - - .934 
Baseline EDSS - 2 (1-5) 5 (2-7.5)  - - - .045* 
Lesioned segments per subject - 4 (0-7) 3 (0-5)  - - - .196 
Number of subjects with NASCT - 8 8  - - - - 
Number of subjects with ≥ 1 lesion - 10 7  - - - - 
Time between scans (months) 12 (10-14) 12 (11-14) 12 (11-15)  .342 - - - 
MRI measures         
Normalized volume 70.8 ± 7.6 66.6 ± 6.4 63.1 ± 13.0  0.076 - - - 
NASCT fM 0.159 ± 0.016 0.148 ± 0.018 0.150 ± 0.008  0.020* 0.042* 0.010* 0.959 
Lesioned tissue fM - 0.143 ± 0.033 0.149 ± 0.018  0.017* 0.007** 0.098 0.847 
Values are reported as median ± interquartile range (range). *Significant at p ≤ 0.05, **p ≤ 0.01. EDSS: Expanded Disability Status Scale. fM: myelin water 
fraction. M: male. MRI: magnetic resonance imaging. MS: multiple sclerosis. NASCT: normal-appearing spinal cord tissue. NMOSD: neuromyelitis optica 
spectrum disorder. NS: non-significant. mm: millimetres. % diff.: percent difference.
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Chapter VI. Conclusion 
 
Summary of presented work 
In this work, I focused on the application of myelin water imaging (MWI) to the study 
of neuromyelitis optica spectrum disorder (NMOSD). Due to the rapid evolution of 
the nosology of NMOSD in the last twelve years, as well as it being a rare disease, 
the body of literature is limited. This is in contrast to the study of multiple sclerosis 
(MS) in which, as a large, active field, a vast range of techniques have been 
applied. Overall, the use of advanced imaging is relatively recent in NMOSD, and 
the field suffers from lack of replication, and the potential of various available 
techniques to inform on the particular pathology of this disease is still being 
assessed. The central thesis of this work is that MWI, and especially mcDESPOT, 
can provide valuable information and inform current research questions in NMSOD 
research. 
In Chapter III, I reported results from a single-scanner reliability study of 
mcDESPOT in healthy older adults. I showed good scan-rescan reliability of T1, T2, 
and myelin water fraction indices in the brain. In the following chapter I then applied 
the method in the brain and cervical cord to investigate NMOSD pathology. 
In Chapter IV, I presented the results of an investigation of subcortical pathology 
using a mcDESPOT protocol. I investigated abnormalities in the normal-appearing 
white matter (WM) and the thalamus in an NMOSD group compared to healthy 
controls. Regional analysis of quantitative parameters revealed reduced myelin 
water fraction and elevated T1 in several regions. The sensitivity of the T1 relaxation 
time to abnormalities in the brain suggests changes in water content as the likely 
substrate behind these observations, which would warrant further investigation. In 
contrast, thalamic indices were normal. Thalamic T1 emerged as a strong predictor 
of performance on a cognitive measure of the speed of information processing, 
supporting further exploration of thalamic involvement in relation to the known 
pattern of neuropsychological deficits in NMOSD. 
In Chapter V, I presented results from a longitudinal study into cervical spinal cord 
pathology in NMOSD and MS subjects and healthy controls over one year. 
Evidence of abnormal myelin content outside of lesioned areas of the cord was 
apparent in both patient groups. Significant cord atrophy occurred over time in the 
NMOSD group only. Despite similar levels of nonfocal pathology at baseline, 
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changes in myelin content over time were only visible in the MS group, in the 
absence of clinical and radiological activity. These results attest to the ability of 
mcDESPOT to show evidence of degenerative processes in the MS cord over a 
relatively short follow-up duration. 
Each chapter being a different, independent project on a different cohort, the 
methodological limitations of each presented study have been detailed in each 
section. Here, I further expand on the limitations inherent to all three studies, as 
well as those routinely encountered in the NMOSD literature, and provide general 
discussion points regarding the use of cord and brain MWI in NMOSD and MS 
research. 
 
Translational potential of MWI 
In this work, I provide evidence for the utility of mcDESPOT as a research tool in 
the study of demyelinating disease. Regarding its translational value, however, 
several factors limit its potential, including absence of histological validation, lack of 
standardisation of protocols and analysis methods, and high post-processing 
requirements both in terms of expertise and computational demands. For instance, 
MR spectroscopy, diffusion tensor imaging (DTI), and magnetisation transfer ratio 
(MTR) measures have shown promise in determining prognosis in clinically isolated 
syndrome cases (Rovira et al., 2015). Research into MWI is also a smaller field 
than the larger bodies of work behind the aforementioned methods, which make 
more likely candidates for acceptance and use in the clinic in the near future. 
For instance, MWI has been recommended as a more appropriate tool to assess 
myelin integrity in vivo than blood/CSF markers or other MRI methods in the study 
of mild traumatic brain injury, due to its high specificity and sensitivity (Weber et al., 
2018; Wright et al., 2016). However, diffusion-weighted and diffusion tensor 
imaging can already be used clinically in the characterisation of ischemia or 
traumatic brain injury (TBI), and tractography also has potential in the study of 
stroke and perioperative planning (Sundgren et al., 2004). DTI has been suggested 
as the most “mature” in terms of development and validation, and to thus be the 
first contender for broader use in clinical trials and translational applications (Martin 
et al., 2016). 
On the individual level, MWI has been used to assess WM changes with higher 
specificity than traditional imaging can afford in a case study of a patient suffering 
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from post-radiation necrosis (Lapointe et al., 2017), and to evaluate the long-term 
effects of stem cell transplantation in a Krabbe disease patient (Laule et al., 2016). 
Current investigations using MWI are also looking at lowering necessary sample 
sizes in clinical trials using advanced methods that yield higher statistical power 
than conventional metrics (i.e. cerebral atrophy), which may lead to lowered costs 
and therefore increased speed in clinical trials and thus drug evaluation and 
deployment, and increased treatment options. 
Defining clinical utility as the capacity of a technique to generate information about 
individual cases – diagnostic, prognostic, and as a biomarker having a relationship 
with clinical measures (Martin et al., 2016) – it is clear that making such use of MWI 
will require further extensive work, including: validation using animal models, 
histology, or other established techniques; assessments of cross-platform and test-
retest reliability; development of consensus methods for analysis; and 
determination of clinical correlations in various samples. The assessment of 
precision, i.e. repeatability and reproducibility, is paramount in a technique meeting 
the standards required for a potential translation to clinical practice (Jackson, 
2018), which I contribute to in Chapter III of the present work. 
 
Limitations and future directions 
I discuss below some of the general limitations to the work presented in this thesis 
and, following up on this, how a number of interesting avenues of investigation can 
be proposed going forward into a new, “exciting” decade of research (Kister and 
Paul, 2015). 
Throughout this work, note is often made of discrepancies between advanced MRI 
studies, especially when it comes to brain investigations. As summarised by Pache 
et al., advanced MRI studies into nonfocal damage in the NMOSD brain have 
yielded results “ranging from: 1) widespread brain damage, 2) damage only in 
visual and sensorimotor systems, or 3) no substantial damage at all” (Pache et al., 
2016). Several reasons can be invoked for this. First, in a relatively young field of 
research, diagnostic criteria have undergone several reappraisals; the potential 
differences in phenotypes across various ethnic groups were also evoked earlier 
(see IV.5.4.2). The difficulty of obtaining homogeneous populations, reflecting the 
plurality of disease presentations in the real world, may be improved in the future as 
larger samples become available, and with better categorisation of existing patient 
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groups due to advances in defining the different ‘branches’ of the NMO spectrum. 
These points will be discussed below. 
With new and improved serological assays, detection rates of AQP4-IgG-positivity 
increase. Comparison between assays in two multi-centre studies showed that 
sensitivity and specificity can be improved with the use of a new generation of tests, 
with cell-based assays yielding the best results overall (Waters et al., 2016, 2012). 
MOG-IgG and AQP4-IgG seropositivity were found to be mutually exclusive in 
nearly all studies; rare evidence to the contrary has been suggested to hinge on the 
sensitivity of the assays used for testing (Sato et al., 2014; Zamvil and Slavin, 
2015). MOG-IgG seropositivity is also only rarely observed in adult MS (Reindl et 
al., 2013). Therefore, as assay methods improve and MOG antibody testing 
becomes more widely conducted, the nosology of NMOSD is likely to require re-
evaluation in the future (Zabad et al., 2017). Several studies have found that MOG-
IgG-positive NMOSD patients present with different demographic, clinical, and 
conventional imaging characteristics, and that different pathogenic mechanisms 
may be at play (Jarius et al., 2016a, 2016b; Sato et al., 2014; van Pelt et al., 2016); 
thus, further exploration of these different profiles may be of interest. To facilitate 
this, studies with larger sample sizes and better-defined patient samples will be 
necessary. 
Inherent to the study of a rare disease, most studies in the field have very small 
sample sizes, and the high prevalence of borderline significant results (many 
examples being cited in Chapter IV, and as evidenced by the results presented in 
the current work) suggests a lack of statistical power. This is a limitation from which 
the two NMOSD studies presented here suffer (with sample sizes of n < 20 for 
patient groups in both Chapter IV and V). This is, however, representative of the 
number of research subjects that can be expected to be recruited from a single 
NMO clinic over a period of approximately one year, which was the case for both 
projects presented here. 
Multi-centre studies are therefore crucial in the study of rare populations, to enable 
stricter inclusion criteria and maximise sample sizes. Recent national and 
international initiatives have seen the implementation of large-scale databases for 
demographic, clinical and biological information in NMOSD, such as the CIRCLES 
study in North America, the NEMOS project in Germany, and the NOMADMUS 
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cohort in France16. All three examples are registry and repositories that aim to 
collect demographic, clinical, and biological data, offering researchers the means to 
conduct investigations with adequate data samples. Imaging data is expected to 
follow soon, which will enable moving past the stage of exploratory, hypothesis-
generating, pilot or replication studies (often with conflicting, or hard to compare 
results, due to differences in populations and techniques) and enable precisely 
addressing research questions. The deployment of such initiatives is a strong 
argument for the validation and use of quantitative imaging techniques with known 
reliability. I contribute to those efforts in this work by providing supporting evidence 
for the use of the technique of interest, mcDESPOT, in a test-rest design. With this 
in mind, multi-centre assessments of reproducibility would also be valuable. For 
instance, a group of healthy controls, and ideally a sample of patients, could be 
scanned across several sites and, pending harmonization of sequences between 
vendors and scanner models. Inter-site reproducibility may be assessed using a 
scheme similar to that used in Chapter III, by registering data within-subject and 
comparing metrics across regions and voxelwise using statistical measures (e.g. 
intraclass correlation coefficients taking into account the effect of scanner, within-
subject coefficients of variation, correlation measures) to investigate the influence 
of site and potential bias. Another obvious extension to the work presented here 
would be assessing the reliability of mcDESPOT-derived measures in the cervical 
cord longitudinally, as a first step to permitting multi-centre and/or longitudinal 
designs in clinical populations. 
Applied to the study of NMOSD, advanced imaging of the brain is important for 
several reasons. As recounted here, brain involvement is greater than previously 
thought, and especially relevant in the understanding of cognitive impairment and 
therefore quality of life. Advanced brain MRI has the potential to feature changes 
brought on by both optic nerves and spinal cord pathology, and therefore reflect 
disease progression comprehensively; the time-course of brain involvement with 
regards to the evolution of opticospinal pathology remains to be explored through 
longitudinal studies involving eye, cord and brain imaging. 
                                                
16 CIRCLES: Collaborative International Research in Clinical Longitudinal Experience in NMO Studies 
(Cook et al., 2016). 
NEMOS: NMO Study Group; https://nemos-net.de/english-summary.html 
NOMADMUS: French Cohort and Biobank of Devic's NMO and Related Neurological Disorders; 
https://clinicaltrials.gov/ct2/show/NCT02850705  
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Considering the fact that each advanced MRI method comes with its own set of 
technical limitations and susceptibility to different biological phenomena, the 
simultaneous use of several, complementary methods has been recommended for 
a more comprehensive characterization of tissue (Groeschel et al., 2016). Earlier 
mention was made of the advantages of concurrent MWI and absolute water 
content mapping. With regards to mcDESPOT itself, it should be possible to make 
use of the other quantitative parameters that the technique affords. In particular, the 
myelin residence time holds promise as a potential marker of myelin sheath 
thickness and integrity (see Chapter II). Recent preliminary work has shown that 
residence time reflects the expected regional variations in the corpus callosum of 
healthy subjects, and may show promise in helping characterise the pathological 
substrates of callosal pathology in NMOSD (Abel et al., 2017). Investigation of this 
parameter in the cervical cord would also be of interest, for instance starting with 
comparing its information potential compared to other metrics of WM integrity in 
healthy controls. 
In regard to Chapter V, a similar longitudinal investigation with a longer follow-up 
duration would be interesting – two or even three years being a feasible duration, to 
balance between power to detect significant pathological changes, while keeping 
the drop-out rate to a minimum due to practical considerations. Increasing the 
number of time points as well as the follow-up duration may also contribute to 
increasing sensitivity, although the latter may have a greater impact (Moccia et al., 
2017). 
A central limitation to this work taken as a whole is the use of different cohorts for 
the brain and cervical cord studies; collecting both datasets from the same sample, 
followed over time, and analysing the two concurrently is an obvious continuation 
and expansion of this work. In the spinal cord, development and deployment of 
advanced techniques is naturally lagging behind that of brain methods; however, 
the field of advanced cord MRI is growing rapidly. In a similar vein to the insights 
that multimodal imaging and longitudinal designs can bring, one particularly 
interesting advance is the development of simultaneous brain and spine imaging 
protocols. Focusing on the possibilities afforded by MWI, investigating the time-
course and relationships between WM alterations in the brain and cord over time, 
and the downstream/upstream effects of each, would be of interest (Lycklama et 
al., 2003). Improvements in image resolution, and segmentation methods for the 
identification of regions and tracts may allow the study of functionally relevant 
 177  
networks, and to explore whether any changes in the cord are mirrored in the brain 
(e.g. brainstem, corticospinal tract, motor cortical areas). 
Methodological work has focused on ways of merging brain and cord datasets, for 
instance the recent creation of a spinal cord atlas compatible with the widely-used 
MNI152 brain template and using the same coordinate system, and of methods 
enabling nonlinear registration and merging of scans (Leener et al., 2017). Other 
advancements include the possibility of acquiring upper cervical cord area 
measures from high-resolution T1-weighted scans of the brain (Liu et al., 2016), 
with appropriate correction for the impact of gradient-induced distortions (Papinutto 
et al., 2018), as well as previously mentioned technical developments enabling 
mcDESPOT in the cord at higher resolution (Ljungberg et al., 2017) (see Chapter 
V). These techniques hold great promise to better capture the extent of pathology in 
the central nervous system. 
In this work, I have shown that mcDESPOT can be a useful, reliable tool for the 
assessment of quantitative parameters in the brain and cervical cord. Although 
complex questions remain that need to be addressed further, the current work 
helps address outstanding questions in NMOSD research. It brings additional 
evidence to characterise the nature and extent of brain involvement, the correlates 
of cognitive impairment, and the existence of subclinical disease progression 
between clinical relapses. It supports the use of mcDESPOT as an informative 
technique in the study of this rare disease in particular, and neurological disorders 
involving WM in general.  
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